


Article

Kinetic Resolution of Alkylidene Norcamphors *via* a Ligand-Controlled Umpolung-Type 1,3-Dipolar Cycloaddition

Chong Shen,
Yuhong Yang,
Liang Wei, Wu-
Wei Dong, Lung
Wa Chung, Chun-
Jiang Wang

oscarchung@sustc.edu.cn
(L.W.C.)
cjwang@whu.edu.cn (C.-J.W.)

HIGHLIGHTS

Kinetic resolution of
racemic alkylidene
norcamphors

Spiro architectures
incorporating norbornane
and pyrrolidine scaffolds

Unique ligand-enabled
umpolung-type 1,3-
dipolar cycloaddition

DATA AND
SOFTWARE

AVAILABILITY

www.ccdc.cam.ac.uk/
getstructures

Shen et al., iScience 11, 146–
159
January 25, 2019 © 2018 The
Author(s).
[https://doi.org/10.1016/
j.isci.2018.12.010](https://doi.org/10.1016/j.isci.2018.12.010)



Article

Kinetic Resolution of Alkylidene Norcamphors via a Ligand-Controlled Umpolung-Type 1,3-Dipolar Cycloaddition

Chong Shen,^{1,2,5} Yuhong Yang,^{4,3,5} Liang Wei,¹ Wu-Wei Dong,¹ Lung Wa Chung,^{3,*} and Chun-Jiang Wang^{1,2,6,*}

SUMMARY

Development of a general catalytic and highly efficient method utilizing readily available precursors for the regio- and stereoselective construction of bioactive natural-product-inspired spiro architectures remains a formidable challenge in chemical research. Transition metal-catalyzed asymmetric 1,3-dipolar cycloaddition of azomethine ylides produces numerous N-heterocycles, but reaction control with the regioselectivity opposite to the conventional fashion has rarely been demonstrated. Herein, we report a unique ligand-controlled Cu(I)-catalyzed umpolung-type 1,3-dipolar cycloaddition of azomethine ylide to realize efficient kinetic resolution of racemic alkylidene norcamphors with the concomitant construction of previously inaccessible spiro N-heterocycles with high levels of regio- and stereoselectivity. The success of this methodology relies on the strategy of kinetic resolution, and the serendipitous discovery of a unique ligand-enabled regioselective cycloaddition, which not only provides evidence for the existence of the minor zwitterionic resonance form in metallated azomethine ylide but also diversifies the existing chemistry of azomethine ylide-involved 1,3-dipolar cycloadditions with rare polarity inversion.

INTRODUCTION

1,3-Dipolar cycloaddition reaction is one of the fundamental processes in organic chemistry (Huisgen, 1963; Padwa, 1984; Padwa and Pearson, 2003). In particular, catalytic asymmetric 1,3-dipolar cycloaddition of *in situ*-formed metallated azomethine ylides (dipoles) from readily available imino esters (Figure 1A) offers the most powerful and diversity-oriented synthesis (Schreiber, 2000) (DOS) for the convergent construction of numerous enantioenriched five- or six-membered nitrogen-containing heterocycles in stereocontrolled fashion (Hashimoto and Maruoka, 2015; Adrio and Carretero, 2011, 2014; Stanley and Sibi, 2008; Álvarez-Corral et al., 2008; Nájera and Sansano, 2005; Pellissier, 2007; Pandey et al., 2006; Coldham and Hufton, 2005), which are very important pharmaceuticals, natural alkaloids, and building blocks in organic synthesis. Metallated azomethine ylide has four π electrons spread over a C-N-C unit, which can be presented by the two most common zwitterionic resonance forms as shown in Figure 1B: the coordinated central N atom is positively charged, and the negative charge is distributed over the two adjacent carbon atoms (Pandey et al., 2006; Coldham and Hufton, 2005). In general, the major zwitterionic resonance form I makes greater contribution to the resonance hybrid structure because the negative charge of the intermediate is delocalized by the neighboring electron-withdrawing ester group, which accounts for the observed regioselectivity of the well-explored 1,3-dipolar cycloaddition controlled by the highest occupied molecular orbital (HOMO) of the azomethine ylide interacting with the lowest unoccupied molecular orbital of the electron-deficient dipolarophiles (Pandey et al., 2006; Coldham and Hufton, 2005; Houk, 1975; Houk et al., 1973). Although the umpolung-type 1,3-dipolar cycloaddition related with the minor zwitterionic resonance form II would give rise to the opposite regioselectivity and thus greatly enhance the diversity of product accessible from azomethine ylide, such polarity inversion reactivity remains elusive so far and was sporadically reported in limited examples (Barr et al., 1989; Kanemasa et al., 1990; Chen et al., 2009; Xu et al., 2018; Feng et al., 2018) or the intramolecular cycloaddition caused by conformational ring constrain (Stohler et al., 2005).

Kinetic resolution (Kagan and Fiaud, 1988; Vedejs and Jure, 2005; Pellissier, 2011) is one of the commonly used strategies to obtain the optically active compounds from racemic starting materials, which was recently also employed in cycloaddition reactions (Cardona et al., 2001; Yu et al., 2010; Takayama et al., 2013; Xu et al., 2016; Yuan et al., 2018). As part of our ongoing research interest in asymmetric 1,3-dipolar cycloaddition (Wang et al., 2008, 2012; He et al., 2013; Li et al., 2014), we considered employing kinetic

¹College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China

²State Key Laboratory of Elemento-organic Chemistry, Nankai University, Tianjin 300071, China

³Department of Chemistry and Shenzhen Grubbs Institute, Southern University of Science and Technology, Shenzhen 518055, China

⁴School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China

⁵These authors contributed equally

⁶Lead Contact

*Correspondence: oscarchung@sustc.edu.cn (L.W.C.), cjwang@whu.edu.cn (C.-J.W.)

<https://doi.org/10.1016/j.isci.2018.12.010>






Figure 1. Rational Design and Serendipity

(A) *In situ*-formed metallated azomethine ylide from readily available imino ester (precursor).

(B) The two most common zwitterionic resonance forms (I and II) of metallated azomethine ylide and the 1,3-dipolar cycloaddition with different regioselectivities.


(C) Kinetic resolution strategy in catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylide to efficiently construct the complex natural-product-inspired architectures incorporating norbornane and pyrrolidine scaffolds concurrently with a serendipitous polarity inversion of azomethine ylide.

(D) Selected bioactive natural products and synthetic drugs or drug candidates containing bicyclic norbornane scaffold.

resolution strategy to develop a new cycloaddition process with readily accessible racemic alkylidene norcamphors as dipolarophiles (Figure 1C). This methodology would not only provide a simple and efficient access to synthetically important chiral building block alkylidene norcamphors but also efficiently assemble complex natural-product-inspired polycyclic spiro architectures incorporating norbornane (bicyclo[2.2.1]heptane) and pyrrolidine scaffolds, both of which are the core structures embedded ubiquitously in natural products and pharmaceuticals, and therefore much attention has been paid to synthetic and biological studies (Reinhard et al., 1992; Suchocki et al., 1991; Demole et al., 1976; Odds, 2001; Chen and Lipton, 2006; Iqbal et al., 2013) (Figure 1D). However, several significant challenges are associated with this design and differentiate it from the majority of azomethine ylide-involved cycloadditions described previously including (1) the lower reactivity of alkylidene norcamphors with the inherent convex skeleton as dipolarophiles because both the upper and lower sides of C=C bond are sterically hindered from a facial recognition standpoint, which would impede the approach of the dipole, and (2) a formidably challenging spiro quaternary stereogenic carbon center (Christoffers and Baro, 2005) is generated on the sterically congested pyrrolidines ring (having up to five substituents) with stereoselectivity control. The paucity of synthetic methodologies available in the literature for the efficient construction of enantioenriched alkylidene norcamphors and spiro[norbornane-pyrrolidines] encouraged us to launch this project. Herein, we report for the first time the highly efficient kinetic resolution of readily available racemic alkylidene norcamphors via Cu(I)-catalyzed 1,3-dipolar cycloaddition with concomitant construction of previously inaccessible spiroheterocycles. Notably, this rationally designed 1,3-dipolar cycloaddition is endowed with the serendipity of realizing the potential polarity inversion of metallated azomethine ylide (Figure 1C), which provides direct and convincing experimental evidence for the existence of the minor zwitterionic resonance form in metallated azomethine ylide.

RESULTS AND DISCUSSION


To test the feasibility of racemic alkylidene norcamphors as dipolarophiles, in preliminary experiments we examined the reaction of commercially available 3-methylene norcamphor **1a** and *N*-(4-chlorobenzylidene)-glycine methyl ester **2a** with Et₃N as the base in the presence of Cu(I)/*rac*-(±)-TF-BiphamPhos



Scheme 1. Initial Test Leading to the Discovery of This Ligand-Controlled Umpolung-Type 1,3-Dipolar Cycloaddition

Initial test on the regio-/diastereoselective control of the 1,3-dipolar cycloaddition of azomethine ylide *in situ*-generated from imino ester **2a** with 3-methylene-2-norbornane **1a** catalyzed by CuBF₄/(\pm)-TF-BiphamPhos (**L1**). The crystal of tosylated *endo'*-**5a** for X-ray analysis was obtained from the corresponding enantioenriched cycloadduct with (*S*)-TF-BiphamPhos **L1** as the chiral ligand.

complex (Wang et al., 2008) as the catalyst (Scheme 1). In view of steric hindrance, terminal alkene moiety connected to the bulky norcamphor scaffold is believed to possess higher reactivity and therefore facilitate the potential cycloaddition process. Racemic TF-BiphamPhos (**L1**) was employed as the ligand to simplify the stereochemical analysis of the cycloadduct because only diastereoselectivity was considered in this case. TF-BiphamPhos, as one of the privileged ligands in 1,3-dipolar cycloaddition (Adrio and Carretero, 2014), exhibited exclusive *endo*-selectivity for a variety of pyrrolidine synthesis, which is the foundation of the hypothetical kinetic resolution of racemic alkylidene norcamphors. Initial experimental results were far from encouraging; full conversions of methylene norcamphor were observed at 5 mol % catalyst loading, but resulted in cycloadducts as two inseparable isomers in 3:1 ratio on silica gel column according to crude ¹H nuclear magnetic resonance, which at first was regarded as the diastereoselective ratio of the *endo*-adduct to the *exo*-adduct. This assumed diastereoselectivity is contradictable with the perfect *endo*-selectivity control exhibited by TF-BiphamPhos in our previous work. Therefore some verification experiments must be carried out to provide the irrefutable evidence on the stereochemical configurations of the two original isomers. Subsequent N-tosylation of the cycloadducts successfully converted the two isomers into separable and crystallizable compounds. To our surprise, X-ray diffraction analysis of the tosylated **3a** and **5a** revealed that both the cycloadducts are regioisomers rather than the assumed diastereomers (see Supplemental Information for the details). It is generally believed that the approach of the azomethine ylide to the methylene norcamphor would occur specifically from the *EXO*-direction due to the “picket fence effect” exhibited by norbornane (Mangan et al., 2016; Corey et al., 1962) (Scheme 2). The major isomer was formed through the *endo*-selective 1,3-dipolar cycloaddition related with the major zwitterionic resonance form I, but the minor one with the opposite regioselectivity was formed via the umpolung-type *endo*-selective 1,3-dipolar cycloaddition related with the minor zwitterionic resonance form II (Scheme 1). Notably, this serendipitous finding regarding the minor isomer **5a** offers direct experimental




Scheme 2. Computed Overall Free-Energy Barrier of the Formation of Several Products from the Reaction of (1R,4S)-1a and 2a Catalyzed by Cu(I)-L1 in Dichloromethane (DCM) Solution by the Polarizable Continuum Model (PCM)-B3LYP//B3LYP Method

The two coordination modes of Ph in the Cu-azomethine ylides (L1_D and L1_U) were considered for the most important intermediates (D: Ar downward; U: Ar upward). The computed NBO charge for the two reacting carbon atoms is also given in an italic form.

evidence on the two zwitterionic resonance structures of a metallated azomethine ylide. Inspired by these promising results, we further investigated the potential regioselectivity and enantioselectivity control to realize the asymmetric variant of this umpolung-type cycloaddition with a series of chiral TF-BiphamPhos ligands, and the results are tabulated in Table 1. With Cu(I)/(S)-L1 complex as the catalyst, cycloadducts (3a + 5a) were separated in 96% yield with moderate regioselective ratio (*rr*) (3:1), and 73% enantiomeric excess (*ee*) for 3a and 20% *ee* for 5a (Table 1, entry 1). When the phenyl group on the phosphorus atom of ligand L1 was replaced by bulky electron-donating 3,5-bis(methyl)phenyl (L2), or electron-withdrawing 3,5-bis(trifluoromethyl)phenyl group (L3), however, the conventional cycloadduct *endo*-3a was formed predominantly in high yields with good to excellent *rr* and good *ee* (Table 1, entries 2 and 3). Chiral ligand L4 containing cyclohexyl groups on the phosphorus atom also displayed normal regioselectivity control with a detrimental effect on the enantioselectivity. To our delight, further ligand screening revealed that ligand L5 incorporating two bromine atoms at the 3,3'-positions of the biphenyl scaffold completely reversed the regioselectivity, affording *endo*-5a in 90% yield with exclusive diastereoselectivity and 92% *ee* (Table 1, entry 5). A subsequent solvent survey indicated that dichloromethane was the best solvent of choice in terms of regioselectivity and diastereo-/enantioselectivity (Table 1, entries 5–10). Lowering the reaction temperature was beneficial for enantioselectivity control, and high yield with 94% *ee* was achieved for *endo*-5a when the reaction was performed at -40°C (Table 1, entry 11).

Having the optimized reaction conditions in hand, we examined the substrate scope of the 1,3-dipolar cycloaddition by treating methylene norcamphor (*rac*-1a) with various imine esters 2 (Table 2). The representative results are tabulated in Table 2. A variety of glycine ester imines are compatible with this umpolung-type 1,3-dipolar cycloaddition reaction, providing the desired cycloadducts in excellent regio- and stereoselectivities. Aryl aldimine esters incorporating different substitution patterns on the phenyl ring were well tolerated in this reaction, and the corresponding cycloadducts 5 were obtained in acceptable yield (59%–94%) with exclusive regioselectivity (>20:1 *rr*), perfect diastereoselectivity (>20:1 *dr*) and



Entry ^a	Ligand	Solvent	<i>rr</i> ^b		Yield (%) ^c	ee (%) ^b
			5a:3a			
1	L1	CH ₂ Cl ₂	1:3		96	73 (3a)
2	L2	CH ₂ Cl ₂	1:14		94	84 (3a)
3	L3	CH ₂ Cl ₂	<1:20		96	89 (3a)
4	L4	CH ₂ Cl ₂	<1:20		83	46 (3a)
5	L5	CH ₂ Cl ₂	>20:1		90	92 (5a)
6	L5	THF	8:1		92	86 (5a)
7	L5	EtOAc	4:1		94	86 (5a)
8	L5	CH ₃ CN	10:1		78	93 (5a)
9	L5	PhMe	18:1		93	88 (5a)
10	L5	CHCl ₃	6:1		88	90 (5a)
11 ^d	L5	CH ₂ Cl ₂	>20:1		91	94 (5a)

Table 1. Optimization of 1,3-Dipolar Cycloaddition of Azomethine Ylide with 3-Methylene-2-Norbornanone 1a


^aAll reactions were carried out with 0.20 mmol of **2a** and 0.40 mmol of **1a** in 2 mL solvent, 48–60 hr CuBF₄ = Cu(MeCN)₄BF₄.

^b*rr* was determined by crude ¹H nuclear magnetic resonance, and ee was determined by high-performance liquid chromatography.

^cIsolated yield of **3a** and **5a** based on **2a**.

^dCarried out at –40°C.

excellent enantioselectivity (93%–97%) (Table 2, entries 1–14). It is worth mentioning that perfect regioselectivity and excellent stereoselectivity could be still achieved with the sterically hindered *ortho*-chloro (**2e**), *ortho*-methyl (**2l**), and 1-naphthyl (**2m**) imino esters (entries 5, 12, and 13). The electronic property of the substituent group on the aryl ring slightly affected the reactivity of this cycloaddition. The cycloaddition reaction furnished quickly with aldimine ester containing strong electron-deficient *p*-NO₂ or *p*-CN substitution on the phenyl ring (entries 6 and 7). Extended reaction time was needed for electron-rich aldimine esters, but the regioselectivity and stereoselectivity still maintained at the excellent level (Table 2, entries 9–12). Aliphatic aldimine esters were not compatible in this reaction, probably due to the reduced reactivity. Notably, α -methyl- or benzyl-substituted aldimine esters were tested to further investigate the



Entry ^a	R	R'	5	Yield (%) ^b	ee (%) ^c
1	<i>p</i> -Cl-C ₆ H ₄	H	5a	91	94
2	<i>m</i> -Cl-C ₆ H ₄	H	5b	88	95
3	<i>p</i> -Br-C ₆ H ₄	H	5c	84	95
4	<i>m</i> -Br-C ₆ H ₄	H	5d	85	94
5	<i>o</i> -Cl-C ₆ H ₄	H	5e	94	94
6	<i>p</i> -NO ₂ -C ₆ H ₄	H	5f	72	98
7	<i>p</i> -CN-C ₆ H ₄	H	5g	83	94
8 ^d	Ph	H	5h	86	93
9 ^d	<i>p</i> -MeO-C ₆ H ₄	H	5i	59	95
10 ^d	<i>p</i> -Me-C ₆ H ₄	H	5j	74	93
11 ^d	<i>m</i> -Me-C ₆ H ₄	H	5k	66	94
12 ^d	<i>o</i> -Me-C ₆ H ₄	H	5l	64	97
13 ^d	1-Naphyl	H	5m	73	95
14 ^d	2-Naphyl	H	5n	88	93
15	<i>p</i> -Cl-C ₆ H ₄	Me	5o	70	97
16 ^d	<i>p</i> -MeO-C ₆ H ₄	Me	5p	57	>99
17 ^d	2-Thienyl	Me	5q	64	96
18 ^{e,f}	<i>p</i> -Cl-C ₆ H ₄	Bn	5r	68	>99

Table 2. Scope of Azomethine Ylides for Cu(I)-Catalyzed 1,3-Dipolar Cycloaddition with 3-Methylene-2-Norbornanone **1a**

^aAll reactions were carried out with 0.20 mmol of **2** and 0.40 mmol of **1a** in 2 mL CH_2Cl_2 in 8–12 hr.

^bIsolated yield based on **2**.

^cdr was determined by crude ¹H nuclear magnetic resonance, and ee was determined by high-performance liquid chromatography.


^dCarried out at -20°C in 36 hr.

^eInorganic base Cs_2CO_3 was used.

^fCarried out at -0°C in 48 hr.

generality of this methodology. The cycloaddition proceeded very well, affording the corresponding spiro [norbornane-pyrrolidines] decorated with one all-carbon and one N-containing quaternary stereogenic center in synthetically useful yields (57%–70%) with exclusive regioselectivity ($>20:1$ *rr*) and excellent stereoselectivities ($>20:1$ *dr*; 96%–>99% *ee*) (Table 2, entries 15–18).

The fact that enantioenriched spirocycloadduct **5a** could be formed regioselectively in an exclusive diastereoselective fashion from racemic methylene norcamphor **1a** (Table 1, entry 11) shows that the two enantiomers of methylene norcamphor have significantly different reactivity in this catalytic system. Therefore kinetic resolution of alkylidene norcamphors employing Cu(I)/(S)-L5-catalyzed cycloaddition should be worthy of our further investigation. In the early study of treating 0.4 mmol of racemic methylene norcamphor **1a** with 0.2 mmol of glycine imino ester **2a** (Table 1, entry 11), when the spirocycloadduct **5a** was

Table 3. Kinetic Resolution of Various *rac*-Alkylidene Norcamphors 1

(Continued on next page)

Entry 9 ^a 5w+3w: 51% y, ^c 2:1 rr 83% ee (major) 1f: 43% y, 99% ee	Entry 10 ^a 5x: 47% y, 93% ee 1g: 46% y, 97% ee C = 51%, ^c S = 116 ^d	Entry 11 ^a 5y: 46% y, 93% ee 1h: 47% y, 94% ee C = 50%, ^c S = 98 ^d	Entry 12 ^a 5z: 42% y, 97% ee 1i: 50% y, 87% ee C = 47%, ^c S = 188 ^d	Entry 13 ^a 5A: 46% y, 94% ee 1j: 46% y, 95% ee C = 50%, ^c S = 121 ^d
Entry 14 ^a 5B: 45% y, 94% ee 1k: 46% y, 91% ee C = 49%, ^c S = 103 ^d	Entry 15 ^a 5C: 46% y, 97% ee 1l: 45% y, 98% ee C = 50%, ^c S = 303 ^d	Entry 16 ^a 5D: 48% y, 96% ee 1m: 45% y, 91% ee C = 49%, ^c S = 156 ^d	Entry 17 ^a 5E: 45% y, 85% ee 1n: 44% y, 90% ee C = 51%, ^c S = 38 ^d	Entry 18 ^a 5F: 47% y, 92% ee 1o: 46% y, 90% ee C = 49%, ^c S = 74 ^d

Table 3. Continued

^aReaction conditions: *rac*-1 (0.4 mmol), **2** (0.6 mmol), Et₃N (0.01 mmol), Cu(I)/(S)-L5 (0.02 mmol) in 2 mL CH₂Cl₂ in 48 hr. Isolated yield was based on **1**, and the maximum possible yield of (1*S*,4*R*)-**1** is 50%. >20:1 dr of **3** was determined by crude ¹H nuclear magnetic resonance. ee of **5** and (1*S*,4*R*)-**1c-1o** was determined by high-performance liquid chromatography, and ee of (1*S*,4*R*)-**1a** and (1*S*,4*R*)-**1b** was determined by gas chromatography.


^bCarried out at -60°C.

^cConversion of (*rac*)-**1** = ee₁/(ee₁ + ee₃).

^dS-factor = ln[(1 - conv)(1 - ee₁)]/ln[(1 - conv)(1 + ee₁)].

^eCarried out at -40°C.

^fThe crystal of (±)-**5u** for X-ray analysis was obtained from the corresponding cycloadduct with (±)-TF-BiphamPhosL5 as the ligand.



Scheme 3. Computed Overall Free Energy Barrier (in kcal/mol) of Formation of the Most Critical Products for the Reactions with 2a, (1R,4S)-1a, and (1S,4R)-1a Catalyzed by Cu(I)-L1 (L1_D) or Cu(I)-L5 (L5_D) in Dichloromethane (DCM) Solution by the Polarizable Continuum Model (PCM)-B3LYP//B3LYP Method

The computed NBO charge for the two reacting carbon atoms in the Cu-azomethine ylide intermediate L5_D is also given in an italic form.

separated in 91% yield (isolated yield based on imino ester 2a) with >20:1 dr and 94% ee, methylene norcamphor 1a was also recovered in 45% yield (isolated yield based on 1a initially used) and 91% ee with high selectivity factor ($S = 103$) albeit within longer reaction time of up to 48 hr. In consideration of the fact that enantioenriched norcamphors are synthetically useful building blocks, we further re-optimized the reaction conditions to develop more efficient kinetic resolution protocol in terms of both the selectivity factor and reaction time. In short, by increasing the feed ratio of imino ester to alkylidene norcamphor and adjusting the reaction temperature (see [Supplemental Information](#) for the details), a variety of racemic alkylidene norcamphors could be resolved more reproducibly with high selectivity factors ($S = 38$ –303) within reduced reaction time (18–24 hr) ([Table 3](#)). Under the re-optimized reaction conditions, terminal methylene norcamphor (*rac*-1a) was resolved efficiently via asymmetric Cu-catalyzed cycloaddition of different aldimine esters with selectivity factors of up to 136 and good yields ([Table 3](#), entries 1–4). Notably, excellent ee values for both spiroadduct 5o and recovered 1a were achieved with high selectivity factors when alanine-derived imino esters 2o were employed as the reaction partner. To better define the substrate scope and limitation with respect to the dipolarophiles, an array of more challenging trisubstituted alkylidene norcamphors were further investigated. (*E*)-benzylidene norcamphors containing various substituents at *para*- or *meta*-position of the phenyl ring were tolerated well, regardless of the electron properties (e.g., electron deficient, electron neutral, or electron rich), affording the desired spirocycloadducts with 93%–97% ee and the recovered norcamphors with 94–99% ee, corresponding to selectivity factors (S) of 98–188. Probably due to disfavored steric hindrance, *ortho*-fluoro-substituted benzylidene norcamphor has detrimental effect on the regioselectivity of the cycloadducts, but still furnishes the recovered norcamphor 1f with an ee value of 99%. Heteroarylidene norcamphors were also well tolerated in this catalytic system ([Table 3](#), entries 14 and 15). Remarkably, 3-pyridin-2-ylidene norcamphor 1l could be resolved efficiently, producing the expected cycloadduct 5C with 97% ee and recovered product 1l with 98% ee, with the highest selectivity factor of 303. Alkyl-substituted alkylidene norcamphors were not viable substrates in this reaction, probably




Figure 2. Computed Structure, the Relative Free Energy, and HOMO Energy of the Cu-Azomethine Ylide Intermediates L1_D, L1_U; L5_D, and L5_U

due to the pretty low reactivity. All the racemic trisubstituted alkylidene norcamphors tested in this work were obtained exclusively with more than 99% (*E*)-geometry via base-promoted condensation between norcamphor and the corresponding aldehyde. Considering that the geometry of C=C double bond has an important influence on the reactivity or stereoselectivity in alkene-involved asymmetric reactions, we further studied the performance of (*Z*)-benzylidene norcamphor **1b**, which could be obtained with 99% configurational purity upon UV light irradiation (Berthelette et al., 1997) of (*E*)-**1b**. Under the same reaction conditions, no reaction took place when racemic (*Z*)-benzylidene norcamphor was tested. No reaction occurred with the racemic methylene camphor as the dipolarophile presumably because the disfavored steric repulsion caused by the bridged 7,7-dimethyl group impedes the approach of the azomethine ylide from the *EXO*-direction. Both racemic methylene *exo*- and *endo*-tricyclo[5.2.1.0^{2,6}]decan-8-one, containing a fused cyclopentane moiety on the norcamphor skeleton, were well tolerated and resolved to afford the corresponding spiroadducts containing seven stereogenic centers and the recovered fused norcamphors with selectivity factors of 156 and 38, respectively (Table 3, entries 16 and 17). *Exo*-**1m** displayed higher reactivity, furnishing the chiral spiro polycyclic adduct with better ee value. Racemic methylene 2-benzonorbornanone **1o** bearing a fused benzene ring was also a viable substrate for this kinetic resolution protocol, providing the cycloadduct **5f** and the recovered **1o** with high enantioselectivity and a selectivity factor of 74 (Table 3, entry 18). The absolute configuration of spirocycloadduct **5b** from methylene norcamphor and **5u** from *para*-bromobenzylidene norcamphor was unambiguously determined by X-ray diffraction crystallography as (1*S*,2*S*,2'*S*,4*R*,5'*R*) and (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*), respectively (see Supplemental Information for the details). The absolute configuration of the recovered methylene norcamphors was assigned as (1*S*,4*R*), which was deduced from the stereochemistry result of kinetic resolution and further confirmed by comparing the optical rotation of **1a** with the data reported in the literature (Krotz and Helmchen, 1994). Those of other spiroadducts and recovered alkylidene norcamphors were deduced based on these results.

To understand the mechanism of the unusual ligand-controlled regioselectivity and kinetic resolution of the cycloaddition reaction, density functional theory (DFT) (B3LYP/6-31G(d)+SDD method) (Wang et al., 2012) calculations were carried out by using Cu(I), substrates **1a** and **2a**, as well as L1 ligand (or L5 for the most important cases) as our system (See Supplemental Information for the details). As shown in Schemes 2 and 3 and Figure 2, the reacting C2 atom of two Cu-azomethine ylide intermediates L1_D and L5_D had a more negative charge (−0.24) and contributed to slightly larger HOMO than the other reacting C4. This result supported the major resonance form I (Scheme 1). For the reaction with (1*R*,4*S*)-**1a**, our computational results showed that intermediate L1_D (using L1 ligand) generally had lower barriers for the cycloaddition toward the *EXO*-direction to the methylene norcamphor than the *ENDO*-direction, owing to the above-mentioned “picket fence effect” (Scheme 2). Moreover, the most kinetically favorable pathway preferred the formation of the normal and major *endo*-selective cycloaddition product **P3a** other than the *exo*-selective **P4a** via the rate-determining Michael-addition-type transition state **3a-L1_D-TS1_{endo}** (Scheme 2 and Figure 3), which had a lower barrier than that for the umpolung-type and minor *endo*-selective cycloaddition product **P5a** via **5a-L1_D-TS1_{endo}** (Michael-addition type) by roughly 3.0 kcal/mol. The norcamphor approached the amine side of L1 ligand and formed a strong hydrogen bond (NH—O: 1.78 Å) in **3a-L1_D-TS1_{endo}**. However, when the norcamphor approached the phosphorus side of L1 ligand to form **P5a**





Figure 3. DFT Calculations

The computed most critical transition states with NBO charge for the two reacting carbon atoms (in an italic form), key bond lengths (in angstrom), and relative free energy (in kcal/mol) for the reactions with **2a**, (1*R*,4*S*)-**1a**, or (1*S*,4*R*)-**1a** catalyzed by Cu(II)-L1 or Cu(II)-L5 in Dichloromethane (DCM) solution by the polarizable continuum model (PCM)-B3LYP//B3LYP method.

in **5a-L1_D-TS1_{endo}**, the amine nitrogen of L1 ligand was found to dissociate from the Cu center and the carbonyl oxygen of the norcamphor coordinated to the metal (Cu–O: 2.14 Å). As the norcamphor was required to approach the phosphorus side of the ligand to afford **P5a**, increasing steric repulsion between the norcamphor and the more bulky phosphine ligand (L2, L3 or L4) should further disfavor the umpolung-type regioselectivity (Table 1). In addition, the reaction of intermediate L1_D with (1*S*,4*R*)-**1a** was computed to have a higher barrier to form **P3a'** by about 2.1 kcal/mol, which demonstrated a lower reactivity of (1*S*,4*R*)-**1a** and explained the observed kinetic resolution.

Interestingly, when replacing L1 ligand by L5 ligand, the most favorable pathway switched to the umpolung regiochemistry to give *endo*-selective **5a** via **5a-L5_D-TS1_{endo}**, which is lower in free energy than the normal regiochemistry to form *endo*-selective **3a** via **3a-L5_D-TS1_{endo}** by ~0.9 kcal/mol (Scheme 3). An electrostatic repulsion between the carbonyl oxygen of the norcamphor and one bromine (Br1) atom of the biphenyl ligand (O–Br: 3.23 Å in **3a-L5_D-TS1_{endo}**, shorter than the sum of their van der Waals radii [3.37 Å]; see Figure 3) was found to weaken the hydrogen bond between the substrate and ligand and, thus, should play a key role in inverting regiocontrol of the cycloaddition. Moreover, the natural bond orbital (NBO) charge of the reacting C2 and C4 atoms were found to become less negatively charged and more negatively charged, respectively, in the key umpolung-type transition states **5a-L1_D-TS1_{endo}** and **5a-L5_D-TS1_{endo}**, showing more contribution of the minor resonance form II (Scheme 1). Furthermore, the reaction of L5_D with (1*S*,4*R*)-**1a** leading to **P5a'** had to overcome a higher barrier height by 1.2 kcal/mol relative to the formation of **P5a** from (1*R*,4*S*)-**1a**. Overall, these computational results were



Scheme 4. Synthetic Versatility of the Present Catalytic System

(A) Scale-up of the kinetic resolution process with as low as 1 mol % catalyst loading.
 (B) Derivatization of recovered optically active alkylidene norbornanone (1*S*,4*R*)-**1b**.
 (C) Facile access to the key intermediate of chiral odorants (*Z*) and (*E*)- β -santalol.

qualitatively consistent with the observed ligand-controlled regioselectivity and kinetic resolution, and also showed the key role of the bromine atoms.

To demonstrate the scalability of this methodology, we carried out the gram-scale kinetic resolution of methylene norcamphor *rac*-**1a** (9.0 mmol, 1.10 g) with imino ester **2a** in the presence of as low as 1 mol % of Cu(I)/(*S*)-L5 catalyst, which furnished (1*S*,4*R*)-**1a** (44% yield, 96% ee) and the spirocycloadduct **5a** (48% yield, 97% ee) with a selectivity factor of 260 at 50% conversion (Scheme 4A). In a similar fashion, benzylidene norcamphor *rac*-**1b** (5.3 mmol, 1.05 g) could also be efficiently resolved with a selectivity factor of 121 at 50% conversion. The synthetic transformations of the resolved benzylidene norcamphor were then evaluated. Luche reduction of the carbonyl group in (1*S*,4*R*)-**1b** with NaBH₄/Ca(OTf)₂ in a highly diastereoselective fashion led to compound *endo*-**6** in 88% yield with the maintained enantioselectivity. Direct hydrogenation of **1b** in the presence of catalytic amount of Pd/C in methanol gave compound *endo*-**7** in 81% yield with exclusive diastereoselectivity control. Subsequent Baeyer-Villiger oxidation of **7** with *meta*-chloroperoxybenzoic acid (*m*-CPBA) in CH₂Cl₂ at room temperature afforded the previously inaccessible bridged lactone **8** in 98% yield without loss of enantiomeric excesses (Scheme 4B). To further demonstrate the potential utility of this methodology, the Cu(I)-catalyzed kinetic resolution of alkylidene norcamphor was successfully applied to the facile synthesis of the key intermediate of (*Z*) and (*E*)- β -santalol (Krotz and Helmchen, 1994) (Scheme 4C). A concise synthetic route was designed to those chiral odorants, which

relies on the highly efficient kinetic resolution of racemic methylenenorcamphor with Cu(I)/(R)-L5 complex, leading to (1*R*,4*S*)-**1a** (40% yield, >99% ee) with excellent efficiency at 54% conversion. (1*R*,4*S*)-**1a** could be readily hydrogenated with Pd/C to deliver compound *endo*-**9** in 99% yield with the maintained enantioselectivity in an excellent diastereoselective manner (>20:1 dr). Treatment of compound **9** with lithium diisopropylamide (LDA) in tetrahydrofuran (THF) followed by the addition of Stowell iodide (Stowell et al., 1983) **10** exclusively afforded the *exo*-alkylation product **11**, the key intermediate for (–)-(*Z*) and (*E*)- β -santalol.

Conclusion

We have developed an expedient kinetic resolution of synthetically important racemic alkylidene norcamphors by Cu(I)-catalyzed umpolung-type 1,3-dipolar cycloaddition of azomethine ylide with the DOS of natural-product-inspired spiro[norbornane-pyrrolidines] containing multiple stereogenic centers. The success of this methodology relies heavily on the rational design, which led to implement the strategy of kinetic resolution, and serendipity, which led to the discovery of a unique ligand-controlled regiospecific cycloaddition, which is especially notable and provides direct experimental evidence for the existence of two zwitterionic resonance forms in metallated azomethine ylide. Beyond the broad utility in organic synthesis, this protocol diversifies the existing chemistry of transition metal-catalyzed 1,3-dipolar cycloadditions of azomethine ylide with rare polarity inversion.

METHODS

All methods can be found in the accompanying [Transparent Methods supplemental file](#).

DATA AND SOFTWARE AVAILABILITY

Crystallographic data have been deposited at the Cambridge Crystallographic Data Center (CCDC) as CCDC 1592399 (tosylated(\pm)-*endo*-**3a**), 1592400 (tosylated *endo*'-**5a**), 1562402 (**5b**), 1562404 (**5s**), 1562405 ((\pm)-**5u**), and 1562406 ((\pm)-**1d**), which can be obtained free of charge from the CCDC via www.ccdc.cam.ac.uk/getstructures.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Transparent Methods, 183 figures, 10 tables, and 6 data files and can be found with this article online at <https://doi.org/10.1016/j.isci.2018.12.010>.

ACKNOWLEDGMENTS

This work was supported by NSFC (21525207, 21772147, 21672096). The Program of Introducing Talents of Discipline to Universities of China (111 Program) and the Shenzhen Nobel Prize Scientists Laboratory Project (C17783101) are also appreciated.

AUTHOR CONTRIBUTIONS

C.-J.W. and C.S. conceived and designed the research. C.S., L.W., and W.-W.D. performed the research. Y.Y. and L.W.C. performed the DFT calculations. C.J.W., L.W.C., and C.S. co-wrote the paper. All authors analyzed the data, discussed the results, and commented on the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: August 29, 2018

Revised: November 15, 2018

Accepted: December 10, 2018

Published: January 25, 2019

REFERENCES

Adrio, J., and Carretero, J.C. (2011). Novel dipolarophiles and dipoles in the metal-catalyzed enantioselective 1,3-dipolar cycloaddition of azomethine ylides. *Chem. Commun.* 47, 6784–6794.

Adrio, J., and Carretero, J.C. (2014). Recent advances in the catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides. *Chem. Commun.* 50, 12434–12446.

Álvarez-Corral, M., Muñoz-Dorado, M., and Rodríguez-García, I. (2008). Silver-mediated synthesis of heterocycles. *Chem. Rev.* 108, 3174–3198.

- Barr, D.A., Grigg, R., and Sridharan, V. (1989). Ti(IV) mediated transesterification and regio- and stereo-specific cycloaddition of imines of α -amino esters. Reversal of normal regiochemistry. *Tetrahedron Lett.* **30**, 4727–4730.
- Berthelette, C., McCooye, C., Leblanc, Y., and Trimble, L.A. (1997). Studies on the dimerization of 2-benzylidene-1-indanone. *J. Org. Chem.* **62**, 4339–4342.
- Cardona, F., Goti, A., and Brandi, A. (2001). Kinetic resolutions by means of cycloaddition reactions. *Eur. J. Org. Chem.* 2999–3011.
- Chen, H.-S.V., and Lipton, S.A. (2006). The chemical biology of clinically tolerated NMDA receptor antagonists. *J. Neurochem.* **97**, 1611–1626.
- Chen, X.-H., Wei, Q., Luo, S.-W., Xiao, H., and Gong, L.-Z. (2009). Organocatalytic synthesis of spiro[pyrrolidin-3,3'-oxindoles] with high enantiopurity and structural diversity. *J. Am. Chem. Soc.* **131**, 13819–13825.
- Christoffers, J., and Baro, A. (2005). *Quaternary Stereocenters: Challenges and Solutions for Organic Synthesis* (Wiley).
- Coldham, I., and Hufton, R. (2005). Intramolecular dipolar cycloaddition reactions of azomethine ylides. *Chem. Rev.* **105**, 2765–2810.
- Corey, E.J., Hartmann, R., and Vatakencherry, P.A. (1962). The synthesis of d,l-b-Santalene and d,l-epi-b-Santalene by stereospecific routes. *J. Am. Chem. Soc.* **84**, 2611–2614.
- Demole, E., Demole, C., and Enggist, P.A. (1976). Chemical investigation of the volatile constituents of East Indian sandalwood oil (*Santalum album* L.). *Helv. Chim. Acta* **59**, 737–747.
- Feng, B., Lu, L.-Q., Chen, J.-R., Feng, G., He, B.-Q., Lu, B., and Xiao, W.-J. (2018). Umpolung of imines enables catalytic asymmetric regio-reversed [3+2] cycloadditions of iminoesters with nitroolefins. *Angew. Chem. Int. Ed.* **57**, 5888–5892.
- Hashimoto, T., and Maruoka, K. (2015). Recent advances of catalytic asymmetric 1,3-dipolar cycloadditions. *Chem. Rev.* **115**, 5366–5412.
- He, Z.-L., Teng, H.-L., and Wang, C.-J. (2013). Fulvenes as effective dipolarophiles in copper(I)-catalyzed [6+3] cycloaddition of azomethine ylides: asymmetric construction of piperidine derivatives. *Angew. Chem. Int. Ed.* **52**, 2934–2938.
- Houk, K.N. (1975). Frontier molecular orbital theory of cycloaddition reactions. *Acc. Chem. Res.* **8**, 361–369.
- Houk, K.N., Sims, J., Watts, C.R., and Luskus, L.J. (1973). Origin of reactivity, regioselectivity, and periselectivity in 1,3-dipolar cycloadditions. *J. Am. Chem. Soc.* **95**, 7301–7315.
- Huisgen, R. (1963). 1,3-dipolar cycloadditions past and future. *Angew. Chem. Int. Ed.* **2**, 565–598.
- Iqbal, Z., Ali, S., Iqbal, J., Abbas, Q., Qureshi, I.Z., and Hameed, S. (2013). Dual action spirobicycloimidazolidine-2,4-diones: Antidiabetic agents and inhibitors of aldose reductase—an enzyme involved in diabetic complications. *Bioorg. Med. Chem. Lett.* **23**, 488–491.
- Kagan, H.B., and Fiaud, J.C. (1988). Kinetic resolution. *Top. Stereochem.* **18**, 249–330.
- Kanemasa, S., Uchida, O., Wada, E., and Yamamoto, H. (1990). Unusual stereo- and regioselectivity observed in cycloadditions of the N-titanated azomethine ylides derived from t-butyl (benzylideneamino)acetate with α,β -unsaturated esters. *Chem. Lett.* **19**, 105–108.
- Krotz, A., and Helmchen, G. (1994). Total syntheses, optical rotations and fragrance properties of sandalwood constituents: (–)-(Z)- and (–)-(E)- β -santalol and their enantiomers, ent- β -santalene. *Liebigs Ann. Chem.* **6**, 601–609.
- Li, Q.-H., We, L., and Wang, C.-J. (2014). Catalytic asymmetric 1,3-dipolar [3+6] cycloaddition of azomethine ylides with 2-Acyl cycloheptatrienes: efficient construction of bridged heterocycles bearing piperidine moiety. *J. Am. Chem. Soc.* **135**, 8685–8692.
- Mangan, D., McNabola, N., Clark, E.H., Bermudez, I., Wonnacott, S., and Southern, J.M. (2016). A new synthesis and preliminary evaluation of some analogues of mercamylamine—a compound with anti-addition properties. *Org. Biomol. Chem.* **14**, 10787–10798.
- Nájera, C., and Sansano, J.M. (2005). Catalytic enantioselective 1,3-dipolar cycloaddition reaction of azomethine ylides and alkenes: the direct strategy to prepare enantioenriched highly substituted proline derivative. *Angew. Chem. Int. Ed.* **44**, 6272–6276.
- Odds, F.C. (2001). Sordarin antifungal agents. *Exp. Opin. Ther. Patents* **11**, 283–294.
- Padwa, A. (1984). *1,3-Dipolar Cycloaddition Chemistry* (Wiley).
- Padwa, A., and Pearson, W.H. (2003). *Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry toward Heterocycles and Natural Products* (Wiley).
- Pandey, G., Banerjee, P., and Gadre, S.R. (2006). Construction of enantiopure pyrrolidine ring system via asymmetric [3+2]-cycloaddition of azomethine ylides. *Chem. Rev.* **106**, 4484–4517.
- Pellissier, H. (2007). Asymmetric 1,3-dipolar cycloadditions. *Tetrahedron* **63**, 3235–3285.
- Pellissier, H. (2011). Catalytic non-enzymatic kinetic resolution. *Adv. Synth. Catal.* **353**, 1611–1666.
- Reinhard, B., Rainer, H., Volker, T., and Hansjorg, U. (1992). Use of a combination of an ace inhibitor with a calcium antagonist in the treatment of proteinuria. *Eur. Pat. Appl.* EP0488059.
- Schreiber, S.L. (2000). Target-oriented and diversity-oriented organic synthesis in drug discovery. *Science* **287**, 1964–1969.
- Stanley, L.M., and Sibi, M.P. (2008). Enantioselective copper-catalyzed 1,3-dipolar cycloadditions. *Chem. Rev.* **108**, 2887–2902.
- Stohler, R., Wahl, F., and Pfaltz, A. (2005). Enantio- and diastereoselective [3+2] cycloadditions of azomethine ylides with Ag(I)-phosphinooxazoline catalysts. *Synthesis* **9**, 1431–1436.
- Stowell, J.C., King, B.T., and Hauck, H.F., Jr. (1983). A simple preparation of α,β -iodoacetal and α,β -iodoketal. *J. Org. Chem.* **48**, 5381–5382.
- Suchocki, J.A., May, E.L., Martin, T.J., George, C., and Martin, B.R. (1991). Synthesis of 2-exo- and 2-endo-mecamylamine analogs. Structure-activity relationships for nicotinic antagonism in the central nervous system. *J. Med. Chem.* **34**, 1003–1010.
- Takayama, H., Jia, Z.-J., Kremer, L., Bauer, J.O., Strohmman, C., Ziegler, S., Antonchick, A.P., and Waldmann, H. (2013). Discovery of inhibitors of the Wnt and hedgehog signaling pathways through the catalytic enantioselective synthesis of an iridoid-inspired compound collection. *Angew. Chem. Int. Ed.* **52**, 12404–12408.
- Vedejs, E., and Jure, M. (2005). Efficiency in nonenzymatic kinetic resolution. *Angew. Chem. Int. Ed.* **44**, 3974–4001.
- Wang, C.-J., Liang, G., Xue, Z.-Y., and Gao, F. (2008). Highly enantioselective 1,3-dipolar cycloaddition of azomethine ylides catalyzed by copper(I)/TF-BiphamPhos complexes. *J. Am. Chem. Soc.* **130**, 17250–17251.
- Wang, M., Wang, C.-J., and Lin, Z. (2012). Copper(I)/TF-BiphamPhos catalyzed reactions of alkylidene bisphosphates and alkylidene malonates with azomethine ylides: Michael addition versus 1,3-dipolar cycloaddition. *Organometallics* **31**, 7870–7876.
- Xu, H., Golz, C., Strohmman, C., Antonchick, A.P., and Waldmann, H. (2016). Enantiodivergent combination of natural product scaffolds enabled by catalytic enantioselective cycloaddition. *Angew. Chem. Int. Ed.* **55**, 7761–7765.
- Xu, S., Zhang, Z.-M., Xu, B., Liu, B., Liu, Y., and Zhang, J. (2018). Enantioselective regio-divergent synthesis of chiral pyrrolidines with two quaternary stereocenters via ligand-controlled copper(I)-catalyzed asymmetric 1,3-dipolar cycloadditions. *J. Am. Chem. Soc.* **140**, 2272–2283.
- Yu, J., Chen, W.-J., and Gong, L.-Z. (2010). Kinetic resolution of racemic 2,3-allenoates by organocatalytic 1,3-dipolar cycloaddition. *Org. Lett.* **12**, 4050–4053.
- Yuan, Y., Zheng, Z.-J., Li, L., Bai, X.-F., Xu, Z., Cui, Y.-M., Cao, J., Yang, K.-F., and Xu, L.-W. (2018). Silicon-based bulky group-tuned parallel kinetic resolution in copper-catalyzed 1,3-dipolar additions. *Adv. Synth. Catal.* **360**, 3002–3008.

ISCI, Volume 11

Supplemental Information

Kinetic Resolution of Alkylidene

Norcamphors *via* a Ligand-Controlled

Umpolung-Type 1,3-Dipolar Cycloaddition

Chong Shen, Yuhong Yang, Liang Wei, Wu-Wei Dong, Lung Wa Chung, and Chun-Jiang Wang

Supplemental Figures for ^1H , ^{13}C and NOESY NMR Spectra and HPLC Spectra




Figure S1. ^1H NMR spectrum of **5a**, related to Table 2.





Figure S2. ^{13}C NMR spectrum of **5a**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   81
Injection Date  : 10/29/2016 12:25:40 PM    Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-51Rac\SC-2-51RAC 2016-10-28 21-24-25\SC-2-ADH-90-10-22ONM-
                    LML.M
Last changed    : 10/29/2016 12:24:25 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-51Rac\SC-2-51RAC 2016-10-28 21-24-25\SC-2-ADH-90-10-22ONM-
                    LML.M (Sequence Method)
Last changed    : 6/16/2017 2:52:17 PM by SYSTEM
                    (modified after loading)
Additional Info  : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution      : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.328	BB	0.4036	2.69613e4	972.11151	49.8290
2	21.726	BB	0.8053	2.71463e4	493.86307	50.1710

Totals : 5.41076e4 1465.97458

Data File E:\DATA\SC\SC-5-33\SC-5-33 2017-05-15 17-26-10\SC-5-33.D
Sample Name: SC-5-33

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   14
Injection Date  : 5/15/2017 5:27:32 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-33\SC-5-33 2017-05-15 17-26-10\SC-2-ADH-90-10-220NM-35MIN-
                  LML.M
Last changed    : 5/15/2017 5:26:10 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-33\SC-5-33 2017-05-15 17-26-10\SC-2-ADH-90-10-220NM-35MIN-
                  LML.M (Sequence Method)
Last changed    : 6/16/2017 2:57:09 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.935	BB	0.4625	1.54707e4	492.44669	96.9206
2	23.800	MM	0.9920	491.53992	8.25880	3.0794

Totals : 1.59622e4 500.70549

Figure S3. HPLC spectrum of 5a, related to Table 2.




Figure S4. ¹H NMR spectrum of **5b**, related to Table 2.





Figure S5. ¹³C NMR spectrum of **5b**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   63
Injection Date  : 11/12/2016 2:12:01 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-56A\SC-2-56A-ASH-95-5 2016-11-11 10-10-39\SC-2-ASH-95-5-
                220NM-1ML.M
Last changed    : 11/12/2016 2:10:39 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-56A\SC-2-56A-ASH-95-5 2016-11-11 10-10-39\SC-2-ASH-95-5-
                220NM-1ML.M (Sequence Method)
Last changed    : 6/3/2017 8:25:05 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
    
```



=====
Area Percent Report
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
    
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.293	BB	0.7806	7588.30518	143.11862	50.0122
2	25.164	MM	1.1146	7584.61230	113.41533	49.9878

Totals : 1.51729e4 256.53395




Figure S7. ¹H NMR spectrum of **5c**, related to **Table 2**.





Figure S8. ¹³C NMR spectrum of **5c**, related to **Table 2**.

=====
Acq. Operator : SYSTEM Seq. Line : 1
Acq. Instrument : 1260 Location : 61
Injection Date : 11/12/2016 12:19:01 AM Inj : 1
 Inj Volume: 5.000 µl
Acq. Method : E:\DATA\SC\SC-2-55A\SC-2-55A-AD 2016-11-11 08-17-41\SC-2-ADH-90-10-DAD-1ML.
M
Last changed : 11/12/2016 12:17:41 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-55A\SC-2-55A-AD 2016-11-11 08-17-41\SC-2-ADH-90-10-DAD-1ML.
M (Sequence Method)
Last changed : 6/3/2017 8:28:43 PM by SYSTEM
(modified after loading)
Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.852	BB	0.3541	1.05875e4	459.02625	49.9002
2	24.706	BB	0.6631	1.06298e4	238.45700	50.0998

Totals : 2.12174e4 697.48325

Data File E:\DATA\SC\SC-2-98\SC-2-98 2016-11-23 22-44-08\SC-2-981.D
Sample Name: SC-2-98B

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   64
Injection Date  : 11/24/2016 3:21:54 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-98\SC-2-98 2016-11-23 22-44-08\SC-2-ADH-90-10-220NM-35MIN-
                  IML.M
Last changed    : 11/24/2016 2:44:08 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-98\SC-2-98 2016-11-23 22-44-08\SC-2-ADH-90-10-220NM-35MIN-
                  IML.M (Sequence Method)
Last changed    : 6/3/2017 8:30:12 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.832	BB	0.5417	2.61814e4	758.56158	97.5340
2	25.275	BB	0.7638	661.94458	10.45325	2.4660

Totals : 2.68434e4 769.01484

Figure S9. HPLC spectrum of **5c**, related to **Table 2**.




Figure S10. ^1H NMR spectrum of **5d**, related to **Table 2**.





Figure S11. ^{13}C NMR spectrum of **5d**, related to **Table 2**.

```

=====
Acq. Operator   : SYSTEM                               Seq. Line :    2
Acq. Instrument : 1260                                 Location  :   71
Injection Date  : 6/4/2017 4:11:54 PM                 Inj       :    1
                                                    Inj Volume: 5.000 µl

Acq. Method    : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-1-ASH-95-5-
                220NM-35MIN.M
Last changed   : 6/4/2017 4:44:06 PM by SYSTEM
                (modified after loading)
Analysis Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-1-ASH-95-5-
                220NM-35MIN.M (Sequence Method)
Last changed   : 6/4/2017 4:54:38 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```


Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.365	BB	1.0263	9953.18359	137.53416	50.0191
2	32.578	MM	1.6737	9945.56934	99.03499	49.9809

Totals : 1.98988e4 236.56915

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                       Location  :   72
Injection Date  : 6/4/2017 4:53:19 PM        Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-1-ASH-95-5-
                220NM-35MIN.M
Last changed    : 6/4/2017 4:44:06 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-1-ASH-95-5-
                220NM-35MIN.M (Sequence Method)
Last changed    : 6/4/2017 5:37:53 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



```
=====
                          Area Percent Report
=====
```

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	18.152	BB	1.0897	3.09856e4	417.08008	98.0133
2	32.726	BB	1.1150	628.07062	6.59519	1.9867

Totals : 3.16137e4 423.67527

Figure S12. HPLC spectrum of 5d, related to Table 2.




Figure S13. ¹H NMR spectrum of **5e**, related to Table 2.





Figure S14. ¹³C NMR spectrum of **5e**, related to Table 2.

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   67
Injection Date  : 11/11/2016 2:22:09 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-62A\SC-2-62A 2016-11-10 22-20-45\SC-1-ASH-90-10-DAD-1ML.M
Last changed    : 11/11/2016 2:20:45 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-62A\SC-2-62A 2016-11-10 22-20-45\SC-1-ASH-90-10-DAD-1ML.M (
Sequence Method)
Last changed    : 6/3/2017 8:38:19 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

```
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.809	MM	0.3740	9799.78125	436.71069	49.9074
2	17.543	MM	0.9290	9836.15918	176.46739	50.0926

Totals : 1.96359e4 613.17809

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   13
Injection Date  : 5/30/2017 9:17:32 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-51-54\SC-5-51-54 2017-05-30 09-16-03\SC-1-ASH-90-10-220NM-
                 30MIN.M
Last changed    : 5/30/2017 9:16:03 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-51-54\SC-5-51-54 2017-05-30 09-16-03\SC-1-ASH-90-10-220NM-
                 30MIN.M (Sequence Method)
Last changed    : 6/3/2017 9:05:01 PM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.394	BB	0.4210	3927.09277	140.99124	96.8526
2	18.262	MM	0.9076	127.61635	2.34348	3.1474

Totals : 4054.70912 143.33472

Figure S15. HPLC spectrum of 5e, related to Table 2.




Figure S16. ¹H NMR spectrum of **5f**, related to Table 2.





Figure S17. ¹³C NMR spectrum of **5f**, related to Table 2.


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   83
Injection Date  : 10/12/2018 5:27:21 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-10-18-19\SC-10-18-19 2018-10-12 17-25-57\SC-2-ADH-70-30-DAD-
                204NM-25MIN-1ML.M
Last changed    : 10/12/2018 5:25:57 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-10-18-19\SC-10-18-19 2018-10-12 17-25-57\SC-2-ADH-70-30-DAD-
                204NM-25MIN-1ML.M (Sequence Method)
Last changed    : 10/30/2018 10:09:17 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```


Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1, Sig=220,4 Ref=355,90, EXT
 Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.357	BB	0.3339	3406.08594	148.89496	50.1254
2	17.650	MM	0.7481	3389.04370	75.50265	49.8746

Totals : 6795.12964 224.39761

=====
Acq. Operator : SYSTEM Seq. Line : 1
Acq. Instrument : 1260 Location : 87
Injection Date : 10/29/2018 9:50:46 PM Inj : 1
 Inj Volume: 5.000 µl
Acq. Method : E:\DATA\SC\SC-10-22\SC-10-22-2 2018-10-29 21-49-15\SC-2-ADH-70-30-22ONM-
 25MIN-1ML.M
Last changed : 10/29/2018 9:49:15 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-10-22\SC-10-22-2 2018-10-29 21-49-15\SC-2-ADH-70-30-22ONM-
 25MIN-1ML.M (Sequence Method)
Last changed : 10/30/2018 10:13:33 PM by SYSTEM
 (modified after loading)
Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.352	BB	0.3377	1.00233e4	431.92621	98.9833
2	17.798	BB	0.3699	102.95480	3.27403	1.0167

Totals : 1.01263e4 435.20023

Figure S18. HPLC spectrum of 5f, related to Table 2.




Figure S19. ¹H NMR spectrum of **5g**, related to Table 2.





Figure S20. ¹³C NMR spectrum of **5g**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                               Seq. Line :    1
Acq. Instrument : 1260                               Location  :   85
Injection Date  : 10/12/2018 4:58:05 PM              Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-10-19A\SC-10-19A-AD-70 2018-10-12 16-56-39\SC-2-ADH-70-30-DAD
                  -1ML.M
Last changed    : 10/12/2018 4:56:39 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-10-19A\SC-10-19A-AD-70 2018-10-12 16-56-39\SC-2-ADH-70-30-DAD
                  -1ML.M (Sequence Method)
Last changed    : 10/30/2018 10:15:12 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By       :      Signal
Multiplier      :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.753	BB	0.2834	3888.39844	200.38562	50.1301
2	15.817	BB	0.5381	3868.21045	100.48194	49.8699

Totals : 7756.60889 300.86756

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   88
Injection Date  : 10/29/2018 10:17:15 PM    Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-10-22\SC-10-22-2 2018-10-29 21-49-15\SC-2-ADH-70-30-22ONM-
                25MIN-1ML.M
Last changed    : 10/29/2018 9:49:15 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-10-22\SC-10-22-2 2018-10-29 21-49-15\SC-2-ADH-70-30-22ONM-
                25MIN-1ML.M (Sequence Method)
Last changed    : 10/30/2018 10:16:38 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By       :      Signal
Multiplier      :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.674	BB	0.2939	2.08546e4	1040.20422	97.0665
2	15.839	BB	0.4449	630.25385	16.75473	2.9335

Totals : 2.14849e4 1056.95895

Figure S21. HPLC spectrum of 5g, related to Table 2.




Figure S22. ¹H NMR spectrum of **5h**, related to Table 2.





Figure S23. ¹³C NMR spectrum of **5h**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   62
Injection Date  : 11/13/2016 2:44:43 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-55B\SC-2-55B-ADH-95-5 2016-11-12 10-43-21\SC-2-ADH-95-5-
                220NM-1ML.M
Last changed    : 11/13/2016 2:43:22 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-55B\SC-2-55B-ADH-95-5 2016-11-12 10-43-21\SC-2-ADH-95-5-
                220NM-1ML.M (Sequence Method)
Last changed    : 6/3/2017 8:47:52 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```


Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.260	BB	0.4462	1.05059e4	351.96869	49.9229
2	28.877	BB	0.7447	1.05383e4	201.66565	50.0771

Totals : 2.10442e4 553.63434

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   64
Injection Date  : 11/26/2016 6:46:08 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-100A\SC-2-100A 2016-11-25 14-44-43\SC-2-ADH-95-5-220NM-
40MIN.M
Last changed    : 11/26/2016 6:44:43 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-100A\SC-2-100A 2016-11-25 14-44-43\SC-2-ADH-95-5-220NM-
40MIN.M (Sequence Method)
Last changed    : 6/3/2017 8:52:57 PM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.860	BB	0.6081	9089.69336	228.97258	96.4986
2	28.613	BB	0.7308	329.81909	5.29420	3.5014

Totals : 9419.51245 234.26678

Figure S24. HPLC spectrum of 5h, related to Table 2.




Figure S25. ¹H NMR spectrum of **5i**, related to Table 2.





Figure S26. ¹³C NMR spectrum of **5i**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                       Location  :   63
Injection Date  : 11/30/2016 2:43:15 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-58B\SC-2-58B-OD-90 2016-11-29 10-41-51\SC-6-ODH-90-10-DAD-
                  LML.M
Last changed    : 11/30/2016 2:41:51 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-58B\SC-2-58B-OD-90 2016-11-29 10-41-51\SC-6-ODH-90-10-DAD-
                  LML.M (Sequence Method)
Last changed    : 6/3/2017 8:56:01 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.387	MM	0.8313	7758.63818	155.54788	50.0589
2	22.552	MM	1.1893	7740.37256	108.47194	49.9411

Totals : 1.54990e4 264.01982

Data File E:\DATA\SC\SC-2-105B\SC-2-105B-OD-90 2016-11-29 11-18-34\SC-2-105B.D
 Sample Name: SC-2-105B-OD-90

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   65
Injection Date  : 11/30/2016 3:20:00 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-105B\SC-2-105B-OD-90 2016-11-29 11-18-34\SC-6-ODH-90-10-DAD
                  -1ML.M
Last changed    : 11/30/2016 3:18:34 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-105B\SC-2-105B-OD-90 2016-11-29 11-18-34\SC-6-ODH-90-10-DAD
                  -1ML.M (Sequence Method)
Last changed    : 6/4/2017 11:14:07 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.718	BB	0.7235	1.61356e4	335.85165	97.6840
2	22.880	MM	1.6828	382.55798	3.78891	2.3160

Totals : 1.65181e4 339.64057

Figure S27. HPLC spectrum of **5i**, related to **Table 2**.




Figure S28. ¹H NMR spectrum of **5j**, related to Table 2.





Figure S29. ¹³C NMR spectrum of **5j**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   62
Injection Date  : 11/30/2016 1:00:52 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method    : E:\DATA\SC\SC-2-58A\SC-2-58A-AD-90 2016-11-29 08-59-27\SC-1-ADH-90-10-DAD-
                IML.M
Last changed   : 11/30/2016 12:59:27 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-58A\SC-2-58A-AD-90 2016-11-29 08-59-27\SC-1-ADH-90-10-DAD-
                IML.M (Sequence Method)
Last changed   : 6/3/2017 9:09:36 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.528	BB	0.4417	7197.94727	247.20734	50.1838
2	19.859	MM	0.8527	7145.23584	139.65518	49.8162

Totals : 1.43432e4 386.86252

```

=====
Acq. Operator   : SYSTEM                       Seq. Line :    1
Acq. Instrument : 1260                        Location  :   64
Injection Date  : 11/30/2016 1:38:14 AM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-105A\SC-2-105A-AD-90 2016-11-29 09-36-48\SC-2-ADH-90-10-
                220NM-35MIN-1ML.M
Last changed    : 11/30/2016 1:36:48 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-105A\SC-2-105A-AD-90 2016-11-29 09-36-48\SC-2-ADH-90-10-
                220NM-35MIN-1ML.M (Sequence Method)
Last changed    : 6/3/2017 9:11:31 PM by SYSTEM
                (modified after loading)
Additional Info  : Peak(s) manually integrated
  
```



```

=====
                        Area Percent Report
=====
  
```

```

Sorted By           :      Signal
Multiplier          :      1.0000
Dilution            :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.776	BB	0.4358	1.86037e4	640.57727	96.6226
2	20.786	BB	0.6269	650.27484	12.17872	3.3774

Totals : 1.92540e4 652.75599

Figure S30. HPLC spectrum of 5j, related to Table 2.


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    5
Acq. Instrument : 1260                        Location  :   73
Injection Date  : 6/5/2017 6:26:01 PM        Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-170605-bu\SC-170605-BU 2017-06-05 16-44-53\SC-2-ADH-90-10-
                220NM-30MIN-1ML.M
Last changed    : 6/5/2017 4:44:53 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170605-bu\SC-170605-BU 2017-06-05 16-44-53\SC-2-ADH-90-10-
                220NM-30MIN-1ML.M (Sequence Method)
Last changed    : 6/5/2017 8:36:55 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.471	MM	0.4238	2678.32300	105.33327	49.9513
2	15.214	BB	0.4838	2683.54980	81.79721	50.0487

Totals : 5361.87280 187.13048


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    6
Acq. Instrument : 1260                      Location  :   74
Injection Date  : 6/5/2017 6:57:27 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-170605-bu\SC-170605-BU 2017-06-05 16-44-53\SC-2-ADH-90-10-
                220NM-30MIN-1ML.M
Last changed    : 6/5/2017 4:44:53 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170605-bu\SC-170605-BU 2017-06-05 16-44-53\SC-2-ADH-90-10-
                220NM-30MIN-1ML.M (Sequence Method)
Last changed    : 6/5/2017 8:38:27 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.469	BB	0.3854	7205.32129	281.66907	97.0994
2	15.411	MM	0.6841	215.24338	5.24432	2.9006

Totals : 7420.56467 286.91338

Figure S33. HPLC spectrum of 5k, related to Table 2.


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                       Location  :   65
Injection Date  : 11/13/2016 10:37:04 AM     Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-70\SC-2-70-ADH-90-10 2016-11-12 18-35-40\SC-2-ADH-90-10-DAD
                                           -1ML.M
Last changed    : 11/13/2016 10:35:40 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-70\SC-2-70-ADH-90-10 2016-11-12 18-35-40\SC-2-ADH-90-10-DAD
                                           -1ML.M (Sequence Method)
Last changed    : 6/3/2017 11:43:56 PM by SYSTEM
                                           (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.875	MM	0.3205	3499.00317	181.92896	50.1422
2	11.334	MM	0.4306	3479.15088	134.67351	49.8578

Totals : 6978.15405 316.60246

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                        Location  :   63
Injection Date  : 12/1/2016 7:59:57 AM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-114\SC-2-109 2016-12-01 07-22-09\SC-2-ADH-90-10-22ONM-35MIN
                  -1ML.M
Last changed    : 12/1/2016 7:22:09 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-109\SC-2-109 2016-12-01 07-22-09\SC-2-ADH-90-10-22ONM-35MIN
                  -1ML.M (Sequence Method)
Last changed    : 6/3/2017 11:46:16 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.672	MM	0.3502	1.30662e4	621.78638	98.4779
2	12.032	MM	0.7140	201.95180	4.71421	1.5221

Totals : 1.32681e4 626.50059

Figure S36. HPLC spectrum of 5l, related to Table 2.




Figure S37. ^1H NMR spectrum of **5m**, related to Table 2.





Figure S38. ^{13}C NMR spectrum of **5m**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   17
Injection Date  : 4/2/2017 8:49:50 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-77B\SC-4-77B-AS-901 2017-04-02 08-48-26\SC-1-ASH-90-10-DAD-
                    IML.M
Last changed    : 4/2/2017 8:48:26 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-77B\SC-4-77B-AS-901 2017-04-02 08-48-26\SC-1-ASH-90-10-DAD-
                    IML.M (Sequence Method)
Last changed    : 6/4/2017 3:13:24 AM by SYSTEM
                    (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.986	MM	0.6069	2.27798e4	625.56281	49.8603
2	15.460	MM	0.7776	2.29075e4	490.98962	50.1397

Totals : 4.56873e4 1116.55243

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                       Location  :   14
Injection Date  : 4/5/2017 11:10:04 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-83\SC-4-83 2017-04-05 23-08-40\SC-1-ASH-90-10-220NM-1ML-
                20MIN.M
Last changed    : 4/5/2017 11:08:40 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-83\SC-4-83 2017-04-05 23-08-40\SC-1-ASH-90-10-220NM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/4/2017 3:04:07 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.799	BB	0.6191	2.35686e4	577.55780	97.6028
2	17.051	BB	0.7913	578.85376	8.58831	2.3972

Totals : 2.41474e4 586.14611

Figure S39. HPLC spectrum of 5m, related to Table 2.




Figure S40. ¹H NMR spectrum of **5n**, related to Table 2.





Figure S41. ¹³C NMR spectrum of **5n**, related to Table 2.

=====

Acq. Operator	: SYSTEM	Seq. Line	: 8
Acq. Instrument	: 1260	Location	: 75
Injection Date	: 6/4/2017 7:14:34 PM	Inj	: 1
		Inj Volume	: 5.000 µl

Acq. Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-1-ASH-90-10-220NM-30MIN.M
Last changed : 6/4/2017 3:54:36 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-1-ASH-90-10-220NM-30MIN.M (Sequence Method)
Last changed : 6/5/2017 8:42:41 PM by SYSTEM
(modified after loading)

Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.079	MM	1.4168	3.99657e4	470.13986	50.0001
2	23.722	MM	1.7954	3.99655e4	371.00281	49.9999

Totals : 7.99312e4 841.14267

```

=====
Acq. Operator   : SYSTEM                               Seq. Line :    9
Acq. Instrument : 1260                                 Location  :   76
Injection Date  : 6/4/2017 7:46:02 PM                 Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method    : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-1-ASH-90-10-
                220NM-30MIN.M
Last changed   : 6/4/2017 3:54:36 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-1-ASH-90-10-
                220NM-30MIN.M (Sequence Method)
Last changed   : 6/5/2017 8:42:41 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.890	MM	1.4420	1.27493e5	1473.53821	96.5719
2	23.959	MM	1.7100	4525.70068	44.11012	3.4281

Totals : 1.32019e5 1517.64833

Figure S42. HPLC spectrum of 5n, related to Table 2.




Figure S43. ¹H NMR spectrum of **5o**, related to **Table 2**.





Figure S44. ¹³C NMR spectrum of **5o**, related to **Table 2**.

```

=====
Acq. Operator   : SYSTEM                               Seq. Line :    1
Acq. Instrument : 1260                               Location  :   31
Injection Date  : 12/4/2016 5:10:04 PM              Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method    : E:\DATA\SC\SC-2-102B\SC-2-102B 2016-12-04 17-08-43\SC-1-ASH-90-10-DAD-1ML.M
Last changed   : 12/4/2016 5:08:43 PM by SYSTEM
Analysis Method: E:\DATA\SC\SC-2-102B\SC-2-102B 2016-12-04 17-08-43\SC-1-ASH-90-10-DAD-1ML.M
                (Sequence Method)
Last changed   : 6/4/2017 3:28:32 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```


Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.379	MM	0.2763	1.45012e4	874.86603	50.0093
2	10.880	MM	1.2352	1.44958e4	195.59187	49.9907

Totals : 2.89970e4 1070.45790

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                      Location  :   73
Injection Date  : 12/5/2016 2:23:10 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-110\SC-2-110 2016-12-05 01-34-33\SC-1-ASH-90-10-220NM-1ML-
                20MIN.M
Last changed    : 12/5/2016 1:34:33 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-110\SC-2-110 2016-12-05 01-34-33\SC-1-ASH-90-10-220NM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/4/2017 3:31:18 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.250	MM	0.3521	660.35010	31.25616	1.6042
2	10.226	BB	1.0170	4.05026e4	605.81183	98.3958

Totals : 4.11630e4 637.06799

Figure S45. HPLC spectrum of **50**, related to Table 2.




Figure S46. ^1H NMR spectrum of **5p**, related to Table 2.





Figure S47. ^{13}C NMR spectrum of **5p**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                       Location  :   74
Injection Date  : 12/5/2016 8:34:34 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-111B\SC-2-111B-AD-70 2016-12-05 08-33-07\SC-2-ADH-70-30-DAD
                  -1ML.M
Last changed    : 12/5/2016 8:33:07 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-111B\SC-2-111B-AD-70 2016-12-05 08-33-07\SC-2-ADH-70-30-DAD
                  -1ML.M (Sequence Method)
Last changed    : 6/4/2017 3:34:18 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.587	MM	0.2991	1.09125e4	608.11237	50.1914
2	9.371	MM	0.4181	1.08293e4	431.73206	49.8086

Totals : 2.17418e4 1039.84442

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   13
Injection Date  : 12/7/2016 7:04:31 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-6\SC-3-6 2016-12-07 19-03-09\SC-2-ADH-70-30-22ONM-25MIN-1ML.M
Last changed    : 12/7/2016 7:03:09 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-6\SC-3-6 2016-12-07 19-03-09\SC-2-ADH-70-30-22ONM-25MIN-1ML.M (Sequence Method)
Last changed    : 6/4/2017 3:36:42 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.583	MM	0.3376	3.67340e4	1813.29407	99.8808
2	9.449	BB	0.2971	43.83621	1.89315	0.1192

Totals : 3.67778e4 1815.18721

Figure S48. HPLC spectrum of 5p, related to Table 2.




Figure S49. ¹H NMR spectrum of **5q**, related to Table 2.





Figure S50. ¹³C NMR spectrum of **5q**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :   13
Acq. Instrument : 1260                       Location  :   77
Injection Date  : 6/4/2017 10:03:37 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-2-ADH-97-3-
                : 220NM-40MIN.M
Last changed    : 6/4/2017 10:37:50 PM by SYSTEM
                : (modified after loading)
Analysis Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-2-ADH-97-3-
                : 220NM-40MIN.M (Sequence Method)
Last changed    : 6/5/2017 8:49:45 PM by SYSTEM
                : (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	31.139	BB	0.8509	3906.25781	65.39045	50.0133
2	34.720	BB	0.9147	3904.18262	58.79784	49.9867

Totals : 7810.44043 124.18829

```

=====
Acq. Operator   : SYSTEM                               Seq. Line : 14
Acq. Instrument : 1260                               Location  : 78
Injection Date  : 6/4/2017 10:50:05 PM              Inj       : 1
                                                    Inj Volume: 5.000 µl
Acq. Method    : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-2-ADH-97-3-
                220NM-40MIN.M
Last changed   : 6/4/2017 10:37:50 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-2-ADH-97-3-
                220NM-40MIN.M (Sequence Method)
Last changed   : 6/5/2017 8:49:45 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	30.499	MM	1.0024	8050.09863	133.84961	97.9675
2	34.222	MM	0.9854	167.01291	2.82470	2.0325

Totals : 8217.11154 136.67431

Figure S51. HPLC spectrum of 5q, related to Table 2.




Figure S52. ¹H NMR spectrum of **5r**, related to Table 2.





Figure S53. ¹³C NMR spectrum of **5r**, related to Table 2.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   11
Injection Date  : 12/24/2016 12:41:09 AM    Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-23\SC-3-23-OD-90 2016-12-24 00-39-48\SC-6-ODH-90-10-DAD-1ML
                                           .M
Last changed    : 12/24/2016 12:39:49 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-23\SC-3-23-OD-90 2016-12-24 00-39-48\SC-6-ODH-90-10-DAD-1ML
                                           .M (Sequence Method)
Last changed    : 6/4/2017 3:48:46 AM by SYSTEM
                                           (modified after loading)
Additional Info  : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.341	MM	0.3040	8805.00684	482.73367	50.0162
2	8.538	VB	0.3355	8799.30664	400.28638	49.9838

Totals : 1.76043e4 883.02005

Data File E:\DATA\SC\SC-3-40\SC-3-40 2016-12-24 01-08-56\SC-3-402.D
 Sample Name: SC-3-40

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                      Location  :   12
Injection Date  : 12/24/2016 1:52:28 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-40\SC-3-40 2016-12-24 01-08-56\SC-6-ODH-95-5-214NM-1ML-
                20MIN.M
Last changed    : 12/24/2016 1:08:56 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-40\SC-3-40 2016-12-24 01-08-56\SC-6-ODH-95-5-214NM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/4/2017 3:51:58 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=214,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.645	MM	0.2381	28.87121	2.02056	0.0809
2	9.095	BB	0.3670	3.56509e4	1464.29285	99.9191

Totals : 3.56798e4 1466.31341

Figure S54. HPLC spectrum of 5r, related to Table 2.




Figure S55. ¹H NMR spectrum of **1a**, related to **Table 3**.





Figure S56. ¹³C NMR spectrum of **1a**, related to **Table 3**.

Data File E:\DATA\SC\SC-2-71\SC-2-71 2016-11-05 21-15-37\3.D
 Sample Name: SC-2-71

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    4
Acq. Instrument : 1260                      Location  :   63
Injection Date  : 11/6/2016 2:05:38 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-71\SC-2-71 2016-11-05 21-15-37\SC-2-ADH-90-10-220NM-35MIN-
                    LML.M
Last changed    : 11/6/2016 12:15:37 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-71\SC-2-71 2016-11-05 21-15-37\SC-2-ADH-90-10-220NM-35MIN-
                    LML.M (Sequence Method)
Last changed    : 7/18/2017 11:24:55 PM by SYSTEM
                    (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.482	BB	0.4626	2.60106e4	818.85400	97.0178
2	22.684	MM	0.9236	799.53644	14.42819	2.9822

Totals : 2.68102e4 833.28219

Figure S58. HPLC spectrum of 5a, related to Table 3.

```

=====
Acq. Operator   : LHC                               Seq. Line :    1
Acq. Instrument : Instrument 2                       Location  : Vial 101
Injection Date  : 18-Nov-16, 09:13:35              Inj       :    1
                                                    Inj Volume: 1 µl
Acq. Method     : D:\GC\SC\Data\SC-2-90-14H\SC-2-90-14H 2016-11-18 09-12-13\CS-1000-150C-
                IML-10MIN.M
Last changed    : 11/9/2016 10:01:13 PM by LHC
Analysis Method : D:\GC\CX\METHOD\CS-1000-180C-IML-1.M
Last changed    : 6/22/2017 10:02:49 AM by DUW
                (modified after loading)
=====
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: FID1 A,

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	4.750	MM	0.0545	4.24453	1.29729	1.38220
2	4.953	MM	0.0634	302.84061	79.56886	98.61780


Totals : 307.08514 80.86615

=====
 *** End of Report ***

Figure S59. HPLC spectrum of **1a**, related to **Table 3**.

Data File E:\DATA\SC\SC-2-90\SC-2-90 2016-11-18 16-30-59\SC-2-902.D
Sample Name: SC-2-90A

```
=====
Acq. Operator   : SYSTEM                               Seq. Line :    3
Acq. Instrument : 1260                               Location  :   64
Injection Date  : 11/19/2016 9:45:12 AM              Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-90\SC-2-90 2016-11-18 16-30-59\SC-1-ASH-95-5-22ONM-35MIN.M
Last changed    : 11/19/2016 8:30:59 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-90\SC-2-90 2016-11-18 16-30-59\SC-1-ASH-95-5-22ONM-35MIN.M
                (Sequence Method)
Last changed    : 6/4/2017 4:00:25 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



```
=====
                          Area Percent Report
=====
```

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.548	BB	0.7806	2.82635e4	532.19116	97.0411
2	26.747	BB	0.8960	861.79474	11.46468	2.9589

Totals : 2.91253e4 543.65584

Figure S60. HPLC spectrum of **5b**, related to Table 3.

```

=====
Acq. Operator   : LHC                               Seq. Line :    1
Acq. Instrument : Instrument 2                       Location  : Vial 101
Injection Date  : 18-Nov-16, 10:46:56              Inj       :    1
                                                    Inj Volume: 1 µl
Acq. Method    : D:\GC\SC\DATA\SC-2-90B-16H\SC-2-90B-16H 2016-11-18 10-45-58\CS-1000-150C-
                IML-10MIN.M
Last changed   : 11/9/2016 10:01:13 PM by LHC
Analysis Method : D:\GC\CX\METHOD\CS-1000-180C-IML-1.M
Last changed   : 6/22/2017 10:07:56 AM by DWU
                (modified after loading)
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: FID1 A,

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	4.741	MM	0.0580	10.73233	3.08488	3.53942
2	4.945	MM	0.0634	292.49060	76.84565	96.46058


Totals : 303.22293 79.93053

=====
 *** End of Report ***

Figure S61. HPLC spectrum of 1a, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    4
Acq. Instrument : 1260                       Location  :   64
Injection Date  : 11/22/2016 2:52:35 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method    : E:\DATA\SC\SC-2-94\SC-2-94 2016-11-21 20-57-32\SC-2-ADH-95-5-220NM-40MIN.M
Last changed   : 11/22/2016 12:57:33 PM by SYSTEM
Analysis Method: E:\DATA\SC\SC-2-94\SC-2-94 2016-11-21 20-57-32\SC-2-ADH-95-5-220NM-40MIN.M
                (Sequence Method)
Last changed   : 6/4/2017 4:04:52 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.953	BB	0.6425	9873.51660	238.74211	97.4101
2	29.459	MM	1.1078	262.51691	3.94956	2.5899

Totals : 1.01360e4 242.69167

Figure S62. HPLC spectrum of 5h, related to Table 3.

Data File D:\GC\SC\DATA\SC-2-92B\SC-2-92B 2016-11-20 15-56-47\102F0201.D
Sample Name: SC-2-93B

```
=====
Acq. Operator   : LHC                               Seq. Line :    2
Acq. Instrument : Instrument 2                       Location  : Vial 102
Injection Date  : 20-Nov-16, 16:08:38              Inj       :    1
                                                    Inj Volume: 1 µl
Acq. Method     : D:\GC\SC\DATA\SC-2-92B\SC-2-92B 2016-11-20 15-56-47\CS-1000-150C-1ML-
                  10MIN.M
Last changed    : 11/9/2016 10:01:13 PM by LHC
Analysis Method : D:\GC\CX\METHOD\CS-1000-180C-1ML-1.M
Last changed    : 6/22/2017 10:11:12 AM by DW0
                  (modified after loading)
=====
```



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: FID1 A,

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	4.738	BB	0.0543	8.69957	2.51797	1.35116
2	4.935	BB	0.0598	635.15985	165.54564	98.64884

Totals : 643.85942 168.06360

=====
*** End of Report ***

Instrument 2 6/22/2017 10:11:20 AM DW0


Page 1 of 1

Figure S63. HPLC spectrum of 1a, related to Table 3.

Data File E:\DATA\SC\SC-5-17\SC-5-17 2017-05-06 22-50-33\SC-5-172.D
 Sample Name: SC-5-17B-18H

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                        Location  :   16
Injection Date  : 5/6/2017 11:49:23 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-17\SC-5-17 2017-05-06 22-50-33\SC-1-ASH-90-10-220NM-1ML-15MIN.M
Last changed    : 5/6/2017 10:50:33 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-17\SC-5-17 2017-05-06 22-50-33\SC-1-ASH-90-10-220NM-1ML-15MIN.M (Sequence Method)
Last changed    : 6/4/2017 4:11:03 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.604	BB	0.2612	521.08728	29.48012	2.9931
2	11.324	BBA	1.1293	1.68887e4	215.03746	97.0069

Totals : 1.74098e4 244.51758

Figure S64. HPLC spectrum of **50**, related to **Table 3**.




Figure S65. ¹H NMR spectrum of **1b**, related to Table 3.





Figure S66. ¹³C NMR spectrum of **1b**, related to Table 3.

```

=====
Acq. Operator   : LHC                      Seq. Line :    1
Acq. Instrument : Instrument 2              Location  : Vial 101
Injection Date  : 24-Aug-16, 21:24:31      Inj       :    1
                                           Inj Volume: 1 µl
Acq. Method     : D:\GC\SC\DATA\SC-1-8\SC-1-8 2016-08-24 21-23-23\CS-1000-180C-1ML.M
Last changed    : 8/24/2016 8:58:35 PM by LHC
Analysis Method : D:\GC\CX\METHOD\CS-1000-180C-1ML-1.M
Last changed    : 6/22/2017 9:48:41 AM by DWW
                 (modified after loading)
=====

```



=====
Area Percent Report
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs

```

Signal 1: FID1 A,


Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	29.137	MM	0.2820	2052.20386	121.26871	50.05061
2	30.773	MM	0.3062	2048.05322	111.49104	49.94939

Totals : 4100.25708 232.75975

=====
*** End of Report ***

```
=====
Acq. Operator   : LHC                               Seq. Line :    1
Acq. Instrument : Instrument 2                       Location  : Vial 101
Injection Date  : 26-Sep-16, 14:52:52              Inj       :    1
                                                    Inj Volume: 1 µl

Acq. Method     : D:\GC\SC\DATA\SC-2-20\SC-2-20C 2016-09-26 14-51-56\CS-1000-180C-1ML-45MIN.
M
Last changed    : 9/15/2016 11:39:41 AM by LHC
Analysis Method : D:\GC\CX\METHOD\CS-1000-180C-1ML-1.M
Last changed    : 6/22/2017 9:52:21 AM by DWU
                (modified after loading)
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
```

Signal 1: FID1 A,

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	29.134	MM	0.2691	20.79435	1.28800	2.78804
2	30.759	MM	0.3049	725.04578	39.63926	97.21196

```
Totals :                745.84012  40.92726
```

=====
*** End of Report ***

Figure S67. HPLC spectrum of 2b, related to Table 3.




Figure S68. ^1H NMR spectrum of **5s**, related to Table 3.





Figure S69. ^{13}C NMR spectrum of **5s**, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                       Location  :   11
Injection Date  : 9/30/2016 11:43:34 AM      Inj       :    1
                                           Inj Volume: 10.000 µl
Acq. Method    : E:\DATA\SC\SC-2-23\SC-2-23 2016-09-29 20-42-11\SC-ASH-90-10-25MIN.M
Last changed   : 9/30/2016 11:42:11 AM by SYSTEM
Analysis Method: E:\DATA\SC\SC-2-23\SC-2-23 2016-09-29 20-42-11\SC-ASH-90-10-25MIN.M (
Sequence Method)
Last changed   : 6/3/2017 9:21:00 AM by SYSTEM
               (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1, Sig=220,4 Ref=355,90, EXT
 Signal has been modified after loading from rawdata file!

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.606	BB	0.3291	2.53283e4	1181.33020	49.9714
2	16.517	MM	1.1469	2.53572e4	368.49432	50.0286

Totals : 5.06855e4 1549.82452




Figure S71. ¹H NMR spectrum of **1c**, related to Table 3.





Figure S72. ¹³C NMR spectrum of **1c**, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   63
Injection Date  : 11/29/2016 12:37:06 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-15C\SC-2-15C-0J-98 2016-11-28 20-35-41\SC-5-0JH-98-2-DAD-
                  LML.M
Last changed    : 11/29/2016 12:35:42 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-15C\SC-2-15C-0J-98 2016-11-28 20-35-41\SC-5-0JH-98-2-DAD-
                  LML.M (Sequence Method)
Last changed    : 6/4/2017 4:15:53 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```


Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.950	MM	0.2637	6139.87939	388.00522	49.9601
2	12.740	BB	0.2714	6149.68896	342.69366	50.0399

Totals : 1.22896e4 730.69888


```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   65
Injection Date  : 12/1/2016 12:02:08 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-114\SC-2-114-S 2016-11-30 23-39-17\SC-5-0JH-98-2-300NM-1ML-20MIN.M
Last changed    : 11/30/2016 11:39:17 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-114\SC-2-114-S 2016-11-30 23-39-17\SC-5-0JH-98-2-300NM-1ML-20MIN.M (Sequence Method)
Last changed    : 6/4/2017 4:17:56 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



```
=====
                          Area Percent Report
=====
```

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.995	BB	0.2319	795.39307	51.88279	1.5593
2	12.420	BB	0.3061	5.02152e4	2440.30078	98.4407

Totals : 5.10105e4 2492.18357

Figure S73. HPLC spectrum of **1c**, related to Table 3.




Figure S74. ^1H NMR spectrum of **5t**, related to **Table 3**.





Figure S75. ^{13}C NMR spectrum of **5t**, related to **Table 3**.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   62
Injection Date  : 11/14/2016 12:11:47 PM    Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method    : E:\DATA\SC\SC-2-42A\SC-2-42A-ASH-90-10 2016-11-13 20-10-27\SC-1-ASH-90-10-
                DAD-1ML.M
Last changed   : 11/14/2016 12:10:27 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-42A\SC-2-42A-ASH-90-10 2016-11-13 20-10-27\SC-1-ASH-90-10-
                DAD-1ML.M (Sequence Method)
Last changed   : 6/3/2017 9:38:50 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.478	BB	0.3717	1.84074e4	756.95520	49.9355
2	17.446	MM	1.7170	1.84550e4	179.13693	50.0645

Totals : 3.68624e4 936.09213

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   67
Injection Date  : 12/1/2016 1:27:31 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-114\SC-2-114-P-8H 2016-12-01 01-04-43\SC-1-ASH-90-10-220NM-
LML-20MIN.M
Last changed    : 12/1/2016 1:04:43 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-114\SC-2-114-P-8H 2016-12-01 01-04-43\SC-1-ASH-90-10-220NM-
LML-20MIN.M (Sequence Method)
Last changed    : 7/12/2017 10:17:31 PM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.347	BB	0.3316	4.74010e4	2188.93872	96.4888
2	16.726	BB	0.9415	1724.90381	21.81492	3.5112

Totals : 4.91259e4 2210.75364

Figure S76. HPLC spectrum of **5t**, related to **Table 3**.




Figure S77. ^1H NMR spectrum of **1d**, related to Table 3.





Figure S78. ^{13}C NMR spectrum of **1d**, related to Table 3.

Data File E:\DATA\SC\SC-2-13C\SC-2-13C-OJ-98 2016-11-28 20-02-24\SC-2-13C.D
 Sample Name: SC-2-13C-OJ-98

```

=====
Acq. Operator   : SYSTEM                               Seq. Line :    1
Acq. Instrument : 1260                               Location  :   62
Injection Date  : 11/29/2016 12:03:47 PM             Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC-2-13C\SC-2-13C-OJ-98 2016-11-28 20-02-24\SC-5-OJH-98-2-DAD-1ML.M
Last changed    : 11/29/2016 12:02:24 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-13C\SC-2-13C-OJ-98 2016-11-28 20-02-24\SC-5-OJH-98-2-DAD-
                  1ML.M (Sequence Method)
Last changed    : 6/4/2017 4:22:41 AM by SYSTEM
                  (modified after loading)
Additional Info  : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.128	BB	0.3062	4947.04688	240.25314	49.9844
2	14.550	BB	0.3186	4950.12793	234.16545	50.0156

Totals : 9897.17480 474.41859

Data File E:\DATA\SC\SC-2-114\SC-2-114-S 2016-11-30 23-39-17\SC-2-114.D
Sample Name: SC-2-114A-S

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   64
Injection Date  : 11/30/2016 11:40:43 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-114\SC-2-114-S 2016-11-30 23-39-17\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M
Last changed    : 11/30/2016 11:39:17 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-114\SC-2-114-S 2016-11-30 23-39-17\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/4/2017 4:22:01 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.938	BV	0.2823	844.58960	45.97598	1.2907
2	13.779	MM	0.4188	6.45924e4	2570.39966	98.7093

Totals : 6.54370e4 2616.37564

Figure S79. HPLC spectrum of 1d, related to Table 3.




Figure S80. ^1H NMR spectrum of **5u**, related to **Table 3**.





Figure S81. ^{13}C NMR spectrum of **5u**, related to **Table 3**.


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   63
Injection Date  : 11/14/2016 1:25:23 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-42B\SC-2-42B-ASH-90-10 2016-11-13 21-24-00\SC-1-ASH-90-10-
DAD-1ML.M
Last changed    : 11/14/2016 1:24:00 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-42B\SC-2-42B-ASH-90-10 2016-11-13 21-24-00\SC-1-ASH-90-10-
DAD-1ML.M (Sequence Method)
Last changed    : 6/3/2017 9:47:50 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.553	MM	0.3897	2.77408e4	1186.50159	50.1726
2	16.777	MM	1.5977	2.75499e4	287.39413	49.8274

Totals : 5.52907e4 1473.89572

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   66
Injection Date  : 12/1/2016 1:06:07 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-114\SC-2-114-P-8H 2016-12-01 01-04-43\SC-1-ASH-90-10-220NM-
LML-20MIN.M
Last changed    : 12/1/2016 1:04:43 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-114\SC-2-114-P-8H 2016-12-01 01-04-43\SC-1-ASH-90-10-220NM-
LML-20MIN.M (Sequence Method)
Last changed    : 6/3/2017 9:52:26 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.582	MM	0.3934	4.45599e4	1888.04858	96.4328
2	16.812	MM	1.3210	1648.31824	20.79683	3.5672

Totals : 4.62082e4 1908.84541

Figure S82. HPLC spectrum of 5u, related to Table 3.




Figure S83. ¹H NMR spectrum of **1e**, related to Table 3.





Figure S84. ¹³C NMR spectrum of **1e**, related to Table 3.

=====
Acq. Operator : SYSTEM Seq. Line : 1
Acq. Instrument : 1260 Location : 68
Injection Date : 11/28/2016 8:55:19 AM Inj : 1
 Inj Volume: 5.000 µl
Acq. Method : E:\DATA\SC\SC-2-15B\SC-2-15B-0J-98 2016-11-27 16-53-53\SC-5-0JH-98-2-DAD-
LML.M
Last changed : 11/28/2016 8:53:53 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-15B\SC-2-15B-0J-98 2016-11-27 16-53-53\SC-5-0JH-98-2-DAD-
LML.M (Sequence Method)
Last changed : 6/4/2017 4:26:12 AM by SYSTEM
 (modified after loading)
Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.429	BB	0.2122	1.42060e4	1003.01691	49.7720
2	12.140	BB	0.2574	1.43361e4	830.58258	50.2280

Totals : 2.85421e4 1833.59949

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   12
Injection Date  : 12/10/2016 10:39:54 PM    Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-13\SC-3-13-S 2016-12-10 22-17-11\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M
Last changed    : 12/10/2016 10:17:11 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-13\SC-3-13-S 2016-12-10 22-17-11\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/4/2017 4:30:49 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



```
=====
                          Area Percent Report
=====
```

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.969	BV	0.1925	387.10367	30.62425	1.9481
2	11.391	BB	0.2471	1.94840e4	1189.20984	98.0519

Totals : 1.98711e4 1219.83409

Figure S85. HPLC spectrum of **1e**, related to **Table 3**.




Figure S86. ^1H NMR spectrum of **5v**, related to Table 3.





Figure S87. ^{13}C NMR spectrum of **5v**, related to Table 3.

```
=====
Acq. Operator   : SYSTEM                               Seq. Line :    1
Acq. Instrument : 1260                               Location  :   66
Injection Date  : 11/14/2016 3:09:16 PM              Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-47A\SC-2-47A-ASH-90-10 2016-11-13 23-07-52\SC-1-ASH-90-10-
                  DAD-1ML.M
Last changed    : 11/14/2016 3:07:52 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-47A\SC-2-47A-ASH-90-10 2016-11-13 23-07-52\SC-1-ASH-90-10-
                  DAD-1ML.M (Sequence Method)
Last changed    : 6/3/2017 10:00:47 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.878	BB	0.4075	2.55858e4	949.24866	50.0718
2	16.473	MM	1.7289	2.55125e4	245.93962	49.9282

Totals : 5.10983e4 1195.18828

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   16
Injection Date  : 12/10/2016 11:54:58 PM    Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method    : E:\DATA\SC\SC-3-13\SC-3-13-P 2016-12-10 23-32-12\SC-1-ASH-90-10-220NM-1ML-20MIN.M
Last changed   : 12/10/2016 11:32:12 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-13\SC-3-13-P 2016-12-10 23-32-12\SC-1-ASH-90-10-220NM-1ML-20MIN.M (Sequence Method)
Last changed   : 6/3/2017 9:57:23 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.909	MM	0.4632	5.46060e4	1964.88562	96.6377
2	16.925	MM	1.5842	1899.86963	19.98772	3.3623

Totals : 5.65059e4 1984.87334

Figure S88. HPLC spectrum of 5v, related to Table 3.




Figure S89. ¹H NMR spectrum of **1f**, related to Table 3.





Figure S90. ¹³C NMR spectrum of **1f**, related to Table 3.

=====
Acq. Operator : SYSTEM Seq. Line : 1
Acq. Instrument : 1260 Location : 11
Injection Date : 4/5/2017 11:00:25 AM Inj : 1
 Inj Volume: 5.000 µl
Acq. Method : E:\DATA\SC\SC-3-12\SC-3-12-AS-90-DAD 2017-04-05 10-59-02\SC-1-ASH-90-10-DAD
 -1ML.M
Last changed : 4/5/2017 10:59:02 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-12\SC-3-12-AS-90-DAD 2017-04-05 10-59-02\SC-1-ASH-90-10-DAD
 -1ML.M (Sequence Method)
Last changed : 6/4/2017 4:33:24 AM by SYSTEM
 (modified after loading)
Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.163	BB	0.1910	4004.91187	320.04797	50.1550
2	8.059	BB	0.2193	3980.16113	275.93500	49.8450

Totals : 7985.07300 595.98297

Data File E:\DATA\SC\SC-4-84\SC-4-84 2017-04-05 18-27-57\SC-4-841.D
Sample Name: SC-4-84-S

```
=====
Acq. Operator   : SYSTEM                               Seq. Line :    2
Acq. Instrument : 1260                               Location  :   11
Injection Date  : 4/5/2017 6:45:12 PM                Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-84\SC-4-84 2017-04-05 18-27-57\SC-1-ASH-90-10-290NM-15MIN-
                  LML.M
Last changed    : 4/5/2017 6:27:57 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-84\SC-4-84 2017-04-05 18-27-57\SC-1-ASH-90-10-290NM-15MIN-
                  LML.M (Sequence Method)
Last changed    : 6/4/2017 4:36:00 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=290,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.126	BB	0.1944	1.57274e4	1236.70776	99.7928
2	8.034	BB	0.1934	32.65266	2.51566	0.2072

Totals : 1.57601e4 1239.22343

Figure S91. HPLC spectrum of **1f**, related to **Table 3**.




Figure S92. ^1H NMR spectrum of **5w**, related to Table 3.





Figure S93. ^{13}C NMR spectrum of **5w**, related to Table 3.

=====

Acq. Operator	: SYSTEM	Seq. Line	: 2
Acq. Instrument	: 1260	Location	: 16
Injection Date	: 6/3/2017 11:57:20 AM	Inj	: 1
		Inj Volume	: 5.000 µl

Acq. Method : E:\DATA\SC\SC-3-12-16\SC-3-12-16-170603 2017-06-03 11-39-21\SC-1-ASH-90-10-220NM-1ML-20MIN.M
Last changed : 6/3/2017 11:39:21 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-12-16\SC-3-12-16-170603 2017-06-03 11-39-21\SC-1-ASH-90-10-220NM-1ML-20MIN.M (Sequence Method)
Last changed : 6/16/2017 2:49:00 PM by SYSTEM
(modified after loading)

Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.304	MM	0.4495	4029.85547	149.41939	49.9231
2	12.846	MM	1.1670	4042.27661	57.72923	50.0769

Totals : 8072.13208 207.14862

Data File E:\DATA\SC\SC-4-84\SC-4-84 2017-04-05 18-27-57\SC-4-842.D
 Sample Name: SC-4-84-P

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                      Location  :   12
Injection Date  : 4/5/2017 7:01:37 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-84\SC-4-84 2017-04-05 18-27-57\SC-1-ASH-90-10-220NM-1ML-20MIN.M
Last changed    : 4/5/2017 6:27:57 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-84\SC-4-84 2017-04-05 18-27-57\SC-1-ASH-90-10-220NM-1ML-20MIN.M (Sequence Method)
Last changed    : 6/16/2017 2:44:56 PM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.469	MM	0.4376	2.42349e4	922.97101	91.3012
2	13.422	MM	1.0329	2309.01538	37.25814	8.6988

Totals : 2.65439e4 960.22915

Figure S94. HPLC spectrum of 5w, related to Table 3.




Figure S95. ¹H NMR spectrum of **1g**, related to Table 3.





Figure S96. ¹³C NMR spectrum of **1g**, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   64
Injection Date  : 11/28/2016 6:33:02 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-3C\SC-2-3C-0J-98 2016-11-27 14-31-38\SC-5-0JH-98-2-DAD-1ML.
                                           M
Last changed    : 11/28/2016 6:31:38 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-3C\SC-2-3C-0J-98 2016-11-27 14-31-38\SC-5-0JH-98-2-DAD-1ML.
                                           M (Sequence Method)
Last changed    : 6/4/2017 4:39:42 AM by SYSTEM
                                           (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.178	MM	0.1983	2893.13599	243.19118	50.0472
2	12.449	BB	0.2435	2887.68091	180.65796	49.9528

Totals : 5780.81689 423.84914


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   11
Injection Date  : 12/8/2016 9:44:23 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-4\SC-3-4-S 2016-12-08 21-43-04\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M
Last changed    : 12/8/2016 9:43:04 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-4\SC-3-4-S 2016-12-08 21-43-04\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/4/2017 4:42:40 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.587	MM	0.1758	948.15851	89.89142	1.5367
2	11.268	MM	0.3380	6.07534e4	2995.76514	98.4633

Totals : 6.17016e4 3085.65656

Figure S97. HPLC spectrum of **1g**, related to **Table 3**.




Figure S98. ^1H NMR spectrum of **5x**, related to Table 3.





Figure S99. ^{13}C NMR spectrum of **5x**, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   64
Injection Date  : 11/14/2016 1:57:12 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-45A\SC-2-45A-ASH-90-10 2016-11-13 21-55-49\SC-1-ASH-90-10-
DAD-1ML.M
Last changed    : 11/14/2016 1:55:49 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-45A\SC-2-45A-ASH-90-10 2016-11-13 21-55-49\SC-1-ASH-90-10-
DAD-1ML.M (Sequence Method)
Last changed    : 6/3/2017 10:56:38 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.686	BB	0.2916	1.40093e4	731.02673	50.0029
2	12.026	BB	0.9290	1.40077e4	232.14807	49.9971

Totals : 2.80170e4 963.17480

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                       Location  :   14
Injection Date  : 12/8/2016 11:57:05 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-4\SC-3-4-P 2016-12-08 23-13-25\SC-1-ASH-90-10-220NM-1ML-20MIN.M
Last changed    : 12/8/2016 11:13:25 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-4\SC-3-4-P 2016-12-08 23-13-25\SC-1-ASH-90-10-220NM-1ML-20MIN.M (Sequence Method)
Last changed    : 6/3/2017 11:02:58 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.695	MM	0.3316	3.67827e4	1848.61414	96.4927
2	12.293	MM	1.2042	1336.98352	18.50492	3.5073

Totals : 3.81197e4 1867.11906

Figure S100. HPLC spectrum of 5x, related to Table 3.




Figure S101. ¹H NMR spectrum of **1h**, related to Table 3.





Figure S102. ¹³C NMR spectrum of **1h**, related to Table 3.

=====
Acq. Operator : SYSTEM Seq. Line : 1
Acq. Instrument : 1260 Location : 63
Injection Date : 11/28/2016 7:07:47 AM Inj : 1
 Inj Volume: 5.000 µl
Acq. Method : E:\DATA\SC\SC-2-3B\SC-2-3B-0J-98 2016-11-27 15-06-24\SC-5-0JH-98-2-DAD-1ML.
M
Last changed : 11/28/2016 7:06:24 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-3B\SC-2-3B-0J-98 2016-11-27 15-06-24\SC-5-0JH-98-2-DAD-1ML.
M (Sequence Method)
Last changed : 6/4/2017 4:44:23 AM by SYSTEM
(modified after loading)
Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.538	VB	0.1775	2.97270e4	2540.16943	49.9502
2	10.503	BB	0.2196	2.97862e4	2013.80249	50.0498

Totals : 5.95132e4 4553.97192

Data File E:\DATA\SC\SC-3-13\SC-3-13-S 2016-12-10 22-17-11\SC-3-13.D
 Sample Name: SC-3-13-S

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   11
Injection Date  : 12/10/2016 10:18:33 PM    Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-13\SC-3-13-S 2016-12-10 22-17-11\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M
Last changed    : 12/10/2016 10:17:11 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-13\SC-3-13-S 2016-12-10 22-17-11\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/4/2017 4:46:06 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.217	MM	0.1686	892.64343	88.22587	3.0682
2	10.051	BB	0.2082	2.82012e4	2027.93701	96.9318

Totals : 2.90938e4 2116.16288

Figure S103. HPLC spectrum of **1h**, related to **Table 3**.




Figure S104. ¹H NMR spectrum of **5y**, related to Table 3.





Figure S105. ¹³C NMR spectrum of **5y**, related to Table 3.


```

=====
Acq. Operator   : SYSTEM                               Seq. Line :    1
Acq. Instrument : 1260                                 Location  :   67
Injection Date  : 11/14/2016 3:35:49 PM              Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-47B\SC-2-47B-ASH-90-10 2016-11-13 23-34-26\SC-1-ASH-90-10-
                  DAD-1ML.M
Last changed    : 11/14/2016 3:34:26 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-47B\SC-2-47B-ASH-90-10 2016-11-13 23-34-26\SC-1-ASH-90-10-
                  DAD-1ML.M (Sequence Method)
Last changed    : 6/3/2017 11:06:28 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.413	MM	0.2941	3.97404e4	2251.75903	49.7197
2	11.657	BB	1.0093	4.01886e4	608.70270	50.2803

Totals : 7.99290e4 2860.46173

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   15
Injection Date  : 12/10/2016 11:33:34 PM     Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\SC\SC-3-13\SC-3-13-P 2016-12-10 23-32-12\SC-1-ASH-90-10-22ONM-1ML-
                20MIN.M
Last changed    : 12/10/2016 11:32:12 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-13\SC-3-13-P 2016-12-10 23-32-12\SC-1-ASH-90-10-22ONM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/3/2017 11:08:38 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.488	MM	0.3157	3.36262e4	1775.29590	96.4275
2	11.771	BB	0.7996	1245.80261	19.01017	3.5725

Totals : 3.48720e4 1794.30607

Figure S106. HPLC spectrum of **5y**, related to Table 3.




Figure S107. ¹H NMR spectrum of **1i**, related to **Table 3**.





Figure S108. ¹³C NMR spectrum of **1i**, related to **Table 3**.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :   18
Acq. Instrument : 1260                      Location  :   80
Injection Date  : 6/5/2017 12:50:07 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-5-0JH-98-2-
                 300NM-1ML-35MIN.M
Last changed    : 6/4/2017 3:54:36 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-5-0JH-98-2-
                 300NM-1ML-35MIN.M (Sequence Method)
Last changed    : 6/5/2017 8:56:33 PM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	23.782	MM	0.6005	1.90182e4	527.81378	50.0455
2	31.213	BB	0.6980	1.89837e4	400.51453	49.9545

Totals : 3.80019e4 928.32831

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :   19
Acq. Instrument : 1260                      Location  :   81
Injection Date  : 6/5/2017 1:26:30 AM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-5-0JH-98-2-
                 300NM-1ML-35MIN.M
Last changed    : 6/4/2017 3:54:36 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170604-bu\SC-170604-BU 2017-06-04 15-54-34\SC-5-0JH-98-2-
                 300NM-1ML-35MIN.M (Sequence Method)
Last changed    : 6/5/2017 8:56:33 PM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	23.873	BB	0.5135	2009.01843	59.26756	6.2881
2	30.813	BB	0.7163	2.99405e4	596.83704	93.7119

Totals : 3.19495e4 656.10460

Figure S109. HPLC spectrum of **1i**, related to **Table 3**.




Figure S110. ¹H NMR spectrum of **5z**, related to Table 3.





Figure S111. ¹³C NMR spectrum of **5z**, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   65
Injection Date  : 11/14/2016 2:16:37 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-45B\SC-2-45B-ASH-90-10 2016-11-13 22-15-12\SC-1-ASH-90-10-
DAD-1ML.M
Last changed    : 11/14/2016 2:15:12 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-45B\SC-2-45B-ASH-90-10 2016-11-13 22-15-12\SC-1-ASH-90-10-
DAD-1ML.M (Sequence Method)
Last changed    : 6/3/2017 11:11:28 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.585	BB	0.5769	3.22033e4	850.27032	50.0591
2	19.325	MM	1.6814	3.21273e4	318.46292	49.9409

Totals : 6.43305e4 1168.73325

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    4
Acq. Instrument : 1260                       Location  :   15
Injection Date  : 12/9/2016 12:18:31 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-4\SC-3-4-P 2016-12-08 23-13-25\SC-2-ASH-90-10-220NM-25MIN-
                                           LML.M
Last changed    : 12/8/2016 11:13:25 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-4\SC-3-4-P 2016-12-08 23-13-25\SC-2-ASH-90-10-220NM-25MIN-
                                           LML.M (Sequence Method)
Last changed    : 6/3/2017 11:14:19 AM by SYSTEM
                                           (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.608	MM	0.6409	3.57025e4	928.50531	98.5633
2	19.501	MM	1.6818	520.39667	5.15701	1.4367

Totals : 3.62229e4 933.66232

Figure S112. HPLC spectrum of **5z**, related to **Table 3**.




Figure S113. ¹H NMR spectrum of **1j**, related to Table 3.





Figure S114. ¹³C NMR spectrum of **1j**, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   93
Injection Date  : 11/28/2016 3:09:57 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-40A\SC-2-40A-IA-99 2016-11-27 23-08-38\SC-3-IA-99-1-DAD-1ML
                                           .M
Last changed    : 11/28/2016 3:08:38 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-40A\SC-2-40A-IA-99 2016-11-27 23-08-38\SC-3-IA-99-1-DAD-1ML
                                           .M (Sequence Method)
Last changed    : 6/4/2017 4:57:47 AM by SYSTEM
                                           (modified after loading)
Additional Info  : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.844	BV	0.4690	2.36626e4	752.19580	49.8919
2	13.360	VB	0.5331	2.37652e4	658.41266	50.1081

Totals : 4.74278e4 1410.60846

Data File E:\DATA\SC\SC-5-14\SC-5-14 2017-05-06 00-24-58\SC-5-141.D
 Sample Name: SC-5-14A-S

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   11
Injection Date  : 5/6/2017 12:47:14 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-14\SC-5-14 2017-05-06 00-24-58\SC-3-IA-99-1-300NM-1ML-20MIN
                                           .M
Last changed    : 5/6/2017 12:24:58 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-14\SC-5-14 2017-05-06 00-24-58\SC-3-IA-99-1-300NM-1ML-20MIN
                                           .M (Sequence Method)
Last changed    : 6/4/2017 4:58:25 AM by SYSTEM
                                           (modified after loading)
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.410	BB	0.4459	6702.06592	224.73598	97.6798
2	12.921	BB	0.3487	159.19275	5.88305	2.3202

Totals : 6861.25867 230.61903

Figure S115. HPLC spectrum of 1j, related to Table 3.




Figure S116. ¹H spectrum of 5A, related to Table 3.





Figure S117. ¹³C NMR spectrum of 5A, related to Table 3.

=====

Acq. Operator	: SYSTEM	Seq. Line	: 1
Acq. Instrument	: 1260	Location	: 38
Injection Date	: 5/5/2017 8:44:20 AM	Inj	: 1
		Inj Volume	: 5.000 µl

Acq. Method : E:\DATA\SC\SC-2-52A\SC-2-52A 2017-05-05 08-42-56\SC-1-ASH-80-20-220NM-1ML-40MIN.M
Last changed : 5/5/2017 8:42:56 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-52A\SC-2-52A 2017-05-05 08-42-56\SC-1-ASH-80-20-220NM-1ML-40MIN.M (Sequence Method)
Last changed : 6/3/2017 11:20:37 AM by SYSTEM
(modified after loading)

Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.932	BB	0.4722	2.12265e4	679.97308	49.8013
2	12.240	MM	1.7772	2.13959e4	200.65399	50.1987

Totals : 4.26223e4 880.62708

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   32
Injection Date  : 5/5/2017 9:07:11 AM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-14A\SC-5-14A 2017-05-05 09-05-49\SC-1-ASH-80-20-220NM-1ML-
                25MIN.M
Last changed    : 5/5/2017 9:05:49 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-14A\SC-5-14A 2017-05-05 09-05-49\SC-1-ASH-80-20-220NM-1ML-
                25MIN.M (Sequence Method)
Last changed    : 6/3/2017 11:24:53 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.794	MM	0.4744	7.14785e4	2511.26685	96.9390
2	11.800	MM	1.3900	2257.01074	27.06268	3.0610

Totals : 7.37355e4 2538.32952

Figure S118. HPLC spectrum of 5A, related to Table 3.




Figure S119. ¹H NMR spectrum of **1k**, related to Table 3.





Figure S120. ¹³C NMR spectrum of **1k**, related to Table 3.

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   17
Injection Date  : 4/9/2017 4:22:22 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-86B\SC-4-86B-0J-90 2017-04-09 16-20-56\SC-5-0JH-90-10-DAD-
                  LML.M
Last changed    : 4/9/2017 4:20:56 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-86B\SC-4-86B-0J-90 2017-04-09 16-20-56\SC-5-0JH-90-10-DAD-
                  LML.M (Sequence Method)
Last changed    : 6/4/2017 5:07:59 AM by SYSTEM
                  (modified after loading)
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1, Sig=320,4 Ref=355,90, EXT
Signal has been modified after loading from rawdata file!


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.386	BB	0.1587	3378.11938	323.76913	50.0061
2	9.415	BB	0.1820	3377.29370	283.40698	49.9939

Totals : 6755.41309 607.17612

Data File E:\DATA\SC\SC-4-108\SC-4-108 2017-04-23 12-57-31\SC-4-1082.D
 Sample Name: SC-4-108B-S

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                       Location  :   32
Injection Date  : 4/23/2017 1:25:12 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-108\SC-4-108 2017-04-23 12-57-31\SC-5-0JH-90-10-320NM-1ML-12MIN.M
Last changed    : 4/23/2017 12:57:32 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-108\SC-4-108 2017-04-23 12-57-31\SC-5-0JH-90-10-320NM-1ML-12MIN.M (Sequence Method)
Last changed    : 6/4/2017 5:10:21 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=320,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.509	MM	0.1707	890.24921	86.93507	4.5118
2	9.512	BB	0.1899	1.88415e4	1506.41113	95.4882

Totals : 1.97317e4 1593.34620

Figure S121. HPLC spectrum of 1k, related to Table 3.




Figure S122. ^1H NMR spectrum of **5B**, related to Table 3.





Figure S123. ^{13}C NMR spectrum of **5B**, related to Table 3.

=====

Acq. Operator	: SYSTEM	Seq. Line	: 1
Acq. Instrument	: 1260	Location	: 19
Injection Date	: 4/9/2017 5:31:57 PM	Inj	: 1
		Inj Volume	: 5.000 µl

Acq. Method : E:\DATA\SC\SC-4-88B\SC-4-88B-AS-90 2017-04-09 17-30-31\SC-1-ASH-90-10-DAD-1ML.M
Last changed : 4/9/2017 5:30:31 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-88B\SC-4-88B-AS-90 2017-04-09 17-30-31\SC-1-ASH-90-10-DAD-1ML.M (Sequence Method)
Last changed : 6/3/2017 11:41:05 AM by SYSTEM
(modified after loading)

Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.636	MM	0.4587	5384.91455	195.66675	50.0037
2	15.629	MM	1.0129	5384.12256	88.59551	49.9963

Totals : 1.07690e4 284.26226

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    6
Acq. Instrument : 1260                      Location  :   34
Injection Date  : 4/23/2017 2:20:52 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-108\SC-4-108 2017-04-23 12-57-31\SC-1-ASH-90-10-22ONM-1ML-
                20MIN.M
Last changed    : 4/23/2017 12:57:32 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-108\SC-4-108 2017-04-23 12-57-31\SC-1-ASH-90-10-22ONM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/3/2017 11:43:14 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.606	MM	0.4606	1.91718e4	693.72382	97.1851
2	15.384	BB	0.7498	555.30835	8.79283	2.8149

Totals : 1.97271e4 702.51664

Figure S124. HPLC spectrum of 5B, related to Table 3.




Figure S125. ^1H NMR spectrum of **11**, related to **Table 3**.





Figure S126. ^{13}C NMR spectrum of **11**, related to **Table 3**.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                       Location  :   94
Injection Date  : 11/28/2016 11:58:46 AM    Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method    : E:\DATA\SC\SC-2-40B\SC-2-40B-0J-98 2016-11-27 19-57-25\SC-5-0JH-98-2-DAD-
                LML.M
Last changed   : 11/28/2016 11:57:25 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-40B\SC-2-40B-0J-98 2016-11-27 19-57-25\SC-5-0JH-98-2-DAD-
                LML.M (Sequence Method)
Last changed   : 6/4/2017 5:14:34 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.188	BB	0.2590	9856.99023	566.47467	49.8885
2	16.989	BB	0.4243	9901.04590	372.22961	50.1115

Totals : 1.97580e4 938.70428

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   35
Injection Date  : 5/7/2017 4:35:49 PM        Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-20\SC-5-20 2017-05-07 16-34-18\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M
Last changed    : 5/7/2017 4:34:18 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-20\SC-5-20 2017-05-07 16-34-18\SC-5-0JH-98-2-300NM-1ML-
                20MIN.M (Sequence Method)
Last changed    : 6/4/2017 5:12:09 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=300,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.881	BB	0.2684	359.14682	20.10318	0.9957
2	17.923	BB	0.3761	3.57117e4	1421.27563	99.0043

Totals : 3.60708e4 1441.37881

Figure S127. HPLC spectrum of **11**, related to **Table 3**.




Figure S128. ^1H NMR spectrum of **5C**, related to Table 3.





Figure S129. ^{13}C NMR spectrum of **5C**, related to Table 3.


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   92
Injection Date  : 11/15/2016 2:24:27 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-2-52B\SC-2-52B-ASH-90-10 2016-11-14 10-23-11\SC-1-ASH-90-10-
DAD-1ML.M
Last changed    : 11/15/2016 2:23:11 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-2-52B\SC-2-52B-ASH-90-10 2016-11-14 10-23-11\SC-1-ASH-90-10-
DAD-1ML.M (Sequence Method)
Last changed    : 6/3/2017 11:45:29 AM by SYSTEM
                 (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.917	BB	0.5172	2.35650e4	700.90344	50.0115
2	14.254	BB	1.0250	2.35542e4	349.17953	49.9885

Totals : 4.71192e4 1050.08298

```

=====
Acq. Operator   : SYSTEM                               Seq. Line :    4
Acq. Instrument : 1260                               Location  :   37
Injection Date  : 5/7/2017 5:29:36 PM                 Inj       :    1
                                                    Inj Volume: 5.000 µl

Acq. Method    : E:\DATA\SC\SC-5-20\SC-5-20 2017-05-07 16-34-18\SC-1-ASH-90-10-220NM-1ML-
                20MIN.M
Last changed   : 5/7/2017 4:34:18 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-20\SC-5-20 2017-05-07 16-34-18\SC-1-ASH-90-10-220NM-1ML-
                20MIN.M (Sequence Method)
Last changed   : 6/3/2017 11:48:08 AM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.049	BB	0.5513	1.99574e4	539.90472	98.4598
2	15.241	MM	1.3013	312.19092	3.99833	1.5402

Totals : 2.02695e4 543.90305

Figure S130. HPLC spectrum of 5C, related to Table 3.




Figure S131. ^1H NMR spectrum of **1m**, related to **Table 3**.





Figure S132. ^{13}C NMR spectrum of **1m**, related to **Table 3**.

=====
Acq. Operator : SYSTEM Seq. Line : 2
Acq. Instrument : 1260 Location : 11
Injection Date : 2/9/2017 5:56:12 PM Inj : 1
 Inj Volume: 5.000 µl
Acq. Method : E:\DATA\SC\SC-3-91\SC-3-91-AS-98 2017-02-09 17-33-55\SC-2-ASH-98-2-DAD-LML.
M
Last changed : 2/9/2017 5:33:55 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-91\SC-3-91-AS-98 2017-02-09 17-33-55\SC-2-ASH-98-2-DAD-LML.
M (Sequence Method)
Last changed : 6/4/2017 5:18:34 AM by SYSTEM
(modified after loading)
Additional Info : Peak(s) manually integrated



=====
Area Percent Report
=====


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.339	BV	0.2036	8708.80078	648.61542	50.2459
2	8.199	VB	0.2263	8623.55371	577.35950	49.7541

Totals : 1.73324e4 1225.97491

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                       Location  :   12
Injection Date  : 2/17/2017 5:33:43 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-1\SC-4-1-S 2017-02-17 16-50-03\SC-1-ASH-98-2-220NM-1ML-
                  15MIN.M
Last changed    : 2/17/2017 4:50:03 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-1\SC-4-1-S 2017-02-17 16-50-03\SC-1-ASH-98-2-220NM-1ML-
                  15MIN.M (Sequence Method)
Last changed    : 6/4/2017 5:16:59 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.545	BV	0.2359	4.08279e4	2662.42480	95.4632
2	8.466	VB	0.2244	1940.30542	130.51927	4.5368

Totals : 4.27682e4 2792.94408

Figure S133. HPLC spectrum of **1m**, related to **Table 3**.




Figure S134. ¹H NMR spectrum of **5D**, related to Table 3.





Figure S135. ¹³C NMR spectrum of **5D**, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    8
Acq. Instrument : 1260                      Location  :   14
Injection Date  : 2/15/2017 12:30:27 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-111\SC-3-111-29H 2017-02-14 22-05-28\SC-3-IA-90-10-220NM-
60MIN-1ML.M
Last changed    : 2/14/2017 10:05:28 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-111\SC-3-111-29H 2017-02-14 22-05-28\SC-3-IA-90-10-220NM-
60MIN-1ML.M (Sequence Method)
Last changed    : 6/3/2017 7:42:10 PM by SYSTEM
(modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.144	MM	0.5275	7642.99609	241.49182	49.9295
2	24.998	BB	1.0049	7664.58838	106.72145	50.0705

Totals : 1.53076e4 348.21327

Data File E:\DATA\SC\SC-4-1\SC-4-1-P 2017-02-18 10-26-39\SC-4-12.D
 Sample Name: SC-4-1B-P

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                        Location  :   14
Injection Date  : 2/18/2017 11:10:20 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-1\SC-4-1-P 2017-02-18 10-26-39\SC-3-IA-90-10-22ONM-35MIN-
                  LML.M
Last changed    : 2/18/2017 10:26:40 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-1\SC-4-1-P 2017-02-18 10-26-39\SC-3-IA-90-10-22ONM-35MIN-
                  LML.M (Sequence Method)
Last changed    : 6/3/2017 7:45:14 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.248	MM	0.5536	2.77871e4	836.48492	98.0368
2	25.541	MM	0.9801	556.45062	9.46207	1.9632

Totals : 2.83435e4 845.94700

Figure S136. HPLC spectrum of 5D, related to Table 3.




Figure S137. ^1H NMR spectrum of **1n**, related to Table 3.





Figure S138. ^{13}C NMR spectrum of **1n**, related to Table 3.


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   17
Injection Date  : 3/30/2017 5:51:21 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-72\SC-4-72 2017-03-30 17-49-49\SC-1-ASH-98-2-220NM-1ML-
                  LOMIN.M
Last changed    : 3/30/2017 5:49:49 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-72\SC-4-72 2017-03-30 17-49-49\SC-1-ASH-98-2-220NM-1ML-
                  LOMIN.M (Sequence Method)
Last changed    : 6/4/2017 5:20:50 AM by SYSTEM
                  (modified after loading)
Additional Info  : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.269	BB	0.1385	4812.08447	532.27582	94.9692
2	6.350	MM	0.1743	254.91188	24.37050	5.0308

Totals : 5066.99635 556.64632

Figure S139. HPLC spectrum of **1n**, related to **Table 3**.




Figure S140. ^1H NMR spectrum of **5E**, related to **Table 3**.





Figure S141. ^{13}C NMR spectrum of **5E**, related to **Table 3**.

```
=====
Acq. Operator   : SYSTEM                               Seq. Line :    1
Acq. Instrument : 1260                               Location  :   15
Injection Date  : 3/28/2017 4:59:01 PM              Inj       :    1
                                                    Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-66\SC-4-66-AD-90 2017-03-28 16-57-31\SC-2-ADH-90-10-DAD-1ML
.M
Last changed    : 3/28/2017 4:57:31 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-66\SC-4-66-AD-90 2017-03-28 16-57-31\SC-2-ADH-90-10-DAD-1ML
.M (Sequence Method)
Last changed    : 6/3/2017 7:53:52 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



```
=====
                          Area Percent Report
=====
```

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.674	BB	0.5771	6402.79102	168.19650	50.0528
2	25.763	BB	0.8068	6389.29053	116.13609	49.9472

```
Totals :                      1.27921e4  284.33259
```

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                        Location  :   18
Injection Date  : 3/30/2017 6:23:47 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-4-72\SC-4-72 2017-03-30 17-49-49\SC-2-ADH-90-10-220NM-30MIN-
                    LML.M
Last changed    : 3/30/2017 5:49:49 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-4-72\SC-4-72 2017-03-30 17-49-49\SC-2-ADH-90-10-220NM-30MIN-
                    LML.M (Sequence Method)
Last changed    : 6/3/2017 7:52:16 PM by SYSTEM
                    (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.467	MM	0.6539	1.72852e4	440.56662	92.4158
2	25.339	MM	0.9111	1418.52429	25.95018	7.5842

Totals : 1.87037e4 466.51680

Figure S142. HPLC spectrum of 5E, related to Table 3.




Figure S143. ^1H NMR spectrum of **1o**, related to **Table 3**.





Figure S144. ^{13}C NMR spectrum of **1o**, related to **Table 3**.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                      Location  :   82
Injection Date  : 6/5/2017 5:38:38 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-170605-bu\SC-170605-BU 2017-06-05 16-44-53\SC-5-0JH-90-10-
                220NM-25MIN-1ML.M
Last changed    : 6/5/2017 5:32:34 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-170605-bu\SC-170605-BU 2017-06-05 16-44-53\SC-5-0JH-90-10-
                220NM-25MIN-1ML.M (Sequence Method)
Last changed    : 6/5/2017 8:33:34 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.187	BB	0.3021	1.22925e4	612.48792	50.0043
2	18.887	BB	0.4516	1.22904e4	413.70169	49.9957

Totals : 2.45829e4 1026.18961

Data File E:\DATA\SC\SC-3-111\SC-3-111 2017-02-15 11-35-47\SC-3-111.D
 Sample Name: SC-3-111A-S

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   35
Injection Date  : 2/15/2017 11:37:17 AM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-111\SC-3-111 2017-02-15 11-35-47\SC-5-0JH-90-10-22ONM-25MIN
                  -1ML.M
Last changed    : 2/15/2017 11:35:47 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-111\SC-3-111 2017-02-15 11-35-47\SC-5-0JH-90-10-22ONM-25MIN
                  -1ML.M (Sequence Method)
Last changed    : 6/4/2017 5:25:01 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.950	BB	0.2716	1571.54919	88.74484	4.9405
2	18.834	BB	0.5058	3.02377e4	858.80731	95.0595

Totals : 3.18092e4 947.55215

Figure S145. HPLC spectrum of **1o**, related to Table 3.




Figure S146. ^1H NMR spectrum of **5F**, related to Table 3.





Figure S147. ^{13}C NMR spectrum of **5F**, related to Table 3.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                      Location  :   13
Injection Date  : 2/13/2017 7:37:23 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-99\SC-3-99-AS-90 2017-02-13 19-36-00\SC-1-ASH-90-10-DAD-1ML
                                           .M
Last changed    : 2/13/2017 7:36:00 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-99\SC-3-99-AS-90 2017-02-13 19-36-00\SC-1-ASH-90-10-DAD-1ML
                                           .M (Sequence Method)
Last changed    : 6/3/2017 8:10:42 PM by SYSTEM
                                           (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.453	BB	0.5783	7806.53467	207.34389	49.4435
2	17.024	MM	1.0002	7982.25781	133.01588	50.5565

Totals : 1.57888e4 340.35977

Data File E:\DATA\SC\SC-3-111\SC-3-111 2017-02-15 11-35-47\SC-3-1114.D
 Sample Name: SC-3-111A-P

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    5
Acq. Instrument : 1260                        Location  :   37
Injection Date  : 2/15/2017 12:57:05 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-3-111\SC-3-111 2017-02-15 11-35-47\SC-2-ASH-90-10-22ONM-25MIN
                  -1ML.M
Last changed    : 2/15/2017 11:35:47 AM by SYSTEM
Analysis Method : E:\DATA\SC\SC-3-111\SC-3-111 2017-02-15 11-35-47\SC-2-ASH-90-10-22ONM-25MIN
                  -1ML.M (Sequence Method)
Last changed    : 6/3/2017 8:09:57 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```


Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.298	MM	0.6114	6.02256e4	1641.77576	96.0791
2	16.813	VB	0.8640	2457.76025	40.84505	3.9209

Totals : 6.26833e4 1682.62081

Figure S148. HPLC spectrum of 5F, related to Table 3.




1a

Data File D:\GC\SC\DATA\SC-5-53\SC-5-53-51-54 2017-05-29 17-57-44\102F0201.D
 Sample Name: SC-5-51

```

=====
Acq. Operator   : LHC                      Seq. Line :    2
Acq. Instrument : Instrument 2              Location  : Vial 102
Injection Date  : 29-May-17, 18:24:29     Inj       :    1
                                           Inj Volume: 1 µl
Acq. Method     : D:\GC\SC\Data\SC-5-53\SC-5-53-51-54 2017-05-29 17-57-44\CS-1000-150C-1ML-
                  10MIN.M
Last changed    : 5/22/2017 8:58:06 PM by dww
Analysis Method : D:\GC\CX\METHOD\CS-1000-180C-1ML-1.M
Last changed    : 6/22/2017 10:33:36 AM by DWW
                  (modified after loading)
=====
  
```



Area Percent Report

```

=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: FID1 A,

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	4.667	MM	0.0698	8.91909	2.12853	2.95628
2	4.864	MM	0.0830	292.78098	58.82206	97.04372

Totals : 301.70006 60.95059

*** End of Report ***

Figure S149. HPLC spectrum of 1a, related to Table 1.




Figure S150. ¹H NMR spectrum of **3a**, related to **Table 1**.





Figure S151. ¹³C NMR spectrum of **3a**, related to **Table 1**.

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   31
Injection Date  : 4/26/2017 9:46:37 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-8A\SC-5-8A 2017-04-26 21-24-14\SC-2-ADH-90-10-22ONM-35MIN-
                    LML.M
Last changed    : 4/26/2017 9:24:14 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-8A\SC-5-8A 2017-04-26 21-24-14\SC-2-ADH-90-10-22ONM-35MIN-
                    LML.M (Sequence Method)
Last changed    : 7/18/2017 11:17:15 PM by SYSTEM
                    (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```


Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.359	BB	0.5769	9443.14355	248.73465	50.0701
2	28.014	MM	1.1189	9416.68848	140.26993	49.9299
Totals :				1.88598e4	389.00458	

Data File E:\DATA\SC\SC-5-27\SC-5-27 2017-05-09 16-45-13\SC-5-271.D
Sample Name: SC-5-27-1H

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   14
Injection Date  : 5/9/2017 5:23:07 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-27\SC-5-27 2017-05-09 16-45-13\SC-2-ADH-90-10-220NM-35MIN-
                    1ML.M
Last changed    : 5/9/2017 4:45:13 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-27\SC-5-27 2017-05-09 16-45-13\SC-2-ADH-90-10-220NM-35MIN-
                    1ML.M (Sequence Method)
Last changed    : 7/18/2017 11:18:05 PM by SYSTEM
                    (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.606	BB	0.6115	1421.97327	33.54998	5.1503
2	27.758	MM	1.1461	2.61873e4	380.80704	94.8497

Totals : 2.76093e4 414.35702

Figure S152. HPLC spectrum of 3a, related to Table 1.




Figure S153. ^1H NMR spectrum of **6**, related to Scheme 4.





Figure S154. ^{13}C NMR spectrum of **6**, related to Scheme 4.

Sample Name: SC-5-57-RAC-AS-95

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Acq. Instrument : 1260                        Location  :   11
Injection Date  : 5/30/2017 9:58:36 PM       Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\SC\SC-5-57\SC-5-57-RAC-AS-95 2017-05-30 21-57-14\SC-1-ASH-95-5-DAD-
                  LML.M
Last changed    : 5/30/2017 9:57:14 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-57\SC-5-57-RAC-AS-95 2017-05-30 21-57-14\SC-1-ASH-95-5-DAD-
                  LML.M (Sequence Method)
Last changed    : 6/22/2017 3:36:03 PM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
    
```



=====
Area Percent Report
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
    
```


Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.180	BV	0.2158	1.15081e4	814.45087	50.2217
2	8.015	VB	0.2388	1.14065e4	728.02155	49.7783

Totals : 2.29146e4 1542.47241

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                      Location  :   12
Injection Date  : 5/30/2017 10:37:03 PM     Inj       :    1
                                           Inj Volume: 5.000 µl

Acq. Method     : E:\DATA\SC\SC-5-57-55-50\SC-5-57-55-50 2017-05-30 22-19-44\SC-1-ASH-95-5-
                254NM-15MIN.M
Last changed    : 5/30/2017 10:19:44 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-57-55-50\SC-5-57-55-50 2017-05-30 22-19-44\SC-1-ASH-95-5-
                254NM-15MIN.M (Sequence Method)
Last changed    : 6/22/2017 3:37:49 PM by SYSTEM
                (modified after loading)
=====
```



=====
Area Percent Report
=====

```
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
```

Signal 1: DAD1 A, Sig=254,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.202	BV	0.2123	1.35220e4	966.21387	97.5301
2	8.051	VB	0.2349	342.43372	22.08290	2.4699

Totals : 1.38644e4 988.29677

Figure S155. HPLC spectrum of **6**, related to Scheme 4.




Figure S156. ^1H NMR spectrum of **7**, related to Scheme 4.





Figure S157. ^{13}C NMR spectrum of **7**, related to Scheme 4.


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    4
Acq. Instrument : 1260                        Location  :   13
Injection Date  : 5/30/2017 11:09:29 PM      Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-57-55-50\SC-5-57-55-50 2017-05-30 22-19-44\SC-5-0JH-95-5-
                220NM-1ML-15MIN.M
Last changed    : 5/30/2017 10:19:44 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-57-55-50\SC-5-57-55-50 2017-05-30 22-19-44\SC-5-0JH-95-5-
                220NM-1ML-15MIN.M (Sequence Method)
Last changed    : 6/22/2017 3:33:11 PM by SYSTEM
                (modified after loading)
Additional Info : Peak(s) manually integrated
  
```



=====
 Area Percent Report
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.081	MM	0.1702	272.87115	26.72730	2.5599
2	11.855	MM	0.3079	1.03864e4	562.25043	97.4401

Totals : 1.06593e4 588.97773

Figure S158. HPLC spectrum of 7, related to Scheme 4.




Figure S159. ¹H NMR spectrum of **8**, related to Scheme 4.




Figure S160. ¹³C NMR spectrum of **8**, related to Scheme 4.






Figure S161. NOESY NMR spectrum of **8**, related to **Scheme 4**.

Data File E:\DATA\SC\SC-5-58\SC-5-58-1 2017-05-31 17-41-54\SC-5-582.D
Sample Name: SC-5-58

```
=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                       Location  :   14
Injection Date  : 5/31/2017 6:55:38 PM       Inj       :    1
                                           Inj Volume: 5.000 µl
Acq. Method     : E:\DATA\SC\SC-5-58\SC-5-58-1 2017-05-31 17-41-54\SC-1-ASH-90-10-210NM-55MIN
                  -1ML.M
Last changed    : 5/31/2017 5:41:54 PM by SYSTEM
Analysis Method : E:\DATA\SC\SC-5-58\SC-5-58-1 2017-05-31 17-41-54\SC-1-ASH-90-10-210NM-55MIN
                  -1ML.M (Sequence Method)
Last changed    : 6/22/2017 11:45:58 AM by SYSTEM
                  (modified after loading)
Additional Info : Peak(s) manually integrated
=====
```



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=210,4 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.922	BB	1.0707	2.74461e4	340.02341	97.9683
2	44.251	MM	1.3646	569.18195	6.95169	2.0317

Totals : 2.80152e4 346.97510

Figure S162. HPLC spectrum of **8**, related to Scheme 4.




Figure S166. ^1H NMR spectrum of **11**, related to Scheme 4.




Figure S167. ^{13}C NMR spectrum of **11**, related to Scheme 4.

Supplemental Figures for X-ray Structures of the Tosylated Cycloadduct (\pm)-**3a**, Tosylated Cycloadduct ($1S,2S,2'S,4R,5'R$)-**5a**, Cycloadduct ($1S,2S,2'S,4R,5'R$)-**5b**, Tosylated ($1S,2R,2'S,4R,4'R,5'R$)-**5s**, Cycloadduct (\pm)-**5u** and Alkylidene Norcamphor (\pm)-**1d**




Figure S168. X-ray structure of tosylated (\pm)-**3a** (Hydrogen atoms were deleted for clarity), related to **Scheme 1**.

Crystal data for tosylated (\pm)-**3a**: $C_{25}H_{26}ClNO_5S$, $M_r = 487.98$, $T = 296$ K, Monoclinic, space group $P2(1)/n$, $a = 10.1095(14)$, $b = 13.7964(19)$, $c = 17.127(2)$ Å, $V = 2338.0(6)$ Å³, $Z = 4$, 4613 unique reflections, final $R_1 = 0.0390$ and $wR_2 = 0.1074$ for 5863 observed [$I > 2\sigma(I)$] reflections. CCDC 1562399 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).




Figure S169. X-ray structure of tosylated ($1S,2S,2'S,4R,5'R$)-**5a** (Hydrogen atoms were deleted for clarity), related to **Scheme 1**.

Crystal data for tosylated ($1S,2S,2'S,4R,5'R$)-**5a**: $2(C_{25}H_{26}ClNO_5S)$, $M_r = 975.95$, $T = 293$ K, Triclinic, space group $P1$, $a = 7.2009(8)$, $b = 7.6006(9)$, $c = 22.280(3)$ Å, $V = 1212.4(3)$ Å³, $Z = 1$, 6117 unique reflections, final $R_1 = 0.0428$ and $wR_2 = 0.1041$ for 7406 observed [$I > 2\sigma(I)$] reflections, Flack $\chi = 0.04(3)$. CCDC 1562400 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union

Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).




Figure S170. X-ray structure of (1*S*,2*S*,2'*S*,4*R*,5'*R*)-**5b** (Hydrogen atoms were deleted for clarity), related to **Table 2**.

Crystal data for (1*S*,2*S*,2'*S*,4*R*,5'*R*)-**5b**: C₁₈H₂₀ClNO₃, $M_r = 333.80$, $T = 296$ K, Orthorhombic, space group $P2(1)2(1)2(1)$, $a = 6.7241(16)$, $b = 6.8383(16)$, $c = 35.075(8)$ Å, $V = 1612.8(7)$ Å³, $Z = 4$, 3043 unique reflections, final $R_1 = 0.0430$ and $wR_2 = 0.1098$ for 4003 observed [$I > 2\sigma(I)$] reflections, Flack $\chi = -0.01(4)$. CCDC 1562402 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).




Figure S171. X-ray structure of tosylated (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*)-**5s** (Hydrogen atoms were deleted for clarity), related to **Table 3**.

Crystal data for tosylated (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*)-**5s**: C₃₁H₃₀ClNO₅S, $M_r = 564.07$, $T = 296$ K, Orthorhombic, space group $P2(1)2(1)2(1)$, $a = 9.509(3)$, $b = 10.371(3)$, $c = 27.390(7)$ Å, $V = 2701.0(12)$ Å³, $Z = 4$, 6637 unique reflections, final $R_1 = 0.0317$ and $wR_2 = 0.0855$ for 6911 observed [$I > 2\sigma(I)$] reflections, Flack $\chi = 0.004(11)$. CCDC 1562404 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).




Figure S172. X-ray structure of (±)-**5u**
(Hydrogen atoms were deleted for clarity), related to **Table 3**.

Crystal data for (±)-**5u**: $C_{24}H_{23}BrClNO_3$, $M_r = 488.79$, $T = 293$ K, Hexagonal, space group $R-3$, $a = 19.3385(9)$, $b = 19.3385(9)$, $c = 30.7638(12)$ Å, $V = 9963.6(8)$ Å³, $Z = 18$, 2697 unique reflections, final $R_1 = 0.0484$ and $wR_2 = 0.1373$ for 5510 observed [$I > 2\sigma(I)$] reflections. CCDC 1562405 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).




Figure S173. X-ray structure of (±)-**1d**
(Hydrogen atoms were deleted for clarity), related to **Table 3**.

Crystal data for (±)-**1d**: $C_{14}H_{13}BrO$, $M_r = 277.15$, $T = 293$ K, Triclinic, space group $P-1$, $a = 6.4885(14)$, $b = 9.451(2)$, $c = 10.440(2)$ Å, $V = 600.7(2)$ Å³, $Z = 2$, 1874 unique reflections, final $R_1 = 0.0376$ and $wR_2 = 0.0904$ for 2960 observed [$I > 2\sigma(I)$] reflections. CCDC 1562406 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: (+44) 1223-336-033; or deposit@ccdc.cam.ac.uk).

Computational Details

Density functional theory (DFT) calculations were carried out to understand the regioselectivity and key kinetic resolution of the ligand-controlled umpolung-type 1,3-dipolar cycloaddition. B3LYP (Becke, 1993; Lee et al., 1988; Stephens et al., 1994) method combined with a mixed basis set of SDD (Dolg et al., 1987) for Cu and 6-31G(d) (Ditchfield et al., 1971; Hehre et al., 1972; Hariharan and Pople, 1973) for the other atoms were used to optimize all the structures in gas phase. Such method was used to study the related Cu-catalyzed 1,3-dipolar cycloaddition (Wang et al., 2012). The effect of the solvent in DCM was then included by single-point calculation with the polarizable continuum model (PCM) (Tomasi et al., 2005; Scalmani and Frisch, 2010) using UAKS radii and including effects of solute-solvent dispersion interaction energy, solute-solvent repulsion interaction energy and solute cavitation energy. The electron distribution, in terms of natural population analysis (NPA) charges, for the two reacting carbon atoms of the complexes with **L1_D**, **L5_D**, **L1_U** and **L5_U** were calculated. All calculations were carried out by Gaussian 09 package (Gaussian 09, Revision D.01, 2009). All 3D images of the optimized structures were illustrated by CYLview (CYL View, version 1.0 b, 2009).

Table S1. The overall free-energy barrier (in kcal/mol) for the formation of several possible products from the reaction with **1a**-(1*R*,4*S*) and **1a**-(1*S*,4*R*) catalyzed by Cu(I)-**LI** in DCM solution by the PCM-B3LYP//B3LYP method, related to **Scheme 2** and **Scheme 3**.

Product ^a	ΔG_{soln}
L1_D^a	
(1 <i>S</i> ,2 <i>S</i> ,2' <i>R</i> ,4 <i>R</i> ,5' <i>R</i>)- 3a	16.4
(1 <i>R</i> ,2 <i>R</i> ,2' <i>S</i> ,4 <i>S</i> ,5' <i>S</i>)- 3a'	18.5
(1 <i>S</i> ,2 <i>S</i> ,2' <i>S</i> ,4 <i>R</i> ,5' <i>S</i>)- 4a	25.6
(1 <i>R</i> ,2 <i>R</i> ,2' <i>R</i> ,4 <i>S</i> ,5' <i>R</i>)- 4a'	27.0
(1 <i>S</i> ,2 <i>S</i> ,2' <i>S</i> ,4 <i>R</i> ,5' <i>R</i>)- 5a	19.4
(1 <i>R</i> ,2 <i>R</i> ,2' <i>R</i> ,4 <i>S</i> ,5' <i>S</i>)- 5a'	20.4
(1 <i>S</i> ,2 <i>S</i> ,2' <i>R</i> ,4 <i>R</i> ,5' <i>S</i>)- 6a	28.9
(1 <i>R</i> ,2 <i>R</i> ,2' <i>S</i> ,4 <i>S</i> ,5' <i>R</i>)- 6a'	28.9
(1 <i>S</i> ,2 <i>R</i> ,2' <i>S</i> ,4 <i>R</i> ,5' <i>S</i>)- 7a	20.0
(1 <i>R</i> ,2 <i>S</i> ,2' <i>R</i> ,4 <i>S</i> ,5' <i>R</i>)- 7a'	19.5
(1 <i>S</i> ,2 <i>R</i> ,2' <i>R</i> ,4 <i>R</i> ,5' <i>R</i>)- 8a	28.0
(1 <i>R</i> ,2 <i>S</i> ,2' <i>S</i> ,4 <i>S</i> ,5' <i>S</i>)- 8a'	28.6
(1 <i>S</i> ,2 <i>R</i> ,2' <i>R</i> ,4 <i>R</i> ,5' <i>S</i>)- 9a	23.2
(1 <i>R</i> ,2 <i>S</i> ,2' <i>S</i> ,4 <i>S</i> ,5' <i>R</i>)- 9a'	21.6
(1 <i>S</i> ,2 <i>R</i> ,2' <i>S</i> ,4 <i>R</i> ,5' <i>R</i>)- 10a	30.4
(1 <i>R</i> ,2 <i>S</i> ,2' <i>R</i> ,4 <i>S</i> ,5' <i>S</i>)- 10a'	29.0
L1_U^a	
(1 <i>S</i> ,2 <i>S</i> ,2' <i>R</i> ,4 <i>R</i> ,5' <i>R</i>)- 3a	22.7
(1 <i>R</i> ,2 <i>R</i> ,2' <i>S</i> ,4 <i>S</i> ,5' <i>S</i>)- 3a'	22.8
(1 <i>S</i> ,2 <i>S</i> ,2' <i>S</i> ,4 <i>R</i> ,5' <i>R</i>)- 5a	19.7
(1 <i>R</i> ,2 <i>R</i> ,2' <i>R</i> ,4 <i>S</i> ,5' <i>S</i>)- 5a'	28.9
(1 <i>S</i> ,2 <i>R</i> ,2' <i>S</i> ,4 <i>R</i> ,5' <i>S</i>)- 7a	23.3
(1 <i>R</i> ,2 <i>S</i> ,2' <i>R</i> ,4 <i>S</i> ,5' <i>R</i>)- 7a'	28.5

a. The two coordination modes of Ar in the Cu-azomethine ylide intermediates (**L1_D** and **L1_U**) were considered (D: Ar downward; U: Ar upward).

Table S2. The overall free-energy barrier (in kcal/mol) for the formation of the most important products from the reaction with **1a**-(1R,4S) and **1a**-(1S,4R) catalyzed by Cu(I)-**L5_D** in DCM solution by the PCM-B3LYP//B3LYP method, related to **Scheme 3**.

Product	ΔG_{soln}
L5_D^a	
(1S,2S,2'R,4R,5'R)-3a	18.9
(1S,2S,2'S,4R,5'R)-5a	18.0
(1R,2R,2'R,4S,5'S)-5a'	19.2
L5_U^a	
(1S,2S,2'R,4R,5'R)-3a	29.3
(1S,2S,2'S,4R,5'R)-5a	22.3
(1R,2R,2'R,4S,5'S)-5a'	25.9

a. The two coordination modes of Ar in the Cu-azomethine ylide intermediates (**L1_D** and **L1_U**) were considered (D: Ar downward; U: Ar upward).




Figure S174. Optimized structures of Cu(I)-LI intermediates (**L1_D** and **L1_U**) with the key bond lengths (in angstrom), the NPA charge of the two reacting carbons and HOMO energies by the B3LYP method. Their relative free energies (in kcal/mol) in DCM solution are given. All hydrogen atoms were omitted for clarification, related to **Scheme 2** and **Figure 2**.




Figure S175. Optimized transition states for the reaction with **1a**-(1R,4S) catalyzed by **L1_D** in DCM solution by the B3LYP method with the key bond lengths (in angstrom). Their relative free energies (in kcal/mol) in DCM are given. Unimportant hydrogen atoms were omitted for clarification, related to **Scheme 2**.




Figure S176. Optimized transition states for the reaction with **1a**-(1R,4S) catalyzed by **L1_D** in DCM solution by the B3LYP method with the key bond lengths (in angstrom). Their relative free energies (in kcal/mol) in DCM are given. Unimportant hydrogen atoms were omitted for clarification, related to **Scheme 2**.




Figure S177. Optimized transition states for the reaction with **1a**-(1S,4R) catalyzed by **L1D** in DCM solution by the B3LYP method with the key bond lengths (in angstrom). Their relative free energies (in kcal/mol) in DCM are given. Unimportant hydrogen atoms were omitted for clarification, related to **Scheme 3**.




Figure S178. Optimized transition states for the reaction with **1a**-(1S,4R) catalyzed by **L1D** in DCM solution by the B3LYP method with the key bond lengths (in angstrom). Their relative free energies (in kcal/mol) in DCM are given. Unimportant hydrogen atoms were omitted for clarification, related to **Scheme 3**.




Figure S179. Optimized key transition states for the reaction with **1a**-(1R,4S) and **1a**-(1S,4R) catalyzed by **L1_U** in DCM solution by the B3LYP method with the key bond lengths (in angstrom). Their relative free energies (in kcal/mol) in DCM are given. Unimportant hydrogen atoms were omitted for clarification, related to **Scheme 2** and **Scheme 3**.




Figure S180. Optimized structures of Cu(I)-L5 intermediates (**L5_D** and **L5_U**) with the key bond lengths (in angstrom), the NPA charge of the two reacting carbons and HOMO energies by the B3LYP method. Their relative free energy (in kcal/mol) in DCM solution are given. All hydrogen atoms were omitted for clarification, related to **Figure 2** and **Scheme 3**.




Figure S181. Optimized key transition states for the reaction with **1a**-(1R,4S) and **1a**-(1S,4R) catalyzed by **L5_D** in DCM solution by the B3LYP method with the key bond lengths (in angstrom). Their relative free energies (in kcal/mol) in DCM are given. Unimportant hydrogen atoms were omitted for clarification, related to **Scheme 3**.





Figure S183. Optimized key transition states for the reaction with **1a**-(1R,4S) and **1a**-(1S,4R) catalyzed by **L5_U** in DCM solution by the B3LYP method with the key bond lengths (in angstrom). Their relative free energies (in kcal/mol) in DCM are given. Unimportant hydrogen atoms were omitted for clarification, related to **Scheme 3**.

Table S3. The absolute (in Hartree) energies in gas phase and single point energies in DCM solution for the reaction catalyzed by Cu(I)-L1 by the B3LYP method, related to **Scheme 2** and **Scheme 3**.

	E_{gas}	$(E+\text{ZPE})_{\text{gas}}$	G_{gas}	E_{soln}
L1				
L1_D	-3975.508919	-3974.926423	-3975.023118	-3975.52314
L1_U	-3975.506122	-3974.923461	-3975.018880	-3975.520437
1a-(1R,4S)				
1a-(1R,4S)	-386.066275	-385.903069	-385.934594	-386.071059
3a-L1_D-TS1_{endo}	-4361.582085	-4360.833287	-4360.937046	-4361.595674
3a-L1_D-TS2_{endo}	-4361.586368	-4360.835435	-4360.937814	-4361.600515
4a-L1_D-TS1_{exo}	-4361.555589	-4360.807283	-4360.913976	-4361.577559
5a-L1_D-TS1_{endo}	-4361.577078	-4360.829568	-4360.933208	-4361.589614
5a-L1_D-TS2_{endo}	-4361.582363	-4360.832560	-4360.936949	-4361.596926
6a-L1_D-TS1_{exo}	-4361.552071	-4360.804264	-4360.911095	-4361.571714
7a-L1_D-TS1_{endo}	-4361.575110	-4360.828142	-4360.933877	-4361.587674
7a-L1_D-TS2_{endo}	-4361.573629	-4360.824295	-4360.930177	-4361.588277
8a-L1_D-TS1_{exo}	-4361.554115	-4360.806019	-4360.912416	-4361.574074
8a-L1_D-TS2_{exo}	-4361.554124	-4360.804736	-4360.911517	-4361.574689
9a-L1_D-TS1_{endo}	-4361.569399	-4360.821073	-4360.925575	-4361.583639
9a-L1_D-TS2_{endo}	-4361.572217	-4360.822106	-4360.927193	-4361.586313
10a-L1_D-TS1_{exo}	-4361.549101	-4360.801350	-4360.908659	-4361.568782
3a-L1_U-TS1_{endo}	-4361.569396	-4360.822588	-4360.928303	-4361.581683
5a-L1_U-TS1_{endo}	-4361.575519	-4360.826951	-4360.931116	-4361.589744
7a-L1_U-TS1_{endo}	-4361.570523	-4360.822318	-4360.927340	-4361.586281
7a-L1_U-TS2_{endo}	-4361.572054	-4360.82152	-4360.924792	-4361.586839
1a-(1S,4R)				
1a-(1S,4R)	-386.066275	-385.903069	-385.934594	-386.071059
3a'-L1_D-TS1_{endo}	-4361.577085	-4360.829957	-4360.934672	-4361.589709
3a'-L1_D-TS2_{endo}	-4361.582370	-4360.832672	-4360.937282	-4361.597447
4a'-L1_D-TS1_{exo}	-4361.556294	-4360.807835	-4360.913993	-4361.57606
5a'-L1_D-TS1_{endo}	-4361.573865	-4360.825507	-4360.929962	-4361.588062
5a'-L1_D-TS2_{endo}	-4361.581261	-4360.830795	-4360.934205	-4361.595991
6a'-L1_D-TS1_{exo}	-4361.552208	-4360.804294	-4360.910853	-4361.572065
7a'-L1_D-TS1_{endo}	-4361.579153	-4360.830461	-4360.934283	-4361.592828
7a'-L1_D-TS2_{endo}	-4361.578478	-4360.828152	-4360.932141	-4361.592043
8a'-L1_D-TS1_{exo}	-4361.553392	-4360.805264	-4360.909320	-4361.575257
9a'-L1_D-TS1_{endo}	-4361.574283	-4360.826857	-4360.930033	-4361.586508
9a'-L1_D-TS2_{endo}	-4361.574809	-4360.825215	-4360.928952	-4361.589161
10a'-L1_D-TS1_{exo}	-4361.553465	-4360.806179	-4360.913208	-4361.570703
3a'-L1_U-TS1_{endo}	-4361.569348	-4360.821439	-4360.925671	-4361.583984
5a'-L1_U-TS1_{endo}	-4361.559387	-4360.812157	-4360.916755	-4361.573373
7a'-L1_U-TS1_{endo}	-4361.559361	-4360.811209	-4360.915814	-4361.576873
7a'-L1_U-TS2_{endo}	-4361.562077	-4360.811858	-4360.914417	-4361.579022

Table S4. The absolute (in Hartree) energies in gas phase and single point energies in DCM solution for the reaction catalyzed by Cu(I)-**L5** by the B3LYP method, related to **Scheme 3**.

	E_{gas}	$(E+ZPE)_{\text{gas}}$	G_{gas}	E_{soln}
L5				
L5_D	-9117.713339	-9117.150688	-9117.248328	-9117.725244
L5_U	-9117.709710	-9117.147019	-9117.245311	-9117.722830
1a-(1R,4S)				
3a-L5_D-TS1_{endo}	-9503.779903	-9503.051551	-9503.156845	-9503.792486
3a-L5_D-TS2_{endo}	-9503.785237	-9503.054985	-9503.159414	-9503.798144
5a-L5_D-TS1_{endo}	-9503.776854	-9503.049918	-9503.158711	-9503.789010
5a-L5_D-TS2_{endo}	-9503.782951	-9503.053872	-9503.161882	-9503.795381
3a-L5_U-TS1_{endo}	-9503.763335	-9503.035774	-9503.141595	-9503.774688
5a-L5_U-TS1_{endo}	-9503.772176	-9503.044009	-9503.150394	-9503.785862
1a-(1S,4R)				
5a'-L5_D-TS1_{endo}	-9503.777596	-9503.049268	-9503.156014	-9503.790568
5a'-L5_U-TS1_{endo}	-9503.764974	-9503.037612	-9503.144511	-9503.778813

Table S5. Re-optimization Studies for Kinetic Resolution of Alkylidene Norcamphors related to **Table 3**.^a

entry	T (°C)	t (h)	ratio 1a:2a	1a		5a		S ^c
				yield (ee) (%) ^b	yield (ee) (%) ^b	yield (ee) (%) ^b	yield (ee) (%) ^b	
1	-20	2	1:1.5	39(98)	47(87)	65		
2	-20	3	1:1	38(99)	48(88)	82		
3	-20	5	1:0.75	38(99)	47(89)	90		
4	-40	4	1:1	41(97)	46(90)	90		
5	-40	8	1:0.75	43(95)	46(90)	70		
6	-60	35	1:1	40(95)	46(92)	89		
7	-60	56	1:0.75	42(91)	45(93)	88		
8	-60	21	1:1.5	44(92)	46(94)	106		

^a All reactions were carried out with 0.40 mmol of *rac*-**1a** in 2 mL of CH₂Cl₂. ^b Isolated yields based on *rac*-**1a**, >20:1 dr was determined by crude ¹H NMR, and ee value of **5a** and the recovered **1a** were determined by HPLC and GC analysis, respectively. ^c S = ln[(1 - Conv.)/(1 - ee₁)]/ln[(1 - Conv.)/(1 + ee₁)], Conv. = ee₁/(ee₁ + ee₅).

Supplemental Item Legends

Table S6. Cartesian Coordinates for Optimized Structures of reactants, related to **Scheme 2 and Figure 2.**

Table S7. Cartesian Coordinates for Optimized Structures of **L1-1a-(1R,4S)**, related to **Scheme 2.**

Table S8. Cartesian Coordinates for Optimized Structures of **L1-1a-(1S,4R)**, related to **Scheme 2 and Scheme 3.**

Table S9. Cartesian Coordinates for Optimized Structures of **L5-1a-(1R,4S)**, related to **Figure 2 and Scheme 3.**

Table S10. Cartesian Coordinates for Optimized Structures of **L5-1a-(1S,4R)**, related to **Scheme 3.**

Data S1. Crystal Data and Structure Refinement for tosylated (\pm)-endo-**3a**, related to **Scheme 1.**

Data S2. Crystal Data and Structure Refinement for tosylated (\pm)-endo-**5a**, related to **Scheme 1.**

Data S3. Crystal Data and Structure Refinement for **5b**, related to **Table 3.**

Data S4. Crystal Data and Structure Refinement for **5s**, related to **Table 3.**

Data S5. Crystal Data and Structure Refinement for (\pm)-**5u**, related to **Table 3.**


Data S6. Crystal Data and Structure Refinement for (\pm)-**1d**, related to **Table 3.**

Transparent Methods

^1H NMR spectra were recorded on a Bruker 400 MHz spectrometer in CDCl_3 . Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data are reported as (s = single, d = double, t = triple, q = quarter, m = multiple or unresolved, br s = broad single, coupling constant(s) in Hz, integration). ^{13}C NMR spectra were recorded on a Bruker 100 MHz spectrometer in CDCl_3 . Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard. Commercially obtained reagents were used without further purification. Solvents were purified prior to use according to the standard methods. Unless otherwise noted, all reactions were carried out under nitrogen atmosphere. Enantiomeric ratios were determined by chiral-phase HPLC and GC analysis in comparison with authentic racemic materials. 3-Methylene-2-norcamphor **1a** is commercially-available or prepared according to the literature procedure (Kleinfelter and Schleyer, 1973; Fehr et al., 2009). Racemic substituted methylene norcamphors **1b-1l** were synthesized by aldol condensation reaction (Satam et al., 2011). Racemic substituted methylene norcamphors **1m** and **1n** were prepared according to the literature procedure (Kleinfelter and Schleyer, 1973; Ghebreghiorgiset al., 2012), **1o**, **1p** and **1q** was prepared according to the literature procedure (Kleinfelter and Schleyer, 1973; Coe et al., 2004; Berthelette et al., 1997; Chuiko et al., 2002). Chiral ligands **L1-L5** were prepared according our previous procedure (Wang et al., 2008).

General Procedure for the Preparation of Alkylidene Norcamphors


Procedure A: Preparation of Racemic Alkylidene Norcamphors 1b-1l:



In a 100 mL round-bottom flask, norcamphor (5.0 mmol, 1.0 equiv.) and aryl aldehyde (5.0 mmol, 1.0 equiv.) were dissolved with 20 mL ethanol, and then sodium hydroxide solution (10% in ethanol, 2.0 mL) was added dropwise to the solution. The reaction mixture was stirred at room temperature until TLC revealed complete conversion of norcamphor. After reaction completed, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in 20 mL of CH_2Cl_2 and washed with 20 mL of sat. NaCl solution. Organic phase was separated and the aqueous phase was extracted with additional CH_2Cl_2 (2×20 mL).


Combined organic phase was dried over Na_2SO_4 and concentrated under reduced pressure, the crude mixture was purified by silica-gel flash column chromatography to obtain the racemic compounds **1b-1l** in moderate to good yields.


Procedure B: Preparation of Racemic **1m**:



Diethylamine (10.0 mmol, 1.0 equiv.) was added over a 15 min. period to formaldehyde (36% in H_2O , 40.0 mmol, 4.0 equiv.) at 0°C . The resultant mixture was treated over a 33 minutes' period with acetic acid (20.0 mmol, 2.0 equiv.). Once the addition was finished, the temperature was increased to room temperature and the mixture was added over a 22 minutes' period to *exo*-octahydro-5H-4,7-methanoinden-5-one (10.0 mmol, 1.0 equiv.) in the presence of a small amount of BHT at 95°C . The mixture was refluxed for 5 hours and cooled down to room temperature. The yellow mixture was hydrolyzed with aqueous 5% HCl and ice ($\text{pH} = 1$). The aqueous layer was extracted twice with Et_2O , and the combined organic layers were washed with H_2O , aqueous 5% NaOH and twice with brine, dried over Na_2SO_4 and filtered off. Et_2O was distilled under atmospheric pressure to give a crude which was purified by silica-gel flash column chromatography to obtain the racemic compound **1m** in 55% yield.

Procedure C: Preparation of Racemic **1n**:






A solution of dicyclopentadiene (40 mmol, 1.0 equiv.) in THF (3.5 mL) was added over 2 minutes at room temperature to a yellow suspension of mercury(II) acetate (40 mmol, 1.0 equiv.) in THF/H₂O (35 mL/35 mL). After 5 minutes, the reaction mixture became colorless and was stirred at the same temperature for 20 minutes. The reaction was carefully quenched with slow addition of 3 M NaOH (44 mL of an aqueous solution) followed by dropwise addition of 0.5 M NaBH₄ (44 mL of a 3M NaOH aqueous solution) at 0°C. Liquid mercury (0) was filtered over celite and rinsed with diethyl ether (70 mL). The organic layer was separated, dried over MgSO₄, reduced under vacuum and the colorless oil obtained was used in the next step without further purification. PCC (80 mmol, 2.0 equiv.) was added over 5 minutes at room temperature to a crude material (40 mmol, 1.0 equiv.) in DCM (80 mL). The mixture was refluxed for 10 hours and cooled down to room temperature. The reaction mixture was filtered through a short plug of silica (eluted with DCM) and the organic layer was washed with 5% KOH, 5% HCl, saturated NaHCO₃, saturated NaCl, and dried over Na₂SO₄. The solvent was removed by rotary evaporation and the crude product was purified by column chromatography (EtOAc:hexane = 1:10) to give *endo*-3,3a,4,6,7,7a-hexahydro-5H-4,7-methanoinden-5-one and 1,3a,4,6,7,7a-hexahydro-5H-4,7-methanoinden-5-one in 50% yield for three steps.

A solution of ketones (20 mmol, 2.96 g) in 20 mL EtOH was added 100 mg Pd/C (10%). The reaction mixture was stirred at 50 °C under hydrogen atmosphere (80 bar) for 48 h. The reaction mixture was filtered through a short plug of silica (eluted with EtOAc) and The solvent was removed by rotary evaporation and the crude product was purified by column chromatography (EtOAc:hexane = 1:10) to give octahydro-5H-4,7-methanoinden-5-one in 60% yield.

Diethylamine (10.0 mmol, 1.0 equiv.) was added over a 15 minutes' period to formaldehyde (36% in H₂O, 40.0 mmol, 4.0 equiv.) at 0 °C. The resultant mixture was treated over a 33 minutes' period with acetic acid (20.0 mmol, 2.0 equiv.). Once the addition was finished, the temperature was increased to room temperature and the mixture was added over a 22 minutes' period to *endo*-octahydro-5H-4,7- methanoinden-5-one (10.0 mmol, 1.0 equiv.) in the presence of a small amount of BHT at 95°C. The mixture was refluxed for 5 hours and cooled down to room temperature. The yellow mixture was hydrolyzed with aqueous 5% HCl and ice (pH = 1). The aqueous layer was extracted twice with Et₂O, and the combined organic layers were washed with H₂O,

aqueous 5% NaOH and twice with brine, dried over Na₂SO₄ and filtered off. Et₂O was distilled under atmospheric pressure to give a crude which was purified by silica-gel flash column chromatography (EtOAc:hexane = 1:20) to obtain the racemic compound **1n** in 40% yield.

Procedure D: Preparation of Racemic **1o**:




1,2-Dibromobenzene (40 mmol, 1 equiv.) and cyclopentadiene (40 mmol, 1 equiv.) were stirred in toluene (40 mL) at 0 °C under N₂. To this solution was added *n*-BuLi (16 mL, 2.5M in hexane, 40 mmol) dropwise over 30 min during which the reaction solution became first yellow then cloudy white. After an additional 10 min at 0 °C the mixture was allowed to warm to room temperature, stirred overnight and treated with H₂O (20 mL) and extracted with hexane (3 × 15 mL). The organic layer was dried over MgSO₄, filtered, and concentrated to obtain a yellow oil. The product was purified by chromatography on silica gel eluting with hexane to provide 1,4-dihydro-1,4-methano-naphthalene as a clear, colorless oil (5.49 g, 97%).

Approximately 7 g (152 mmol, 4 equiv.) of 98–100% formic acid is added to 5.49 g (38 mmol, 1 equiv.) of 1,4-dihydro-1,4-methano-naphthalene in a 100 mL round-bottomed flask equipped with a condenser, and the mixture is boiled under reflux for 4 hours. The dark solution is cooled and formic acid was removed by rotary evaporation. The crude product was purified by column chromatography to give 1,2,3,4-tetrahydro-1,4-methanonaphthalen-2-yl formate in 58% yield. A solution of 4.14 g (22 mmol, 1 equiv.) of 1,2,3,4-tetrahydro-1,4-methanonaphthalen-2-yl formate in 10 mL of reagent grade acetone is contained in a 100 mL three-necked flask equipped with a thermometer, stirrer, and dropping funnel containing 8 N chromic acid solution. The flask is cooled with an ice bath and the oxidant is added at a rate such that the reaction temperature is maintained at 20–30 °C. Approximately 11 mL of oxidant solution is required; completion of the

reaction being shown by the persistence of the brownish orange color. A slight excess of oxidant is added, and the solution is stirred overnight at room temperature. Solid sodium bisulfite is added in portions to reduce the excess oxidant. The reaction mixture is poured into a large separatory funnel. The dark green chromic sulfate sludge, which has formed during the course of the reaction, is separated either by decantation and washing or by drawing it off from the bottom of the funnel. The acetone solution is washed three times with 10–15 mL portions of an aqueous saturated potassium carbonate solution and finally is dried over anhydrous Na₂SO₄ and concentrated. The product was purified by silica-gel flash column chromatography to provide 3,4-dihydro-1,4-methanonaphthalen-2(1H)-one as a clear, colorless oil (2.78 g, 80%).


Diethylamine (10.0 mmol, 1.0 equiv.) was added over a 15 minutes' period to formaldehyde (36% in H₂O, 40.0 mmol, 4.0 equiv.) at 0°C. The resultant mixture was treated over a 33 minutes' period with acetic acid (20.0 mmol, 2.0 equiv.). Once the addition was finished, the temperature was increased to room temperature and the mixture was added over a 22 minutes' period to 3,4-dihydro-1,4-methanonaphthalen-2(1H)-one (10.0 mmol, 1.0 equiv.) in the presence of a small amount of BHT at 95°C. The mixture was refluxed for 5 hours and cooled down to room temperature. The yellow mixture was hydrolyzed with aqueous HCl 5% and ice (pH = 1). The aqueous layer was extracted twice with Et₂O, and the combined organic layers were washed with H₂O, aqueous NaOH 5% and twice with brine, dried over Na₂SO₄ and filtered off. Et₂O was distilled under atmospheric pressure to give a crude which was purified by silica-gel flash column chromatography to obtain the racemic compound **1o** in 45% yield.

Procedure E: Preparation of Racemic **1p**:




(*E*)-3-benzylidenebicyclo[2.2.1]heptan-2-one **1b** (0.500 g, 2.5 mmol) was dissolved in CH₃CN (60 mL) and irradiated with a UV mercury lamp for 48 h while stirring at room temperature. The solvent was removed under reduced pressure, and the product was purified by silica-gel flash column chromatography to provide **1p** in 30% yield.

Procedure F: Preparation of Racemic 1q:




In 10 ml of anhydrous DMSO were dissolved 1.52 g (10 mmol) of camphor and 11 mmol of benzaldehyde. To a mixture of 0.96 g (12 mmol) of *t*-BuOLi and 10 ml of anhydrous DMSO was added dropwise the solution of reagents controlling the rate of addition so as the temperature of the reaction mixture did not exceed 20 °C; the reaction mixture was cooled with water bath. The stirring was continued till complete consumption of the camphor. Then the reaction mixture was poured into 150 ml of ice water containing 5 ml of acetic acid. The precipitate was filtered off, washed with water, and recrystallized from ethanol.

General Procedure for the Umpolung-Type 1,3-Dipolar Cycloaddition of 3-Methylene-2-Norcamphor with Azomethine Ylides




(*S*)-TF-BiphamPhos **L5** (17.6 mg, 0.022 mmol) and Cu(CH₃CN)₄BF₄ (6.3 mg, 0.020 mmol) were dissolved in 2.0 mL CH₂Cl₂, and stirred at room temperature for about 30 min. Then, the reaction temperature was dropped to -40 °C (unless otherwise noted) and the imino ester **2** (0.20 mmol), Et₃N (0.060 mmol) were added sequentially. Then 3-methylene-2-norcamphor **1a** (0.40 mmol) was added. After the reaction completed, the reaction mixture was quenched by silica-gel. The organic solvent was removed and the residue was purified by column chromatography to give the products, which was then directly analyzed by chiral-phase HPLC to determine the enantiomeric excess.




Methyl (1*S*,2*S*,2'*S*,4*R*,5'*R*)-5'-(4-chlorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]

-2'-carboxylate (5a): Yield (91%); yellow solid; m.p. 109-111 °C; $[\alpha]^{30}_{\text{D}} = +21.5$ (c 0.52, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.47 (d, $J = 8.4$ Hz, 2H), 7.32 (d, $J = 8.4$ Hz, 2H), 4.14 (dd, $J = 11.6, 5.2$ Hz, 1H), 3.84 (s, 1H), 3.68 (s, 3H), 2.70 – 2.62 (m, 2H), 2.30 – 2.24 (m, 1H), 2.06 – 1.86 (m, 3H), 1.80 – 1.68 (m, 3H), 1.53 – 1.39 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 217.8, 173.2, 139.8, 133.4, 128.7, 128.5, 68.6, 64.8, 62.2, 52.3, 48.9, 45.1, 40.3, 34.7, 25.1, 23.4.; HRMS (ESI+) Calcd. For $\text{C}_{18}\text{H}_{20}\text{ClNNaO}_3$ ($[\text{M}+\text{Na}]^+$): 356.1024, found: 356.1022. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AD-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_{\text{r}} = 12.94$ and 23.80 min.




Methyl (1*S*,2*S*,2'*S*,4*R*,5'*R*)-5'-(3-chlorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-


2'-carboxylate (5b): Yield (88%); white solid; m.p. 130-132 °C; $[\alpha]^{30}_{\text{D}} = +42.1$ (c 0.3, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.52 (s, 1H), 7.43 (d, $J = 6.8$ Hz, 1H), 7.32 – 7.24 (m, 2H), 4.14 (dd, $J = 11.6, 5.2$ Hz, 1H), 3.85 (s, 1H), 3.68 (s, 3H), 2.68 – 2.63 (m, 2H), 2.60 (brs, 1H), 2.31 – 2.24 (m, 1H), 2.11 – 1.97 (m, 2H), 1.96 – 1.86 (m, 1H), 1.83 – 1.65 (m, 3H), 1.51 – 1.41 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 217.7, 173.1, 143.5, 134.3, 129.9, 127.8, 127.3, 125.1, 68.6, 64.7, 62.3, 52.3, 48.9, 45.1, 40.2, 34.7, 25.1, 23.4.; HRMS (ESI+) Calcd. For $\text{C}_{18}\text{H}_{21}\text{ClNO}_3$ ($[\text{M}+\text{H}]^+$): 334.1204, found: 334.1207. The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralpak ASH, *i*-propanol/hexane = 5/95, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_{\text{r}} = 14.72$ and 24.80 min.




Methyl (1*S*,2*S*,2'*S*,4*R*,5'*R*)-5'-(4-bromophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5c): Yield (84%); white solid; m.p. 108-110 °C; $[\alpha]_D^{30} = +12.3$ (*c* 0.33, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.51 – 7.45 (m, 2H), 7.44 – 7.38 (m, 2H), 4.13 (dd, *J* = 11.6, 5.2 Hz, 1H), 3.84 (s, 1H), 3.68 (s, 3H), 2.68 – 2.64 (m, 2H), 2.31 – 2.24 (m, 1H), 2.09 – 1.97 (m, 2H), 1.95 – 1.86 (m, 1H), 1.79 – 1.66 (m, 3H), 1.51 – 1.41 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 217.7, 173.2, 140.4, 131.7, 128.8, 121.5, 68.6, 64.8, 62.2, 52.3, 48.9, 45.1, 40.2, 34.7, 25.1, 23.4.; HRMS (ESI+) Calcd. For C₁₈H₂₀BrNNaO₃ ([M+Na]⁺): 400.0519, found: 400.0520. The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 13.83 and 25.28 min.




Methyl (1*S*,2*S*,2'*S*,4*R*,5'*R*)-5'-(3-bromophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5d): Yield (85%); white solid; m.p. 117-118 °C; $[\alpha]_D^{30} = +36.2$ (*c* 0.46, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 1.2 Hz, 1H), 7.48 (d, *J* = 7.6 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.23 (td, *J* = 7.6, 2.0 Hz, 1H), 4.13 (dd, *J* = 11.6, 4.8 Hz, 1H), 3.84 (s, 1H), 3.68 (s, 3H), 2.67 – 2.63 (m, 2H), 2.59 (brs, 1H), 2.32 – 2.24 (m, 1H), 2.11 – 1.96 (m, 2H), 1.96 – 1.85 (m, 1H), 1.81 – 1.65 (m, 3H), 1.50 – 1.41 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 217.7, 173.1, 143.8, 130.8, 130.3, 130.2, 125.6, 122.6, 68.6, 64.7, 62.2, 52.3, 48.9, 45.0, 40.2, 34.7, 25.1, 23.4.; HRMS (ESI+) Calcd. For C₁₈H₂₀BrNNaO₃ ([M+Na]⁺): 400.0519, found: 400.0521. The product was analyzed by HPLC to determine the enantiomeric excess: 96% ee (Chiralpak AS-H, *i*-propanol/hexane = 5/95, flow rate 1.0 mL/min, λ = 220 nm); t_r = 18.15 and 32.73 min.




Methyl (1S,2S,2'S,4R,5'R)-5'-(2-chlorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5e): Yield (94%); white solid; m.p. 128-130 °C; $[\alpha]^{30}_{\text{D}} = +53.5$ (*c* 0.53, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.95 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.32 (m, 2H), 7.20 (m, 1H), 4.67 (dd, *J* = 11.6, 4.8 Hz, 1H), 3.90 (s, 1H), 3.67 (s, 3H), 2.71 – 2.63 (m, 2H), 2.59 (brs, 1H), 2.30 – 2.24 (m, 1H), 2.23 – 2.16 (m, 1H), 1.97 – 1.86 (m, 2H), 1.80 – 1.69 (m, 3H), 1.51 – 1.42 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 217.5, 173.2, 139.1, 133.2, 129.3, 128.5, 127.5, 127.4, 68.1, 64.5, 58.3, 52.1, 49.0, 45.0, 38.7, 34.8, 25.1, 23.3.; HRMS (ESI+) Calcd. For C₁₈H₂₁ClNO₃ ([M+H]⁺): 334.1204, found: 334.1204. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 10.39 and 18.26 min.




methyl (1S,2S,2'S,4R,5'R)-5'-(4-nitrophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5f): Yield (72%); yellow solid; m.p. 102 – 103 °C; $[\alpha]^{15}_{\text{D}} = +7.4$ (*c* 0.61, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.25 – 8.17 (m, 2H), 7.82 – 7.70 (m, 2H), 4.32 (dd, *J* = 11.7, 5.3 Hz, 1H), 3.91 (s, 1H), 3.68 (s, 3H), 2.69 – 2.64 (m, 2H), 2.30 – 2.25 (m, 1H), 2.16 – 2.10 (m, 1H), 2.07 – 2.01 (m, 1H), 1.97 – 1.89 (m, 1H), 1.83 – 1.70 (m, 3H), 1.51 – 1.43 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 217.0, 173.1, 149.7, 147.3, 127.9, 123.7, 68.3, 64.6, 61.8, 52.2, 48.9, 44.8, 40.1, 34.8, 25.1, 23.2.; HRMS (ESI+) Calcd. For C₁₈H₂₁N₂O₅ ([M+H]⁺): 345.1445, found: 345.1443. The product was analyzed by HPLC to determine the enantiomeric excess: 98% ee (Chiralpak AD-H, *i*-propanol /hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); t_r = 10.35 and 17.80 min.



methyl (1S,2S,2'S,4R,5'R)-5'-(4-cyanophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5g): Yield (83%); white solid; m.p. 107 – 108 °C; $[\alpha]^{15}_{\text{D}} = +20.0$ (c 0.60, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.73 – 7.61 (m, 4H), 4.25 (dd, $J = 11.7, 5.2$ Hz, 1H), 3.88 (s, 1H), 3.68 (s, 3H), 2.70 – 2.62 (m, 2H), 2.31 – 2.22 (m, 1H), 2.14 – 2.05 (m, 1H), 2.07 – 1.99 (m, 1H), 2.01 – 1.86 (m, 1H), 1.85 – 1.65 (m, 3H), 1.52 – 1.40 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 217.1, 173.2, 147.5, 132.4, 127.9, 118.8, 111.4, 68.3, 64.7, 62.2, 52.3, 48.9, 44.9, 40.1, 34.8, 25.1, 23.3.; HRMS (ESI+) Calcd. For $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): 325.1547, found: 325.1549. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_{\text{r}} = 8.67$ and 15.84 min.




Methyl (1S,2S,2'S,4R,5'R)-3-oxo-5'-phenylspiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5h): Yield (86%); white thick liquid; $[\alpha]^{30}_{\text{D}} = +44.7$ (c 0.43, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.56 – 7.49 (m, 2H), 7.41 – 7.33 (m, 2H), 7.32 – 7.28 (m, 1H), 4.15 (dd, $J = 10.0, 6.8$ Hz, 1H), 3.85 (s, 1H), 3.68 (s, 3H), 2.72 – 2.67 (m, 1H), 2.67 – 2.62 (m, 1H), 2.31 – 2.27 (m, 1H), 2.09 – 2.07 (m, 1H), 2.07 – 2.03 (m, 1H), 1.95 – 1.86 (m, 1H), 1.80 – 1.68 (m, 3H), 1.50 – 1.43 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 218.1, 173.2, 140.9, 128.6, 127.8, 127.0, 68.7, 64.9, 62.9, 52.3, 48.9, 45.2, 40.4, 34.7, 25.1, 23.5.; HRMS (ESI+) Calcd. For $\text{C}_{18}\text{H}_{22}\text{NO}_3$ ($[\text{M}+\text{H}]^+$): 300.1594, found: 300.1597. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AD-H, *i*-propanol/hexane = 5/95, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_{\text{r}} = 16.86$ and 28.61 min.




Methyl (1S,2S,2'S,4R,5'R)-5'-(4-methoxyphenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5i):

Yield (59%); yellow thick liquid; $[\alpha]_D^{30} = +36.2$ (*c* 0.39, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.46 – 7.40 (m, 2H), 6.94 – 6.86 (m, 2H), 4.12 (dd, *J* = 9.0, 8.4 Hz, 1H), 3.84 (s, 1H), 3.81 (s, 3H), 3.68 (s, 3H), 2.77 (s, 1H), 2.71 – 2.68 (m, 1H), 2.66 – 2.63 (m, 1H), 2.30 – 2.26 (m, 1H), 2.05 – 2.01 (m, 2H), 1.95 – 1.86 (m, 1H), 1.78 – 1.68 (m, 3H), 1.50 – 1.42 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 218.2, 173.1, 159.2, 132.7, 128.2, 114.0, 68.4, 64.8, 62.2, 55.3, 52.3, 48.9, 45.1, 40.2, 34.7, 25.1, 23.5.; HRMS (ESI+) Calcd. For C₁₈H₂₂NO₃ ([M+H]⁺): 330.1700, found: 330.1700. The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralpak OD-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 16.72 and 22.88 min.




Methyl (1S,2S,2'S,4R,5'R)-3-oxo-5'-(p-tolyl)spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5j):


Yield (74%); yellow solid; m.p. 76-78 °C; $[\alpha]_D^{30} = +49.4$ (*c* 0.36, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, *J* = 8.0 Hz, 2H), 7.17 (d, *J* = 8.0 Hz, 2H), 4.15 – 4.08 (m, 1H), 3.83 (s, 1H), 3.68 (s, 3H), 2.72 – 2.67 (m, 1H), 2.67 – 2.62 (m, 1H), 2.35 (s, 3H), 2.32 – 2.26 (m, 1H), 2.06 – 2.04 (m, 1H), 2.03 – 2.00 (m, 1H), 1.97 – 1.84 (m, 1H), 1.80 – 1.66 (m, 3H), 1.50 – 1.40 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 218.2, 173.2, 137.9, 137.5, 129.3, 127.0, 68.8, 65.0, 62.7, 52.3, 48.9, 45.2, 40.4, 34.7, 25.1, 23.6, 21.1.; HRMS (ESI+) Calcd. For C₁₉H₂₃NO₃ ([M+H]⁺): 314.1751, found: 314.1751. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AD-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 11.78 and 20.79 min.




Methyl (1S,2S,2'S,4R,5'R)-3-oxo-5'-(m-tolyl)spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5k): Yield (66%); yellow thick liquid; $[\alpha]^{30}_{\text{D}} = +40.6$ (c 0.48, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.35 – 7.28 (m, 2H), 7.24 (t, $J = 7.6$ Hz, 1H), 7.11 (d, $J = 7.2$ Hz, 1H), 4.12 (dd, $J = 9.6, 7.6$ Hz, 1H), 3.84 (s, 1H), 3.68 (s, 3H), 2.71 – 2.67 (m, 1H), 2.67 – 2.62 (m, 1H), 2.36 (s, 3H), 2.35 – 2.25 (m, 2H), 2.07 – 2.05 (m, 1H), 2.05 – 2.02 (m, 1H), 1.94 – 1.86 (m, 1H), 1.79 – 1.71 (m, 2H), 1.50 – 1.43 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 218.3, 173.1, 140.7, 138.3, 128.6, 128.5, 127.7, 124.1, 68.8, 64.9, 62.9, 52.3, 48.9, 45.2, 40.3, 34.6, 25.1, 23.6, 21.4.; HRMS (ESI+) Calcd. For $\text{C}_{19}\text{H}_{23}\text{NO}_3$ ($[\text{M}+\text{H}]^+$): 314.1751, found: 314.1751. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AD-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_{\text{r}} = 12.47$ and 15.41 min.




Methyl (1S,2S,2'S,4R,5'R)-3-oxo-5'-(o-tolyl)spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5l): Yield (64%); white solid; m.p. 126-128 °C; $[\alpha]^{30}_{\text{D}} = +58.7$ (c 0.45, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, $J = 7.6$ Hz, 1H), 7.27 – 7.23 (m, 1H), 7.18 (m, 2H), 4.35 (dd, $J = 10.4, 6.0$ Hz, 1H), 3.85 (s, 1H), 3.68 (s, 3H), 2.73 – 2.69 (m, 1H), 2.68 – 2.63 (m, 1H), 2.57 (brs, 1H), 2.41 (s, 3H), 2.34 – 2.28 (m, 1H), 2.08 – 2.01 (m, 2H), 1.96 – 1.86 (m, 1H), 1.80 – 1.67 (m, 3H), 1.51 – 1.43 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 218.3, 173.1, 138.6, 136.3, 130.3, 127.4, 126.5, 125.3, 68.7, 64.7, 58.6, 52.3, 48.9, 45.3, 39.2, 34.6, 25.1, 23.6, 19.4.; HRMS (ESI+) Calcd. For $\text{C}_{19}\text{H}_{23}\text{NO}_3$ ($[\text{M}+\text{H}]^+$): 314.1751, found: 314.1751. The product was analyzed by HPLC to determine the enantiomeric excess: 97% ee (Chiralpak AD-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_{\text{r}} = 8.67$ and 12.03 min.




Methyl (1S,2S,2'S,4R,5'R)-5'-(naphthalen-1-yl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5m): Yield (73%); yellow solid; m.p. 123-125 °C; $[\alpha]^{30}_{\text{D}} = +77.0$ (*c* 0.46, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, *J* = 8.4 Hz, 1H), 7.86 (d, *J* = 8.0 Hz, 1H), 7.79 (m, 2H), 7.56 – 7.46 (m, 3H), 4.87 (d, *J* = 8.4 Hz, 1H), 3.95 (s, 1H), 3.66 (s, 3H), 2.87 – 2.75 (m, 1H), 2.71 – 2.63 (m, 1H), 2.38 – 2.33 (m, 1H), 2.32 – 2.25 (m, 1H), 2.25 – 2.16 (m, 1H), 1.97 – 1.88 (m, 1H), 1.81 – 1.70 (m, 3H), 1.54 – 1.46 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 218.4, 172.8, 136.0, 133.7, 132.0, 128.6, 128.2, 126.1, 125.6, 125.5, 123.8, 122.9, 69.0, 64.4, 58.4, 52.3, 48.9, 45.5, 38.6, 34.6, 25.1, 23.7.; HRMS (ESI+) Calcd. For C₂₂H₂₄NO₃ ([M+H]⁺): 350.1751, found: 350.1751. The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 10.80 and 17.05 min.




Methyl (1S,2S,2'S,4R,5'R)-5'-(naphthalen-2-yl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5n): Yield (88%); white solid; m.p. 138-140 °C; $[\alpha]^{30}_{\text{D}} = +34.4$ (*c* 0.43, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.88 – 7.81 (m, 3H), 7.72 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.50 – 7.44 (m, 2H), 4.33 (dd, *J* = 10.8, 6.0 Hz, 1H), 3.89 (s, 1H), 3.71 (s, 3H), 2.74 – 2.69 (m, 1H), 2.69 – 2.65 (m, 1H), 2.35 – 2.29 (m, 1H), 2.21 – 2.10 (m, 2H), 1.98 – 1.87 (m, 1H), 1.83 – 1.70 (m, 3H), 1.54 – 1.44 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 218.1, 173.2, 138.4, 133.3, 133.0, 128.5, 127.9, 127.6, 126.1, 125.9, 125.0, 68.9, 65.0, 63.1, 52.4, 49.0, 45.3, 40.3, 34.7, 25.1, 23.6.; HRMS (ESI+) Calcd. For C₂₂H₂₄NO₃ ([M+H]⁺): 350.1751, found: 350.1751. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 14.89 and 23.96 min.




Methyl (1S,2S,2'S,4R,5'R)-5'-(4-chlorophenyl)-2'-methyl-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5o): Yield (70%); white solid; m.p. 116-118 °C; $[\alpha]_D^{30} = +14.1$ (*c* 1.02, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 4.15 (dd, *J* = 9.2, 7.2 Hz, 1H), 3.69 (s, 3H), 3.11 (brs, 1H), 2.79 – 2.74 (m, 1H), 2.65 – 2.59 (m, 1H), 2.34 – 2.23 (m, 2H), 2.11 – 2.02 (m, 1H), 1.92 – 1.72 (m, 2H), 1.71 – 1.61 (m, 1H), 1.59 – 1.53 (m, 1H), 1.56 (s, 3H), 1.51 – 1.42 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 220.5, 174.2, 139.9, 133.1, 128.6, 72.0, 65.7, 59.5, 52.6, 49.4, 44.0, 42.1, 35.6, 25.9, 25.9, 22.0.; HRMS (ESI+) Calcd. For C₁₉H₂₃ClNO₃ ([M+H]⁺): 348.1361, found: 348.1361. The product was analyzed by HPLC to determine the enantiomeric excess: 97% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 6.25 and 10.23 min.



Methyl (1S,2S,2'S,4R,5'R)-5'-(4-methoxyphenyl)-2'-methyl-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5p): Yield (57%); white solid; m.p. 106-109 °C; $[\alpha]_D^{30} = +7.6$ (*c* 0.46, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.47 – 7.42 (m, 2H), 6.90 – 6.85 (m, 2H), 4.13 (dd, *J* = 9.6, 6.8 Hz, 1H), 3.80 (s, 3H), 3.69 (s, 3H), 3.16 (brs, 1H), 2.81 – 2.75 (m, 1H), 2.64 – 2.59 (m, 1H), 2.32 – 2.24 (m, 2H), 2.14 – 2.06 (m, 1H), 1.93 – 1.72 (m, 2H), 1.72 – 1.62 (m, 1H), 1.56 (s, 3H), 1.55 – 1.52 (m, 1H), 1.52 – 1.42 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 220.7, 174.4, 158.9, 133.3, 128.4, 113.9, 72.0, 65.9, 59.7, 55.3, 52.6, 49.4, 44.3, 42.2, 35.6, 26.1, 25.9, 22.1.; HRMS (ESI+) Calcd. For C₂₀H₂₆NO₄ ([M+H]⁺): 344.1856, found: 344.1856. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, *i*-propanol/hexane = 30/70, flow rate 1.0 mL/min, λ = 220 nm); t_r = 6.58 and 9.45 min.




Methyl (1*S*,2*S*,2'*S*,4*R*,5'*R*)-2'-methyl-3-oxo-5'-(thiophen-2-yl)spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5q): Yield (64%); yellow solid; m.p. 94-96 °C; $[\alpha]^{30}_{\text{D}} = +3.1$ (*c* 0.32, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.25 – 7.19 (m, 1H), 7.10 (d, *J* = 2.4 Hz, 1H), 6.97 (m, 1H), 4.46 – 4.36 (m, 1H), 3.69 (s, 3H), 3.23 (brs, 1H), 2.79 – 2.73 (m, 1H), 2.64 – 2.58 (m, 1H), 2.43 – 2.35 (m, 1H), 2.31 – 2.23 (m, 1H), 2.22 – 2.13 (m, 1H), 1.94 – 1.74 (m, 2H), 1.72 – 1.64 (m, 1H), 1.59 – 1.56 (m, 1H), 1.56 (s, 3H), 1.53 – 1.45 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 220.1, 174.0, 144.4, 126.7, 124.6, 124.5, 72.0, 65.8, 55.7, 52.6, 49.2, 44.6, 42.0, 35.7, 26.0, 25.8, 22.0.; HRMS (ESI+) Calcd. For C₁₇H₂₁NNaO₃S⁺ ([M+Na]⁺): 342.1134, found: 342.1137. The product was analyzed by HPLC to determine the enantiomeric excess: 96% ee (Chiralpak AS-H, *i*-propanol/hexane = 3/97, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 30.50 and 34.22 min.




Methyl (1*S*,2*S*,2'*S*,4*R*,5'*R*)-2'-benzyl-5'-(4-chlorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5r): Yield (68%); colorless thick liquid; $[\alpha]^{30}_{\text{D}} = -16.3$ (*c* 0.42, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.42 (m, 2H), 7.33 – 7.28 (m, 2H), 7.24 – 7.19 (m, 5H), 4.27 (dd, *J* = 10.0, 6.0 Hz, 1H), 3.52 (s, 3H), 3.42 (d, *J* = 13.2 Hz, 1H), 3.00 (brs, 1H), 2.99 (d, *J* = 13.2 Hz, 1H), 2.78 – 2.73 (m, 1H), 2.67 – 2.63 (m, 1H), 2.43 – 2.37 (m, 1H), 2.09 – 2.02 (m, 1H), 1.96 – 1.73 (m, 4H), 1.69 – 1.66 (m, 1H), 1.52 – 1.45 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 220.7, 173.2, 140.0, 136.6, 133.1, 130.4, 128.58, 128.56, 128.0, 126.8, 76.7, 65.8, 59.0, 52.2, 49.3, 44.7, 41.6, 39.2, 35.8, 26.5, 25.5.; HRMS (ESI+) Calcd. For C₂₅H₂₆ClNNaO₃⁺ ([M+Na]⁺): 446.1493, found: 446.1493. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak OD-H, *i*-propanol/hexane = 5/95, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 7.65 and 9.10 min.

General Procedure for the Efficient Kinetic Resolution of Alkylidene Norcamphors with Azomethine Ylides




(*S*)-TF-BiphamPhos **L5** (17.6 mg, 0.022 mmol) and Cu(CH₃CN)₄BF₄ (6.3 mg, 0.020 mmol) were dissolved in 2.0 mL CH₂Cl₂, and stirred at room temperature for about 30 min. Then, the reaction temperature was dropped to -20 °C (unless otherwise noted) and the imino ester **2** (0.60 mmol), Et₃N (0.060 mmol) were added sequentially. Then 3-alkylidene-2-norcamphor **1** (0.40 mmol) was added. After the reaction completed (monitored by chiral-phase GC and HPLC), the reaction mixture was quenched by silica-gel. The organic solvent was removed and the residue was purified by column chromatography to give the recovered **1** and the cycloadduct **5**, which were then directly analyzed by chiral-phase GC or HPLC to determine the enantiomeric excess.




(1a)

(1*S,4R*)-3-methylenebicyclo[2.2.1]heptan-2-one (1a): 44% yield; yellow liquid; [α]³⁰_D = -3.0 (*c* 0.29, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 5.73 (s, 1H), 5.17 (s, 1H), 3.17 – 3.10 (m, 1H), 2.78 – 2.68 (m, 1H), 1.92 – 1.85 (m, 2H), 1.77 – 1.73 (m, 1H), 1.65 – 1.61 (m, 1H), 1.60 – 1.51 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 206.0, 149.9, 111.8, 49.1, 42.4, 36.8, 28.0, 23.6.; The product was analyzed by GC to determine the enantiomeric excess: 92% ee (Chiral Select-1000, 30 m \times 0.25 mm, column temperature: 150 °C, carrier gas: N₂, 1.0 mL/min); *t*_r = 4.75 and 4.95 min.




(1b)

(1S,4R)-3-((E)-benzylidene)bicyclo[2.2.1]heptan-2-one: 46% yield; yellow solid; $[\alpha]^{30}_{\text{D}} = -552.1$ (c 0.38, CH_2Cl_2); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.52 – 7.46 (m, 2H), 7.44 – 7.31 (m, 3H), 7.16 (s, 1H), 3.66 – 3.61 (m, 1H), 2.82 – 2.77 (m, 1H), 2.11 – 1.92 (m, 2H), 1.78 – 1.65 (m, 4H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 206.9, 141.6, 135.3, 129.7, 128.9, 128.6, 127.3, 48.6, 40.2, 37.8, 27.3, 24.3.; The product was analyzed by GC to determine the enantiomeric excess: 94% ee (Chiral Select-1000, 30 m \times 0.25 mm, column temperature: 180 $^\circ\text{C}$, carrier gas: N_2 , 1.0 mL/min); $t_{\text{r}} = 29.13$ and 30.76 min.




(1c)

(1S,4R)-3-((E)-4-chlorobenzylidene)bicyclo[2.2.1]heptan-2-one (1c): 45% yield; yellow solid; $[\alpha]^{30}_{\text{D}} = -415.9$ (c 0.27, CH_2Cl_2); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.44 – 7.34 (m, 4H), 7.09 (s, 1H), 3.63 – 3.55 (m, 1H), 2.84 – 2.76 (m, 1H), 2.10 – 1.93 (m, 2H), 1.79 – 1.61 (m, 4H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 206.6, 142.1, 134.8, 133.8, 130.9, 128.9, 125.9, 48.5, 40.2, 37.8, 27.3, 24.3.; The product was analyzed by HPLC to determine the enantiomeric excess: 97% ee (Chiralpak OJ-H, i -propanol/hexane = 2/98, flow rate 1.0 mL/min, $\lambda = 300$ nm); $t_{\text{r}} = 11.00$ and 12.42 min.




(1d)

(1S,4R)-3-((E)-4-bromobenzylidene)bicyclo[2.2.1]heptan-2-one (1d): 45% yield; white solid; m.p. 85-86 °C; $[\alpha]_D^{30} = -331.4$ (*c* 0.36, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.57 – 7.49 (m, 2H), 7.37 – 7.30 (m, 2H), 7.07 (s, 1H), 3.61 – 3.55 (m, 1H), 2.84 – 2.77 (m, 1H), 2.11 – 1.92 (m, 2H), 1.80 – 1.62 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 206.5, 142.2, 134.2, 131.9, 131.1, 125.9, 123.1, 48.5, 40.2, 37.7, 27.2, 24.3.; HRMS (ESI+) Calcd. For C₁₄H₁₃BrNaO⁺ ([M+Na]⁺): 299.0042, found: 299.1110. The product was analyzed by HPLC to determine the enantiomeric excess: 97% ee (Chiralpak OJ-H, *i*-propanol/hexane = 2/98, flow rate 1.0 mL/min, λ = 300 nm); t_r = 12.94 and 13.78 min.




(1S,4R)-3-((E)-3-chlorobenzylidene)bicyclo[2.2.1]heptan-2-one (1e): 45% yield; yellow liquid; $[\alpha]_D^{30} = -313.1$ (*c* 0.26, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.44 (s, 1H), 7.37 – 7.28 (m, 3H), 7.07 (s, 1H), 3.64 – 3.57 (m, 1H), 2.85 – 2.77 (m, 1H), 2.12 – 1.93 (m, 2H), 1.79 – 1.63 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 206.5, 142.9, 137.2, 134.6, 129.9, 129.3, 128.8, 127.9, 125.6, 48.5, 40.2, 37.7, 27.3, 24.3.; HRMS (ESI+) Calcd. For C₁₄H₁₃ClNaO⁺ ([M+Na]⁺): 255.0547, found: 255.0551. The product was analyzed by HPLC to determine the enantiomeric excess: 96% ee (Chiralpak OJ-H, *i*-propanol/hexane = 2/98, flow rate 1.0 mL/min, λ = 300 nm); t_r = 9.97 and 11.39 min.




(1S,4R)-3-((E)-2-fluorobenzylidene)bicyclo[2.2.1]heptan-2-one (1f): 43% yield; yellow liquid; $[\alpha]_D^{25} = -261.1$ (*c* 0.26, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.47 (t, *J* = 7.6 Hz, 1H), 7.37 – 7.28 (m, 2H), 7.18 (t, *J* = 7.6 Hz, 1H), 7.14 – 7.06 (m, 1H), 3.54 – 3.48 (m, 1H), 2.85 – 2.77 (m, 1H), 2.10 – 1.92 (m, 2H), 1.81 – 1.65 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 206.3, 161.2 (d, *J* = 251.0 Hz), 143.5, 130.5 (d, *J* = 8.0 Hz), 130.1 (d, *J*


= 3.0 Hz), 124.0 (d, $J = 4.0$ Hz), 123.3 (d, $J = 13.0$ Hz), 119.4 (d, $J = 5.0$ Hz), 115.8 (d, $J = 22.0$ Hz), 48.6, 40.4 (d, $J = 2.0$ Hz), 37.6, 27.3, 24.3.; HRMS (ESI+) Calcd. For $C_{14}H_{13}FNaO^+$ ($[M+Na]^+$): 239.0843, found: 239.0845. The product was analyzed by HPLC to determine the enantiomeric excess: 99% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 290$ nm); $t_r = 7.13$ and 8.03 min.




(1S,4R)-3-((E)-4-methylbenzylidene)bicyclo[2.2.1]heptan-2-one (1g): 46% yield; $[\alpha]^{30}_D = -529.1$ (c 0.47, CH_2Cl_2); 1H NMR (400 MHz, $CDCl_3$) δ 7.39 (d, $J = 8.4$ Hz, 2H), 7.21 (d, $J = 8.0$ Hz, 2H), 7.13 (s, 1H), 3.65 – 3.61 (m, 1H), 2.80 – 2.75 (m, 1H), 2.38 (s, 3H), 2.09 – 1.91 (m, 2H), 1.79 – 1.63 (m, 4H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 207.1, 140.8, 139.2, 132.5, 129.8, 129.4, 127.4, 48.6, 40.3, 37.9, 27.3, 24.4, 21.4.; The product was analyzed by HPLC to determine the enantiomeric excess: 97% ee (Chiralpak OJ-H, *i*-propanol/hexane = 2/98, flow rate 1.0 mL/min, $\lambda = 300$ nm); $t_r = 8.59$ and 11.27 min.




(1S,4R)-3-((E)-3-methylbenzylidene)bicyclo[2.2.1]heptan-2-one (1h): 47% yield; yellow liquid; $[\alpha]^{30}_D = -293.9$ (c 0.36, CH_2Cl_2); 1H NMR (400 MHz, $CDCl_3$) δ 7.32 – 7.27 (m, 3H), 7.18 – 7.14 (m, 1H), 7.13 (s, 1H), 3.66 – 3.61 (m, 1H), 2.81 – 2.76 (m, 1H), 2.38 (s, 3H), 2.10 – 1.91 (m, 2H), 1.78 – 1.61 (m, 4H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 207.0, 141.5, 138.3, 135.2, 130.5, 129.7, 128.5, 127.4, 126.8, 48.6, 40.3, 37.8, 27.3, 24.3, 21.4.; HRMS (ESI+) Calcd. For $C_{15}H_{16}NaO^+$ ($[M+Na]^+$): 235.1093, found: 235.1104. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak OJH, *i*-propanol/hexane = 2/98, flow rate 1.0 mL/min, $\lambda = 300$ nm); $t_r = 8.22$ and 10.05 min.



(1S,4R)-3-((E)-4-methoxybenzylidene)bicyclo[2.2.1]heptan-2-one (1i): 50% yield; $[\alpha]^{30}_D = -416.0$ (c 0.30, CH_2Cl_2); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.46 (d, $J = 8.0$ Hz, 2H), 7.11 (s, 1H), 6.93 (d, $J = 8.4$ Hz, 2H), 3.84 (s, 3H), 3.66 – 3.58 (m, 1H), 2.80 – 2.74 (m, 1H), 2.09 – 1.91 (m, 2H), 1.79 – 1.60 (m, 4H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 207.0, 160.2, 139.5, 131.4, 127.8, 127.1, 114.1, 55.3, 48.5, 40.2, 38.0, 27.3, 24.4.; The product was analyzed by HPLC to determine the enantiomeric excess: 87% ee (Chiralpak OJ-H, *i*-propanol/hexane = 2/98, flow rate 1.0 mL/min, $\lambda = 300$ nm); $t_r = 23.87$ and 30.81 min.




(1S,4R,E)-3-(naphthalen-2-ylmethylene)bicyclo[2.2.1]heptan-2-one (1j): 46% yield; yellow solid; m.p. 91-93 °C; $[\alpha]^{30}_D = -504.2$ (c 0.28 CH_2Cl_2); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.93 (s, 1H), 7.89 – 7.80 (m, 3H), 7.61 (dd, $J = 8.4, 1.6$ Hz, 1H), 7.54 – 7.47 (m, 2H), 7.32 (s, 1H), 3.78 – 3.71 (m, 1H), 2.86 – 2.79 (m, 1H), 2.15 – 2.05 (m, 1H), 2.04 – 1.94 (m, 1H), 1.85 – 1.76 (m, 2H), 1.73 – 1.67 (m, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 206.9, 141.9, 133.24, 133.22, 132.8, 130.1, 128.33, 128.29, 127.7, 127.4, 126.9, 126.5, 48.6, 40.3, 37.9, 27.4, 24.4.; HRMS (ESI+) Calcd. For $\text{C}_{18}\text{H}_{16}\text{NaO}^+$ ($[\text{M}+\text{Na}]^+$): 271.1093, found: 271.1100. The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralpak IA, *i*-propanol /hexane = 1/99, flow rate 1.0 mL/min, $\lambda = 300$ nm); $t_r = 11.41$ and 12.92 min.




(1k)

(1S,4R,E)-3-(thiophen-2-ylmethylene)bicyclo[2.2.1]heptan-2-one (1k): 46% yield; sepia liquid; $[\alpha]^{30}_D = -513.5$ (*c* 0.17, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.45 (dd, *J* = 4.8, 0.8 Hz, 1H), 7.31 – 7.24 (m, 2H), 7.11 – 7.05 (m, 1H), 3.76 – 3.70 (m, 1H), 2.81 – 2.75 (m, 1H), 2.04 – 1.90 (m, 2H), 1.82 – 1.77 (m, 1H), 1.72 – 1.67 (m, 1H), 1.66 – 1.57 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 206.7, 139.1, 139.0, 132.3, 129.0, 127.7, 120.1, 48.8, 40.6, 37.6, 27.1, 24.6.; HRMS (ESI+) Calcd. For C₁₂H₁₂NaOS⁺ ([M+Na]⁺): 227.0501, found: 227.0486. The product was analyzed by HPLC to determine the enantiomeric excess: 91% ee (Chiralpak OJ-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 320 nm); *t_r* = 8.51 and 9.51 min.




(1l)

(1S,4R,E)-3-(pyridin-2-ylmethylene)bicyclo[2.2.1]heptan-2-one (1l): 45% yield; yellow liquid; $[\alpha]^{30}_D = -219.2$ (*c* 0.25, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, *J* = 3.6 Hz, 1H), 7.74 – 7.63 (m, 1H), 7.39 (d, *J* = 8.0 Hz, 1H), 7.26 – 7.14 (m, 1H), 7.08 (s, 1H), 4.34 – 4.26 (m, 1H), 2.83 – 2.75 (m, 1H), 2.08 – 1.89 (m, 2H), 1.83 – 1.75 (m, 1H), 1.74 – 1.61 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 207.5, 154.7, 149.9, 145.2, 136.2, 126.1, 125.0, 122.7, 48.6, 40.2, 37.0, 27.3, 24.2.; HRMS (ESI+) Calcd. For C₁₃H₁₄NO⁺ ([M+Na]⁺): 200.1070, found: 200.1068. The product was analyzed by HPLC to determine the enantiomeric excess: 98% ee (Chiralpak OJ-H, *i*-propanol /hexane = 2/98, flow rate 1.0 mL/min, λ = 300 nm); *t_r* = 13.88 and 17.92 min.




(1m)

(3aR,4R,7S,7aS)-6-methyleneoctahydro-5H-4,7-methanoinden-5-one (1m): 45% yield; $[\alpha]^{30}_D = -0.7$ (*c* 0.19, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 5.71 (s, 1H), 5.13 (s, 1H), 2.91 – 2.85 (m, 1H), 2.54 – 2.47 (m, 1H), 2.24 – 2.13 (m, 2H), 2.04 – 1.95 (m, 2H), 1.85 – 1.76 (m, 2H), 1.58 – 1.51 (m, 1H), 1.34 (m, 1H), 1.17 – 1.05 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 206.0, 149.8, 111.3, 53.9, 47.0, 46.9, 41.8, 32.1, 31.8, 30.5, 27.9.; The product was analyzed by HPLC to determine the enantiomeric excess: 91% ee (Chiralpak AS-H, *i*-propanol/hexane = 2/98, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 7.55 and 8.47 min.




(1n)

(3aS,4R,7S,7aR)-6-methyleneoctahydro-5H-4,7-methanoinden-5-one (1n): 44% yield; $[\alpha]^{30}_D = +25.0$ (*c* 0.02, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 5.82 (s, 1H), 5.12 (s, 1H), 3.01 – 2.95 (m, 1H), 2.82 – 2.70 (m, 2H), 2.68 – 2.62 (m, 1H), 1.94 – 1.86 (m, 1H), 1.85 – 1.78 (m, 1H), 1.60 – 1.48 (m, 3H), 1.42 – 1.27 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 206.4, 148.1, 113.1, 54.9, 47.2, 46.1, 45.1, 39.9, 28.0, 27.9, 27.8.; The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralpak AS-H, *i*-propanol/hexane = 2/98, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 5.27 and 6.35 min.




(1o)

(1R,4S)-3-methylene-3,4-dihydro-1,4-methanonaphthalen-2(1H)-one (1o): 46% yield; $[\alpha]^{30}_D = +36.3$ (*c* 0.47, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.24 (m, 2H), 7.19 – 7.09 (m, 2H), 5.78 (s, 1H), 5.28 (s, 1H), 4.07 – 4.02 (m, 1H), 3.72 – 3.66 (m, 1H), 2.62 – 2.55 (m, 1H), 2.33 – 2.27 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 202.4, 147.5, 145.2, 140.9, 127.6, 126.9, 123.5, 121.4, 112.6, 56.8, 50.5, 48.9.; The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralpak OJ-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 13.95 and 18.83 min.




(1p)

(Z)-3-benzylidenebicyclo[2.2.1]heptan-2-one (1p): 30% yield; ^1H NMR (400 MHz, CDCl_3) δ 7.98 – 7.85 (m, 2H), 7.39 – 7.28 (m, 3H), 6.60 (s, 1H), 3.17 – 3.08 (m, 1H), 2.81 – 2.71 (m, 1H), 1.97 – 1.82 (m, 3H), 1.67 – 1.56 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 205.1, 141.8, 134.7, 133.1, 130.4, 129.1, 128.0, 51.8, 46.8, 37.1, 28.5, 23.7.



(1q)


(E)-3-benzylidene-7,7-dimethylbicyclo[2.2.1]heptan-2-one (1q): 50% yield; ^1H NMR (400 MHz, CDCl_3) δ 7.51 – 7.45 (m, 2H), 7.44 – 7.31 (m, 3H), 7.24 (s, 1H), 3.11 (d, $J = 4.2$ Hz, 1H), 2.23 – 2.14 (m, 1H), 1.83 – 1.74 (m, 1H), 1.65 – 1.48 (m, 2H), 1.03 (s, 3H), 1.00 (s, 3H), 0.80 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 208.3, 142.0, 135.6, 129.7, 128.7, 128.6, 127.5, 57.1, 49.1, 46.7, 30.6, 25.9, 20.6, 18.3, 9.3.




(5s)

Methyl (1S,2R,2'S,4R,4'R,5'R)-5'-(4-chlorophenyl)-3-oxo-4'-phenylspiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5s): Yield (48%); yellow liquid; $[\alpha]^{30}_{\text{D}} = +57.5$ (c 0.28, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.46 (d, $J = 8.4$ Hz, 2H), 7.27 – 7.03 (m, 7H), 4.64 (d, $J = 11.2$ Hz, 1H), 3.98 (s, 1H), 3.76 (d, $J = 11.2$ Hz, 1H), 3.73 (s, 3H), 2.85 – 2.78 (m, 1H), 2.66 – 2.61 (m, 1H), 2.24 – 2.17 (m, 1H), 1.67 – 1.56 (m, 1H), 1.56 – 1.48 (m, 1H), 1.17 – 1.06 (m, 1H), 1.06 – 0.96 (m, 1H), 0.83 – 0.72 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 217.9, 173.0, 138.2, 137.0, 133.5, 129.1, 128.8, 128.2, 127.2, 69.1, 68.5, 65.7, 56.1, 52.5, 49.3, 44.7, 36.3, 24.8, 23.0.; HRMS (ESI+) Calcd. $\text{C}_{24}\text{H}_{24}\text{ClNNaO}_3^+$ ($[\text{M}+\text{Na}]^+$): 432.1337, found: 432.1337. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AS-H,


i-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 6.56$ and 15.95 min.




Methyl (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*) -4',5'-bis(4-chlorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5t): Yield (49%); yellow solid; m.p. 145-147 °C; $[\alpha]_D^{30} = +21.5$ (*c* 0.67, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.43 (m, 2H), 7.26 (d, *J* = 8.4 Hz, 2H), 7.19 – 6.83 (m, 4H), 4.57 (d, *J* = 11.2 Hz, 1H), 3.96 (s, 1H), 3.73 (s, 3H), 3.72 (d, *J* = 11.2 Hz, 1H), 2.83 – 2.78 (m, 1H), 2.67 – 2.62 (m, 1H), 2.26 – 2.18 (m, 1H), 1.71 – 1.61 (m, 1H), 1.59 – 1.52 (m, 1H), 1.22 – 1.10 (m, 1H), 1.05 – 0.94 (m, 1H), 0.86 – 0.76 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 217.7, 173.0, 138.0, 135.6, 133.8, 133.1, 129.1, 128.9, 128.5, 69.2, 68.5, 65.7, 55.5, 52.6, 49.3, 44.8, 36.4, 24.8, 23.2.; HRMS (ESI+) Calcd. For C₂₄H₂₃Cl₂NNaO₃⁺ ([M+Na]⁺): 466.0947, found: 466.0949. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 6.35$ and 16.73 min.



Methyl (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*) -4'-(4-bromophenyl)-5'-(4-chlorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5u): Yield (50%); yellow solid; m.p. 148-150 °C; $[\alpha]_D^{30} = +15.3$ (*c* 0.17, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.43 (m, 2H), 7.27 (m, 4H), 6.99 (s, 2H), 4.57 (d, *J* = 11.2 Hz, 1H), 3.96 (s, 1H), 3.73 (s, 3H), 3.70 (d, *J* = 11.2 Hz, 1H), 2.82 – 2.78 (m, 1H), 2.67 – 2.63 (m, 1H), 2.26 – 2.18 (m, 1H), 1.71 – 1.60 (m, 1H), 1.59 – 1.52 (m, 1H), 1.22 – 1.11 (m, 1H), 1.05 – 0.94 (m, 1H), 0.86 – 0.76 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 217.7, 173.0, 138.0, 136.1, 133.8, 131.4, 129.1, 129.0, 121.2, 69.1, 68.5, 65.8, 55.6, 52.6, 49.3, 44.8, 36.4, 24.8, 23.2.; HRMS (ESI+) Calcd. For C₂₄H₂₃BrClNNaO₃⁺ ([M+Na]⁺): 510.0442, found: 510.0446. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 6.58$ and 16.81 min.




Methyl (1S,2R,2'S,4R,4'R,5'R) -4'-(3-chlorophenyl)-5'-(4-chlorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5v): Yield (48%); white solid; m.p. 123-125 °C; $[\alpha]^{30}_{\text{D}} = +39.0$ (*c* 0.41, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, *J* = 8.4 Hz, 2H), 7.27 (d, *J* = 8.4 Hz, 2H), 7.21 – 6.85 (m, 4H), 4.62 (d, *J* = 10.8 Hz, 1H), 3.93 (s, 1H), 3.724 (s, 3H), 3.723 (d, *J* = 10.8 Hz, 1H), 3.24 (s, 1H), 2.87 – 2.78 (m, 1H), 2.72 – 2.61 (m, 1H), 2.23 – 2.17 (m, 1H), 1.72 – 1.60 (m, 1H), 1.59 – 1.52 (m, 1H), 1.23 – 1.13 (m, 1H), 1.01 (d, *J* = 6.4 Hz, 1H), 0.79 (d, *J* = 10.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 217.4, 172.7, 139.1, 137.7, 134.2, 133.8, 129.5, 129.2, 129.0, 127.5, 68.9, 68.4, 65.6, 55.6, 52.6, 49.2, 44.7, 36.3, 24.7, 23.1.; HRMS (ESI⁺) Calcd. For C₂₄H₂₃Cl₂NNaO₃⁺ ([M+Na]⁺): 466.0947, found: 466.0953. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 6.91 and 16.93 min.




Methyl (1S,2R,2'S,4R,4'R,5'R) -5'-(4-chlorophenyl)-4'-(2-fluorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5w): Yield (51%); yellow liquid; $[\alpha]^{30}_{\text{D}} = +48.6$ (*c* 0.66, CH₂Cl₂); Major (5w): ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 8.4 Hz, 3H), 7.27 – 7.21 (m, 3H), 6.93 – 6.86 (m, 2H), 4.60 (d, *J* = 10.0 Hz, 1H), 4.14 (s, 1H), 3.76 (s, 3H), 3.46 (d, *J* = 10.0 Hz, 1H), 2.91 – 2.84 (m, 1H), 2.68 – 2.64 (m, 1H), 2.54 (brs, 1H), 2.14 – 2.06 (m, 1H), 1.76 – 1.63 (m, 1H), 1.54 – 1.48 (m, 1H), 1.33 – 1.07 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 219.0, 172.5, 161.1 (d, *J* = 244 Hz), 138.4, 133.5, 132.9, 128.81, 128.75, 125.4 (d, *J* = 14 Hz), 124.5 (d, *J* = 4 Hz), 116.2 (d, *J* = 22 Hz), 70.4, 68.0, 66.7, 58.3, 52.6, 49.4, 44.3 (d, *J* = 2 Hz), 36.1, 25.7, 23.6. Minor (3w): ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.28 (m, 3H), 7.21 – 7.15 (m, 3H), 7.02 – 6.96 (m, 2H), 4.35 (d, *J* = 9.2 Hz, 1H), 4.03 (s, 1H), 3.99 (d, *J* = 9.2 Hz, 1H), 3.77 (s, 3H), 2.74 – 2.67 (m, 1H), 2.65 – 2.55 (m, 1H), 2.09 – 2.00 (m, 1H), 1.76 – 1.63 (m, 1H), 1.52 – 1.47 (m, 1H), 1.33 – 1.07 (m, 3H). ¹³C NMR

(100 MHz, CDCl₃) δ 217.75, 171.75, 161.1 (d, $J = 246$ Hz), 137.7, 133.7, 132.8, 129.4, 129.3, 126.8 (d, $J = 15$ Hz), 124.3 (d, $J = 3$ Hz), 115.7 (d, $J = 23$ Hz), 69.0 (d, $J = 4$ Hz), 67.52, 66.6, 58.3, 52.7, 49.6, 43.57, 35.8, 25.6, 23.9.; HRMS (ESI+) Calcd. For C₂₄H₂₃ClFNNaO₃⁺ ([M+Na]⁺): 450.1243, found: 450.1243. The product was analyzed by HPLC to determine the enantiomeric excess: 83% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 7.47$ and 13.42 min.




Methyl (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*) -5'-(4-chlorophenyl)-3-oxo-4'-(*p*-tolyl)spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5x): Yield (47%); yellow solid; m.p. 124-126 °C; $[\alpha]_D^{30} = +40.8$ (c 0.66, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.47 – 7.43 (m, 2H), 7.24 (m, 2H), 6.97 (m, 4H), 4.59 (d, $J = 11.2$ Hz, 1H), 3.96 (s, 1H), 3.73 (s, 3H), 3.72 (d, $J = 11.2$ Hz, 1H), 2.80 – 2.76 (m, 1H), 2.64 – 2.60 (m, 1H), 2.24 (s, 3H), 2.22 – 2.17 (m, 1H), 1.67 – 1.57 (m, 1H), 1.57 – 1.49 (m, 1H), 1.16 – 0.98 (m, 2H), 0.89 – 0.80 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 218.1, 173.1, 138.5, 136.8, 133.9, 133.5, 129.2, 129.0, 128.8, 69.3, 68.5, 65.9, 55.9, 52.5, 49.4, 44.9, 36.4, 24.9, 23.1, 21.0.; HRMS (ESI+) Calcd. For C₂₅H₂₆ClNNaO₃⁺ ([M+Na]⁺): 446.1493, found: 446.1497. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 5.70$ and 12.29 min.




Methyl (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*) -5'-(4-chlorophenyl)-3-oxo-4'-(*m*-tolyl)spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5y): Yield (46%); white to yellow solid; m.p. 118-120 °C; $[\alpha]_D^{30} = +45.1$ (c 0.90, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, $J = 8.4$ Hz, 2H), 7.25 (d, $J = 8.4$ Hz, 2H), 7.10 – 6.71 (m, 4H), 4.62 (d, $J = 11.2$ Hz, 1H), 3.96 (s, 1H), 3.73 (s, 3H), 3.71 (d, $J = 11.2$ Hz, 1H), 2.81 – 2.78 (m, 1H), 2.65 – 2.62 (m, 1H), 2.22 (s, 3H), 2.21 – 2.12 (m, 1H), 1.69 – 1.57 (m, 1H), 1.56 – 1.48 (m, 1H), 1.16 – 0.97 (m, 2H),

0.85 – 0.71 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 218.0, 173.0, 138.4, 133.5, 129.2, 128.8, 128.1, 128.0, 69.3, 68.5, 65.8, 56.2, 52.5, 49.4, 44.8, 36.4, 24.9, 23.1, 21.2.; HRMS (ESI+) Calcd. For C₂₅H₂₆ClNNaO₃⁺ ([M+Na]⁺): 446.1493, found: 446.1493. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 5.49 and 11.77 min.




Methyl (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*) -5'-(4-chlorophenyl)-4'-(4-methoxyphenyl)-3-oxospiro[bicyclo [2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5z): Yield (42%); yellow solid; m.p. 140-141 °C; [α]³⁰_D = +36.0 (*c* 0.42, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.48 – 7.42 (m, 2H), 7.26 – 7.22 (m, 2H), 7.00 (s, 2H), 6.70 (d, *J* = 7.6 Hz, 2H), 4.58 (d, *J* = 11.6 Hz, 1H), 3.95 (s, 1H), 3.73 (s, 3H), 3.721 (s, 3H), 3.719 (d, *J* = 11.6 Hz, 1H), 2.81 – 2.75 (m, 1H), 2.65 – 2.60 (m, 1H), 2.24 – 2.19 (m, 1H), 1.67 – 1.58 (m, 1H), 1.56 – 1.51 (m, 1H), 1.18 – 1.07 (m, 1H), 1.05 – 0.96 (m, 1H), 0.86 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 218.1, 173.2, 158.6, 138.5, 133.5, 129.2, 128.8, 128.7, 113.6, 69.2, 68.4, 65.7, 55.4, 55.0, 52.5, 49.4, 44.9, 36.4, 24.9, 23.1.; HRMS (ESI+) Calcd. For C₂₅H₂₆ClNNaO₄⁺ ([M+Na]⁺): 462.1443, found: 462.1443. The product was analyzed by HPLC to determine the enantiomeric excess: 97% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 8.61 and 19.50 min.




Methyl (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*) -5'-(4-chlorophenyl)-4'-(naphthalen-2-yl)-3-oxospiro[bicyclo[2.2.1] heptane-2,3'-pyrrolidine]-2'-carboxylate (5A): Yield (46%); white solid; m.p. 140-142 °C; [α]³⁰_D = +10.5 (*c* 0.75, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.80 – 7.34 (m, 9H), 7.22 (d, *J* = 8.4 Hz, 2H), 4.73 (d, *J* = 11.2 Hz, 1H), 4.03 (s, 1H), 3.91 (d, *J* = 11.2 Hz, 1H), 3.76 (s, 3H), 2.90 – 2.85 (m, 1H), 2.66 – 2.63 (m, 1H), 2.24 –

2.19 (m, 1H), 1.59 – 1.48 (m, 2H), 1.10 – 0.73 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 218.1, 173.1, 153.5, 138.3, 133.6, 133.0, 132.4, 129.2, 128.8, 127.9, 127.7, 127.5, 126.2, 125.9, 69.4, 68.7, 66.4, 56.9, 52.6, 49.3, 44.8, 36.3, 24.9, 23.3.; HRMS (ESI+) Calcd. For $\text{C}_{28}\text{H}_{26}\text{ClNNaO}_3^+$ ($[\text{M}+\text{Na}]^+$): 482.1493, found: 482.1493. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AS-H, *i*-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 220 nm); t_r = 5.79 and 11.80 min.




Methyl (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*) -5'-(4-chlorophenyl)-3-oxo-4'-(thiophen-2-yl)spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5B): Yield (45%); yellow solid; m.p. 157-159 °C; $[\alpha]_D^{30} = +82.6$ (*c* 0.35, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, $J = 8.4$ Hz, 2H), 7.79 (d, $J = 8.8$ Hz, 2H), 7.10 (dd, $J = 4.8, 0.8$ Hz, 1H), 6.82 (dd, $J = 4.8, 3.6$ Hz, 1H), 6.70 (d, $J = 3.6$ Hz, 1H), 4.52 (d, $J = 11.2$ Hz, 1H), 4.08 (d, $J = 11.2$ Hz, 1H), 3.98 (s, 1H), 3.73 (s, 3H), 2.85 – 2.80 (m, 1H), 2.68 – 2.64 (m, 1H), 2.28 – 2.22 (m, 1H), 1.76 – 1.66 (m, 1H), 1.61 – 1.55 (m, 1H), 1.25 – 1.16 (m, 2H), 0.79 – 0.67 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 217.5, 173.3, 139.2, 138.5, 133.8, 129.4, 128.8, 126.8, 126.0, 124.4, 68.8, 68.7, 66.9, 52.5, 51.7, 49.4, 45.0, 36.7, 25.8, 22.6.; HRMS (ESI+) Calcd. For $\text{C}_{22}\text{H}_{22}\text{ClNNaO}_3\text{S}^+$ ($[\text{M}+\text{Na}]^+$): 416.1082, found: 416.1085. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 7.61 and 15.38 min.




Methyl (1*S*,2*R*,2'*S*,4*R*,4'*R*,5'*R*) -5'-(4-chlorophenyl)-3-oxo-4'-(pyridin-2-yl)spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-2'-carboxylate (5C): Yield (46%); yellow solid; m.p. 162-164 °C; $[\alpha]_D^{30} = +15.0$ (*c* 0.24, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.51 (dd, $J = 4.8, 0.8$ Hz, 1H), 7.55 – 7.49 (m, 2H), 7.45 (td, $J = 8.0, 2.0$ Hz, 1H), 7.26 – 7.20 (m, 2H), 7.08 (ddd, $J = 7.2, 4.8, 0.8$ Hz, 1H), 6.92 (d, $J = 7.6$ Hz, 1H), 4.90 (d, $J =$

10.0 Hz, 1H), 4.16 (s, 1H), 3.75 (s, 3H), 3.71 (d, $J = 10.0$ Hz, 1H), 2.93 – 2.86 (m, 1H), 2.66 – 2.62 (m, 1H), 2.17 – 2.12 (m, 1H), 1.69 – 1.60 (m, 1H), 1.55 – 1.49 (m, 1H), 1.22 – 1.13 (m, 1H), 1.08 – 1.00 (m, 1H), 0.49 – 0.40 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 218.3, 173.0, 158.1, 149.2, 139.3, 136.1, 133.2, 129.2, 128.5, 124.5, 122.2, 69.4, 69.2, 66.3, 59.1, 52.4, 49.5, 44.3, 36.2, 25.2, 23.4.; HRMS (ESI+) Calcd. For $\text{C}_{23}\text{H}_{23}\text{ClN}_2\text{NaO}_3^+$ ($[\text{M}+\text{Na}]^+$): 433.1289, found: 433.1287. The product was analyzed by HPLC to determine the enantiomeric excess: 97% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 9.05$ and 15.24 min.




Methyl (2S,3S,3a'R,4'R,5R,7'S,7a'S)-5-(4-chlorophenyl)-6'-oxooctahydrospiro[pyrrolidine-3,5'-[4,7]methanoindene]-2-carboxylate (5D): Yield (48%); yellow liquid; $[\alpha]_D^{30} = -37.8$ (*c* 0.27, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.48 (d, $J = 8.4$ Hz, 2H), 7.32 (d, $J = 8.4$ Hz, 2H), 4.15 (dd, $J = 12.0, 4.8$ Hz, 1H), 3.82 (s, 1H), 3.67 (s, 3H), 2.52 (brs, 1H), 2.46 – 2.41 (m, 2H), 2.38 – 2.30 (m, 1H), 2.13 – 1.79 (m, 8H), 1.40 – 1.29 (m, 1H), 1.23 – 1.11 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 217.4, 173.2, 139.9, 133.3, 128.7, 128.4, 68.7, 64.2, 62.0, 53.7, 52.3, 49.1, 42.9, 41.9, 39.6, 32.1, 31.9, 28.9, 27.8.; HRMS (ESI+) Calcd. For $\text{C}_{21}\text{H}_{25}\text{ClNO}_3^+$ ($[\text{M}+\text{H}]^+$): 374.1517, found: 374.1517. The product was analyzed by HPLC to determine the enantiomeric excess: 96% ee (Chiralpak IA, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 220$ nm); $t_r = 11.25$ and 25.54 min.




Methyl (2S,3S,3a'R,4'R,5R,7'S,7a'R)-5-(4-chlorophenyl)-6'-oxooctahydrospiro[pyrrolidine-3,5'-[4,7]methanoindene]-2-carboxylate (5E): Yield (45%); white liquid; $[\alpha]_D^{30} = +2.1$ (*c* 0.33, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.47 (d, $J = 8.4$ Hz, 2H), 7.33 (d, $J = 8.4$ Hz, 2H), 4.21 (dd, $J = 12.0, 4.4$ Hz, 1H), 3.90 (s, 1H), 3.67 (s, 3H), 2.90 – 2.82 (m, 2H), 2.70 – 2.66 (m, 1H), 2.58 – 2.54 (m, 1H), 2.43 – 2.33 (m, 2H), 2.11 – 2.03 (m,

1H), 1.85 – 1.78 (m, 2H), 1.63 – 1.47 (m, 4H), 1.38 – 1.29 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 217.2, 173.1, 139.9, 133.4, 128.7, 128.5, 70.6, 67.0, 62.3, 54.5, 52.3, 47.4, 47.1, 45.7, 40.2, 39.3, 27.5, 27.2, 26.8.; HRMS (ESI+) Calcd. For C₂₁H₂₄ClNNaO₃⁺ ([M+Na]⁺): 396.1337, found: 396.1337. The product was analyzed by HPLC to determine the enantiomeric excess: 85% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 15.47 and 25.34 min.




Methyl (1'*R*,2*S*,3*S*,4'*S*,5*R*)-5-(4-chlorophenyl)-3'-oxo-3',4'-dihydro-1'H-spiro[pyrrolidine-3,2'-[1,4]methanonaphthalene]-2-carboxylate (5F): Yield (47%); yellow solid; m.p. 166-167 °C; [α]³⁰_D = -183.8 (*c* 0.40, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, *J* = 8.4 Hz, 2H), 7.32 – 7.28 (m, 2H), 7.27 – 7.25 (m, 2H), 7.19 – 7.12 (m, 2H), 4.28 (dd, *J* = 12.0, 4.8 Hz, 1H), 3.96 (s, 1H), 3.73 (s, 3H), 3.65 – 3.58 (m, 2H), 2.82 – 2.76 (m, 1H), 2.68 (brs, 1H), 2.61 – 2.55 (m, 1H), 1.90 – 1.80 (m, 1H), 1.36 – 1.29 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 213.0, 172.9, 146.3, 140.0, 139.5, 133.3, 128.6, 128.3, 127.4, 127.3, 123.5, 123.1, 68.7, 61.9, 60.9, 56.6, 52.5, 51.6, 47.2, 44.8.; HRMS (ESI+) Calcd. For C₂₂H₂₀ClNNaO₃⁺ ([M+H]⁺): 404.1024, found: 404.1024. The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralpak AS-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); t_r = 9.30 and 16.81 min.

Cu(I)/L3-Catalyzed Kinetic Resolution of 3-Methylene-2-Norcamphor




(*S*)-TF-BiphamPhos **L3** (20.1 mg, 0.022 mmol) and Cu(CH₃CN)₄BF₄ (6.3 mg, 0.020 mmol) were dissolved in 2.0 mL CH₂Cl₂, and stirred at room temperature for about 30 min. Then, the reaction temperature was dropped to -60 °C and the imino ester **2a** (0.40 mmol), Et₃N (0.060 mmol) were added sequentially. Then 3-methylene-2-norcamphor **1a** (0.40 mmol) was added. After the reaction completed in 1 h (monitored by chiral-phase GC and HPLC), the reaction mixture was quenched by silica-gel. The organic solvent was removed and the residue was purified by column chromatography to give the recovered **1a** and the cycloadduct **3a**, which were then directly analyzed by chiral-phase GC and HPLC to determine the enantiomeric excess, respectively.




Methyl (1*S*,2*S*,2'*R*,4*R*,5'*R*)-2'-(4-chlorophenyl)-3-oxospiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-5'-carboxylate (3a**):** Yield (46%); yellow liquid; $[\alpha]_D^{24} = +3.5$ (*c* 0.31, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.27 (s, 4H), 4.17 (s, 1H), 3.94 (t, *J* = 8.0 Hz, 1H), 3.82 (s, 3H), 2.94 (s, 1H), 2.55 – 2.48 (m, 1H), 2.32 – 2.25 (m, 3H), 1.84 – 1.64 (m, 3H), 1.54 – 1.40 (m, 2H), 1.35 – 1.30 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 219.0, 173.6, 138.6, 133.7, 129.4, 128.6, 71.5, 63.5, 58.5, 52.3, 49.7, 45.2, 38.1, 34.5, 26.0, 24.7.; HRMS (ESI+) Calcd. For C₁₈H₂₀ClNNaO₃ ([*M*+Na]⁺): 356.1024, found: 356.1022. The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralpak AD-H, *i*-propanol /hexane = 10/90, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 17.61 and 27.76 min.


Gram Scales and Synthetic Transformations




(S)-TF-BiphamPhos **L5** (79.0 mg, 0.099 mmol) and Cu(CH₃CN)₄BF₄ (28.3 mg, 0.090 mmol) were dissolved in 9.0 mL CH₂Cl₂, and stirred at room temperature for about 30 min. Then, the reaction temperature was dropped to -60 °C and the imino ester **2a** (1.90 g, 9.00 mmol), Et₃N (0.14 g, 1.35 mmol) were added sequentially. Then 3-methylene-2-norcamphor **1a** (1.10 g, 9.00 mmol) was added. After the reaction completed (monitored by chiral-phase GC and HPLC), the reaction mixture without quenched and the residue was purified by column chromatography rapidly to give the recovered **1a** and the cycloadduct **5a**, which were then directly analyzed by chiral-phase GC and HPLC to determine the enantiomeric excess, respectively. Meanwhile, nearly 80% yield of chiral ligand **L5** could be recovered, which can be reused in the model reaction in Table 1 under standard reaction condition without loss of yield and enantioselectivity control.




(S)-TF-BiphamPhos **L5** (46.3 mg, 0.058 mmol) and Cu(CH₃CN)₄BF₄ (16.7 mg, 0.053 mmol) were dissolved in 5.0 mL CH₂Cl₂, and stirred at room temperature for about 30 min. Then, the reaction temperature was dropped to -20 °C and the imino ester **2a** (0.74 g, 3.50 mmol), Et₃N (0.08 g, 0.80 mmol) were added sequentially. Then 3-benzylidene-2-norcamphor **1b** (1.05 g, 5.30 mmol) was added. After the reaction completed (monitored by chiral-phase GC and HPLC), the reaction mixture without quenched and the residue was purified by column chromatography rapidly to give the recovered **1a** and the cycloadduct **5q**, which were then directly analyzed by chiral-phase GC and HPLC to determine the enantiomeric excess, respectively. Meanwhile, nearly 80% yield of chiral ligand **L5** could be recovered, which can be reused in the model reaction in Table 1 under standard reaction condition without loss of yield and enantioselectivity control.



To a suspension of NaBH_4 (2.0 mmol, 75.7 mg) in THF (6 mL) was added in one portion $\text{Ca}(\text{OTf})_2$ (0.5 mmol, 169.1 mg) and (1*S*,4*R*)-**1b** (0.80 mmol, 158.6 mg, 95% ee) in MeOH (0.5 mL). The reaction mixture was stirred for 30 min at rt until consumption of the starting material (monitored by TLC). The reaction mixture was quenched with H_2O (3 mL) and the aqueous phase was extracted with Et_2O (3×4 mL). The combined organic layers were washed with brine, dried over MgSO_4 and the solvent was evaporated under reduced pressure. The crude material was purified by column chromatography ($\text{EtOAc}:\text{hexane} = 1:10$ to $1:5$) to give **6** in 88% yield which was then directly analyzed by HPLC to determine the enantiomeric excess.




(1*S*,2*S*,4*R*)-3-((*E*)-benzylidene)bicyclo[2.2.1]heptan-2-ol (6): Yield (88%); white solid; m.p. 108-110 °C; $[\alpha]_D^{30} = -300.8$ (c 0.41, CH_2Cl_2); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.35 – 7.29 (m, 4H), 7.23 – 7.17 (m, 1H), 6.37 (s, 1H), 4.52 (brs, 1H), 3.26 (d, $J = 3.2$ Hz, 1H), 2.49 – 2.41 (m, 1H), 1.91 – 1.79 (m, 3H), 1.63 – 1.52 (m, 2H), 1.45 – 1.41 (m, 2H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 150.9, 137.8, 128.3, 128.0, 126.3, 120.9, 77.0, 41.9, 41.6, 36.2, 29.5, 19.4. The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralpak AS-H, *i*-propanol/hexane = 5/95, flow rate 1.0 mL/min, $\lambda = 254$ nm); $t_r = 7.20$ and 8.05 min.




A solution of (1*S*,4*R*)-**1b** (0.80 mmol, 158.6 mg, 95% ee) in 4 mL MeOH was added 16 mg Pd/C (10%).

The reaction mixture was stirred at room temperature under hydrogen atmosphere (1 bar) for 4 h. The reaction mixture was filtered through a short plug of silica (eluted with EtOAc) and the solvent was removed by rotary evaporation and the crude product was purified by column chromatography (EtOAc:hexane = 1:20) to give (1*S*,3*R*,4*R*)-3-benzylbicyclo[2.2.1]heptan-2-one **7** in 81% yield which was then directly analyzed by HPLC to determine the enantiomeric excess.

To a solution of *m*-CPBA (0.22 mmol) and NaHCO₃ (0.22 mmol) in DCM (6 mL) at 0-5 °C, was added **7** (0.2 mmol) in DCM (1 mL) dropwise over 10 min, the reaction was allowed to warm to rt. After 6 h the reaction was filtrated, the residue was washed with DCM. The organic filtrate was washed with sat. NaHCO₃, sat. NaCl, dried over Na₂SO₄ and concentrated in vacuum. The concentrate was directly purified by column chromatography (EtOAc:hexane = 1:10 to 1:3) to give **8** in 98% yield which was then directly analyzed by HPLC to determine the enantiomeric excess.




(1*S*,3*R*,4*R*)-3-benzylbicyclo[2.2.1]heptan-2-one (7): Yield (81%); colorless liquid; $[\alpha]^{30}_{\text{D}} = -35.3$ (*c* 0.37, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.26 (m, 2H), 7.24 – 7.17 (m, 3H), 3.13 (dd, *J* = 14.0, 3.6 Hz, 1H), 2.70 – 2.65 (m, 1H), 2.49 – 2.46 (m, 1H), 2.42 (dd, *J* = 14.0, 2.4 Hz, 1H), 2.36 – 2.29 (m, 1H), 1.91 – 1.76 (m, 2H), 1.68 – 1.62 (m, 2H), 1.58 – 1.53 (m, 1H), 1.52 – 1.44 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 218.8, 140.3, 128.48, 128.47, 126.1, 55.9, 50.5, 37.9, 36.9, 32.0, 25.4, 21.2.; HRMS (ESI+) Calcd. For C₁₄H₁₆NaO⁺ ([M+Na]⁺): 223.1093, found: 223.1093. The product was analyzed by HPLC to determine the enantiomeric excess: 95% ee (Chiralpak OJ-H, *i*-propanol/hexane = 5/95, flow rate 1.0 mL/min, λ = 220 nm); *t_r* = 11.08 and 11.86 min.




(1*S*,4*R*,5*R*)-4-benzyl-3-oxabicyclo[3.2.1]octan-2-one (8): Yield (98%); white solid; m.p. 70-72 °C; $[\alpha]^{30}_{\text{D}} = +20.7$ (*c* 0.15, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.28 (m, 2H), 7.26 – 7.23 (m, 1H), 7.22 – 7.19 (m,

2H), 4.52 (ddd, $J = 8.4, 6.4, 2.4$ Hz, 1H), 3.06 (dd, $J = 13.6, 6.4$ Hz, 1H), 2.94 – 2.88 (m, 1H), 2.83 (dd, $J = 13.6, 8.4$ Hz, 1H), 2.29 – 2.22 (m, 1H), 2.13 – 2.05 (m, 1H), 1.99 – 1.87 (m, 3H), 1.79 – 1.69 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 174.5, 136.6, 129.3, 128.6, 126.7, 85.9, 41.8, 39.0, 35.9, 33.2, 29.4, 21.0.; HRMS (ESI+) Calcd. For $\text{C}_{14}\text{H}_{16}\text{NaO}_2^+$ ($[\text{M}+\text{Na}]^+$): 239.1043, found: 239.1043. The product was analyzed by HPLC to determine the enantiomeric excess: 96% ee (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1.0 mL/min, $\lambda = 210$ nm); $t_r = 27.92$ and 44.25 min.




A solution of (1*R*,4*S*)-**1a** (2.50 mmol, 305 mg, >99% ee) in 5 mL MeOH was added 50 mg 10% Pd/C. The reaction mixture was stirred at room temperature under hydrogen atmosphere (1 bar) for 2 h. The reaction mixture was filtered through a short plug of silica (eluted with Et₂O) and The solvent was removed by rotary evaporation and the crude product was purified by column chromatography (Et₂O:hexane = 1:20) to give (1*R*,3*S*,4*S*)-3-methylbicyclo[2.2.1]heptan-2-one **9** in 99% yield which was then directly analyzed by GC to determine the enantiomeric excess.

A 2.5 M solution of *n*-butyllithium in hexane (0.60 mL, 1.50 mmol) was added dropwise to a solution of THF (2 mL) and diisopropylamine (161.9 mg, 1.60 mmol) at 0 °C and let stir under argon for 10 min. And (1*R*,3*S*,4*S*)-3-methylbicyclo[2.2.1] heptan-2-one **9** (124.2 mg, 1.00 mmol) was added. After 30 min, 2-(2-iodoethyl)-1,3-dioxolane **10** (342 mg, 1.50 mmol) was added dropwise. The mixture was refluxed for 20 hours and cooled down to room temperature. The reaction mixture was quenched with saturated NaHCO₃ and extracted with EtOAc then the organic was dried over Na₂SO₄ and concentrated to give an oil. The crude product was purified by column chromatography (Et₂O:hexane = 1:20) to give (1*R*,3*R*,4*S*)-3-(2-(1,3-dioxolan-2-yl) ethyl)-3-methylbicyclo[2.2.1]heptan-2-one **11** in 70% yield.



9

(1R,3S,4S)-3-methylbicyclo[2.2.1]heptan-2-one (9): Yield (99%); colorless liquid; $[\alpha]^{30}_D = -46.1$ (c 0.54, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 2.63 – 2.58 (m, 1H), 2.57 – 2.50 (m, 1H), 2.17 – 2.07 (m, 1H), 1.88 – 1.78 (m, 1H), 1.70 (m, 1H), 1.66 – 1.54 (m, 3H), 1.44 – 1.35 (m, 1H), 1.02 (d, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 220.8, 50.3, 48.3, 40.4, 37.2, 25.3, 20.9, 10.7.; HRMS (ESI+) Calcd. For $\text{C}_8\text{H}_{12}\text{NaO}^+$ ($[\text{M}+\text{Na}]^+$): 147.0780, found: 147.0780. The product was analyzed by GC to determine the enantiomeric excess: >99% ee (Chiral Select-1000, 30 m \times 0.25 mm, column temperature: 150 $^\circ\text{C}$, carrier gas: N_2 , 1.0 mL/min); $t_r = 8.88$ and 9.42 min.



11

(1R,3R,4S)-3-(2-(1,3-dioxolan-2-yl)ethyl)-3-methylbicyclo[2.2.1]heptan-2-one (11): Yield (70%); $[\alpha]^{22}_D = -79.3$ (c 3.10, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 4.83 (t, $J = 4.4$ Hz, 1H), 4.00 – 3.93 (m, 2H), 3.87 – 3.78 (m, 2H), 2.59 – 2.54 (m, 1H), 2.37 – 2.30 (m, 1H), 2.01 (d, $J = 10.4$ Hz, 1H), 1.86 – 1.81 (m, 1H), 1.79 – 1.70 (m, 2H), 1.69 – 1.56 (m, 2H), 1.54 – 1.42 (m, 4H), 0.99 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 222.1, 104.4, 64.9, 50.0, 49.2, 43.4, 34.8, 28.6, 28.4, 25.0, 23.1, 18.3.;

X. References

- Becke, A. D. (1993). Density-functional thermochemistry. III. The role of exact exchange. *J. Chem. Phys.* 98, 5648-5652.
- Berthelette, C., McCooye, C., Leblanc, Y., and Trimble, L. A. (1997). Studies on the Dimerization of 2-Benzylidene-1-indanone. *J. Org. Chem.* 62, 4339-4342.
- Chuiko, V. A., Vinarskaya, Z.V., Izotova, L.V., and Tychinskaya, L.Y. (2002). Synthesis and Properties of Benzylidene Derivatives of Terpenoid Ketones. *Russ. J. Org. Chem.* 38, 196-199.
- Coe J. W., Wirtz M. C., Bashore C. G., and Candler J. (2004). Formation of 3-Halobenzynes: Solvent Effects and Cycloaddition Adducts. *Org. Lett.* 6, 1589-1592.

CYL View, version 1.0 b, Legault, C. Y. Universite de Sherbrooke, Sherbrooke, Quebec, Canada, 2009, <http://www.cylview.org>.

Ditchfield, R., Hehre, W. J., and Pople J. A. (1971). Self-Consistent Molecular-Orbital Methods. IX. An Extended Gaussian-Type Basis for Molecular-Orbital Studies of Organic Molecules. *J. Chem. Phys.* *54*, 724-728.

Dolg, M., Wedig, U., Stoll, H., and Preuss, H. (1987). Energy-adjusted ab initio pseudopotentials for the first row transition elements *J. Chem. Phys.* *86*, 866-872.

Fehr, C., and Vuagnoux, M. (2009). Process for the preparation of β -santalol and derivatives thereof. WO2009141781-A1.

Gaussian 09, Revision D.01, Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G. A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H. P., Izmaylov, A. F., Bloino, J., Zheng, G., Sonnenberg, J. L., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Montgomery, J. A., Jr., Peralta, J. E., Ogliaro, F., Bearpark, M., Heyd, J. J., Brothers, E., Kudin, K. N., Staroverov, V. N., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A., Burant, J. C., Iyengar, S. S., Tomasi, J., Cossi, M., Rega, N., Millam, J. M., Klene, M., Knox, J. E., Cross, J. B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R. E., Yazyev, O., Austin, A. J., Cammi, R., Pomelli, C., Ochterski, J. W., Martin, R. L., Morokuma, K., Zakrzewski, V. G., Voth, G. A., Salvador, P., Dannenberg, J. J., Dapprich, S., Daniels, A. D., Farkas, Ö., Foresman, J. B., Ortiz, J. V., Cioslowski, J., and Fox, D. J. (2009). Gaussian, Inc., Wallingford CT.

Ghebregiorgis, T., Biannic, B., Kirk, B. H., and Ess, D. H. Aponick, A. (2012). The Importance of Hydrogen Bonding to Stereoselectivity and Catalyst Turnover in Gold-Catalyzed Cyclization of Monoallylic Diols. *J. Am. Chem. Soc.* *134*, 16307-16318.

Hariharan, P. C., and Pople, J. A. (1973). The influence of polarization functions on molecular orbital hydrogenation energies. *Theor. Chem. Acc.* *28*, 213-222.

Hehre, W. J., Ditchfield, R., and Pople J. A. (1972). Self-Consistent Molecular Orbital Methods. XII. Further Extensions of Gaussian-Type Basis Sets for Use in Molecular Orbital Studies of Organic Molecules. *J. Chem. Phys.* *56*, 2257-2261.

Kleinfelter, D. C., and Schleyer, P. R. (1962). 2-NORBORNANONE. *Org. Synth.* *42*, 79-82.

Lee, C., Yang, W., and Parr, R. G. (1988). Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. *Phys. Rev. B* *37*, 785-789.

- Satam, V., Bandi, R. K., Behera, A. K., Mishra, B. K., Tzou¹, S., Brockway, O., Babu, B., Zeller, M., Westbrook, C., Mooberry, S. L., Lee, M., and Pati, H. (2011). Design, Synthesis, and Cytotoxicity of Novel 3 - Arylidenones Derived from Alicyclic Ketones. *Chem. Biol. Drug. Des.* *78*, 700-708.
- Scalmani, G., and Frisch, M. J. (2010). Continuous surface charge polarizable continuum models of solvation. I. General formalism. *J. Chem. Phys.* *132*, 114110.
- Stephens, P. J., Devlin, F. J., Chabalowski, C. F., and Frisch, M. J. (1994). Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields. *J. Phys. Chem.* *98*, 11623-11627.
- Tomasi, J., Mennucci, B., and Cammi, R. (2005). Quantum Mechanical Continuum Solvation Models. *Chem. Rev.* *105*, 2999-3094.
- Wang, C.-J., Liang, G., Xue, Z.-Y., and Gao, F. (2008). Highly Enantioselective 1,3-Dipolar Cycloaddition of Azomethine Ylides Catalyzed by Copper(I)/TF-Biphosphonate Complexes. *J. Am. Chem. Soc.* *130*, 17250-17251.
- Wang, M., Wang, C.-J., and Lin, Z. (2012). Cu(I)/TF-Biphosphonate Catalyzed Reactions of Alkylidene Bisphosphates and Alkylidene Malonates with Azomethine Ylides: Michael Addition versus 1,3-Dipolar Cycloaddition. *Organometallics* *31*, 7870-7876.